Amedeo Smart

Free Medical Literature Service

 

Amedeo

Diabetes
  Free Subscription

Articles published in
Diabetes Obes Metab
    May 2024
  1. LASSEN MCH, Johansen ND, Modin D, Nealon J, et al
    Effects of high-dose versus standard-dose quadrivalent influenza vaccine among patients with diabetes: A post-hoc analysis of the DANFLU-1 trial.
    Diabetes Obes Metab. 2024;26:1821-1829.
    >> Share

  2. THIRUMALAI A, Chao JH, Kaleru T, Dong X, et al
    Bridging dose of U-100 glargine with first dose of insulin degludec improves glycaemia in the 48 h after transition in twice-daily glargine users.
    Diabetes Obes Metab. 2024;26:1868-1876.
    >> Share

  3. TAN YH, Tan WL, Eichinger V, Ruch B, et al
    Blood glucose control using a mobile health application in Singapore, Philippines and Hong Kong: a retrospective real-world data analysis.
    Diabetes Obes Metab. 2024;26:1990-1992.
    >> Share

  4. WU Y, Zhang C, Duan S, Li Y, et al
    TEAD1, MYO7A and NDUFC2 are novel functional genes associated with glucose metabolism in BXD recombinant inbred population.
    Diabetes Obes Metab. 2024;26:1775-1788.
    >> Share

  5. SALERNO PRVO, Qian A, Dong W, Deo S, et al
    County-level socio-environmental factors and obesity prevalence in the United States.
    Diabetes Obes Metab. 2024;26:1766-1774.
    >> Share

  6. YEW MJ, Heywood SE, Ng J, West OM, et al
    ACAD10 is not required for metformin's metabolic actions or for maintenance of whole-body metabolism in C57BL/6J mice.
    Diabetes Obes Metab. 2024;26:1731-1745.
    >> Share

  7. GILBERT MP, Skelly J, Hernandez AF, Green JB, et al
    Effect of albiglutide on cardiovascular outcomes in older adults: A post hoc analysis of a randomized controlled trial.
    Diabetes Obes Metab. 2024;26:1714-1722.
    >> Share

  8. DIALLO A, Diallo MF, Carlos-Bolumbu M, Galtier F, et al
    Uric acid-lowering effects of sodium-glucose cotransporter 2 inhibitors for preventing cardiovascular events and mortality: A systematic review and meta-analysis.
    Diabetes Obes Metab. 2024;26:1980-1985.
    >> Share

  9. CHAN SY, Zhang H, Wong JT, Chang HF, et al
    Higher early pregnancy plasma myo-inositol associates with increased postprandial glycaemia later in pregnancy: Secondary analyses of the NiPPeR randomized controlled trial.
    Diabetes Obes Metab. 2024;26:1658-1669.
    >> Share

  10. DE GERMAY S, Pambrun E, Pariente A, Grenet G, et al
    Use of sodium-glucose cotransporter-2 inhibitors in France: Analysis of French nationwide health insurance database.
    Diabetes Obes Metab. 2024;26:1678-1686.
    >> Share

  11. SOURIJ C, Oulhaj A, Aziz F, Tripolt NJ, et al
    Impact of glycaemic status on the cardiac effects of empagliflozin when initiated immediately after myocardial infarction: A post-hoc analysis of the EMMY trial.
    Diabetes Obes Metab. 2024;26:1971-1975.
    >> Share

  12. VERNSTROM L, Gullaksen S, Sorensen SS, Funck KL, et al
    Separate and combined effects of empagliflozin and semaglutide on vascular function: A 32-week randomized trial.
    Diabetes Obes Metab. 2024;26:1624-1635.
    >> Share

    April 2024

  13. Correction to "Defining diabetes status using medication groups in Medicare data: Trends in prescribing diabetes medications to patients without a diabetes diagnosis over time".
    Diabetes Obes Metab. 2024 Apr 19. doi: 10.1111/dom.15618.
    >> Share

  14. MALIK RA, Hwu CM, Jammah AA, Arteaga-Diaz JM, et al
    Real-world effectiveness and safety of insulin glargine 100 U/mL plus lixisenatide in adults with type 2 diabetes: An international, multicentre, 12-month, prospective observational study.
    Diabetes Obes Metab. 2024 Apr 18. doi: 10.1111/dom.15599.
    >> Share

  15. WILSON M, Al-Hamid A, Abbas I, Birkett J, et al
    Identification of diagnostic biomarkers used in the diagnosis of cardiovascular diseases and diabetes mellitus: A systematic review of quantitative studies.
    Diabetes Obes Metab. 2024 Apr 18. doi: 10.1111/dom.15593.
    >> Share

  16. HU Y, Li X, Wang X, Ma H, et al
    Smoking timing, genetic susceptibility and the risk of incident type 2 diabetes: A cohort study from the UK Biobank.
    Diabetes Obes Metab. 2024 Apr 15. doi: 10.1111/dom.15603.
    >> Share

  17. DE OLIVEIRA COSTA J, Lin J, Milder TY, Greenfield JR, et al
    Geographic variation in sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide-1 receptor agonist use in people with type 2 diabetes in New South Wales, Australia.
    Diabetes Obes Metab. 2024 Apr 15. doi: 10.1111/dom.15597.
    >> Share

  18. JEONG SI, Ban MS, Hwang JG, Park MK, et al
    The effect of renal function on the pharmacokinetics and pharmacodynamics of enavogliflozin, a potent and selective sodium-glucose cotransporter-2 inhibitor, in type 2 diabetes.
    Diabetes Obes Metab. 2024 Apr 15. doi: 10.1111/dom.15573.
    >> Share

  19. WANG Y, Jiang C, Dong X, Chen M, et al
    Combination of retagliptin and henagliflozin as add-on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double-blind, active-controlled, phase 3 trial.
    Diabetes Obes Metab. 2024 Apr 15. doi: 10.1111/dom.15596.
    >> Share

  20. DENG S, Hu X, Zhang X
    Association of single-point insulin sensitivity estimator index (SPISE) with future cardiovascular outcomes in patients with type 2 diabetes.
    Diabetes Obes Metab. 2024 Apr 15. doi: 10.1111/dom.15600.
    >> Share

  21. IRLIK K, Aldosari H, Hendel M, Kwiendacz H, et al
    Artificial intelligence-enhanced electrocardiogram analysis for identifying cardiac autonomic neuropathy in patients with diabetes.
    Diabetes Obes Metab. 2024 Apr 11. doi: 10.1111/dom.15578.
    >> Share

  22. GRANDO ALVES G, Cunha L, Henkes Machado R, Lins de Menezes V, et al
    Safety and efficacy of teplizumab in the treatment of type 1 diabetes mellitus: An updated systematic review and meta-analysis of randomized controlled trials.
    Diabetes Obes Metab. 2024 Apr 11. doi: 10.1111/dom.15581.
    >> Share

  23. GUO L, Tian F, Liu L, Chen M, et al
    Retagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double-blind, placebo-controlled, phase 3 trial.
    Diabetes Obes Metab. 2024 Apr 11. doi: 10.1111/dom.15601.
    >> Share

  24. GUO L, Xi Y, Li L, Guo K, et al
    Real-world treatment satisfaction with dulaglutide, and its influencing factors, in a Chinese population with type 2 diabetes mellitus.
    Diabetes Obes Metab. 2024 Apr 10. doi: 10.1111/dom.15590.
    >> Share

  25. SAID F, Arnott C, Voors AA, Heerspink HJL, et al
    Prediction of new-onset heart failure in patients with type 2 diabetes derived from ALTITUDE and CANVAS.
    Diabetes Obes Metab. 2024 Apr 8. doi: 10.1111/dom.15592.
    >> Share

  26. SIMON SL, Snell-Bergeon JK, Schafer M, Barker AJ, et al
    Sleep duration and association with cardiometabolic health in adolescents and adults with type 1 diabetes: Results from the BCQR-T1D study.
    Diabetes Obes Metab. 2024 Apr 8. doi: 10.1111/dom.15582.
    >> Share

  27. VIVIAN EM, Chewning BA, Voils CI, Brown RL, et al
    Healthy Outcomes through Peer Educators: Feasibility of a peer support diabetes prevention programme for African-American grandmother caregivers.
    Diabetes Obes Metab. 2024 Apr 3. doi: 10.1111/dom.15574.
    >> Share

  28. CHEN GL, Liu Y, Gao XF, Wu KQ, et al
    Safety, tolerability, pharmacokinetic, pharmacodynamic and immunogenicity profiles of Exendin-4-IgG4-Fc in healthy subjects: A phase 1, single-centre, randomized, double-blind, dose escalation study.
    Diabetes Obes Metab. 2024;26:1395-1406.
    >> Share

  29. GUY A, Azab AN, Liberty IF, Afawi Z, et al
    Adherence to liraglutide among individuals with overweight and obesity: Patient characteristics and clinical measures.
    Diabetes Obes Metab. 2024;26:1346-1354.
    >> Share

  30. LAU D, Gamble JM
    Suicidality among users of glucagon-like peptide-1 receptor agonists: An emerging signal?
    Diabetes Obes Metab. 2024;26:1150-1156.
    >> Share

  31. HOPE DCD, Ansari S, Choudhury S, Alexiadou K, et al
    Adaptive infusion of a glucagon-like peptide-1/glucagon receptor co-agonist G3215, in adults with overweight or obesity: Results from a phase 1 randomized clinical trial.
    Diabetes Obes Metab. 2024;26:1479-1491.
    >> Share

  32. BAZYDLO-GUZENDA K, Jarus-Dziedzic K, Gierczak-Pachulska A, Buda P, et al
    First-in-human study of CPL207280, a novel G-protein-coupled receptor 40/free fatty acid receptor 1 agonist, in healthy volunteers after single and multiple administration.
    Diabetes Obes Metab. 2024;26:1376-1385.
    >> Share

  33. CUKIERMAN-YAFFE T, Ramasundarahettige C, Bosch J, Gerstein HC, et al
    Effect of basal insulin and omega 3 fatty acids on cognitive impairment in dysglycaemia: An exploratory analysis of the ORIGIN trial.
    Diabetes Obes Metab. 2024;26:1180-1187.
    >> Share

  34. NERILD HH, Bronden A, Haddouchi AE, Ellegaard AM, et al
    Elucidating the glucose-lowering effect of the bile acid sequestrant sevelamer.
    Diabetes Obes Metab. 2024;26:1252-1263.
    >> Share

  35. TOMLINSON JW
    Bardet-Biedl syndrome: A focus on genetics, mechanisms and metabolic dysfunction.
    Diabetes Obes Metab. 2024;26 Suppl 2:13-24.
    >> Share

  36. GOLUBIC R, Kennet J, Parker V, Robertson D, et al
    Dual glucagon-like peptide-1 and glucagon receptor agonism reduces energy intake in type 2 diabetes with obesity.
    Diabetes Obes Metab. 2024 Apr 1. doi: 10.1111/dom.15579.
    >> Share

  37. LUO J, Zhao X, Li Q, Zou B, et al
    Evaluating the global impact of low physical activity on type 2 diabetes: Insights from the global burden of disease 2019 study.
    Diabetes Obes Metab. 2024 Apr 1. doi: 10.1111/dom.15568.
    >> Share

  38. SAFDAR NZ, Alobaid AM, Hopkins M, Dempsey PC, et al
    Short, frequent, light-intensity walking activity improves postprandial vascular-inflammatory biomarkers in people with type 1 diabetes: The SIT-LESS randomized controlled trial.
    Diabetes Obes Metab. 2024 Apr 1. doi: 10.1111/dom.15564.
    >> Share

  39. KUHNE T, Wallace E, Herzig D, Helleputte S, et al
    Combined intake of caffeine and low-dose glucose to reduce exercise-related hypoglycaemia in individuals with type 1 diabetes on ultra-long-acting insulin degludec: A randomized, controlled, double-blind, cross-over trial.
    Diabetes Obes Metab. 2024 Apr 1. doi: 10.1111/dom.15580.
    >> Share

  40. DARSALIA V, Vercalsteren E, Karampatsi D, Romanitan MO, et al
    The need for registry-based studies in diabetes and stroke: A unique opportunity to understand whether diabetic treatments improve post-stroke outcome.
    Diabetes Obes Metab. 2024 Apr 1. doi: 10.1111/dom.15577.
    >> Share

  41. CHRISTOFIDES EA, Puente O, Norwood P, Denham D, et al
    Immunogenicity, efficacy, and safety of biosimilar insulin glargine (Gan & Lee glargine) compared with originator insulin glargine (Lantus(R)) in patients with type 2 diabetes after 26 weeks' treatment: A randomized open label study.
    Diabetes Obes Metab. 2024 Apr 1. doi: 10.1111/dom.15560.
    >> Share

  42. HUANG ZG, Gao JW, Zhang HF, You S, et al
    Cardiovascular health metrics defined by Life's Essential 8 scores and subsequent macrovascular and microvascular complications in individuals with type 2 diabetes: A prospective cohort study.
    Diabetes Obes Metab. 2024 Apr 1. doi: 10.1111/dom.15583.
    >> Share

  43. TALHA KM, Green J, Filippatos G, Pocock S, et al
    Impact of empagliflozin on insulin needs in patients with heart failure and diabetes: An EMPEROR-Pooled analysis.
    Diabetes Obes Metab. 2024 Apr 1. doi: 10.1111/dom.15572.
    >> Share

  44. MAHMOUD F, Mueller T, Mullen A, Sainsbury C, et al
    Patterns of initial and first-intensifying antidiabetic drug utilization among patients with type 2 diabetes mellitus in Scotland, 2010-2020: A retrospective population-based cohort study.
    Diabetes Obes Metab. 2024 Apr 1. doi: 10.1111/dom.15584.
    >> Share

  45. ANSON M, Henney AE, Zhao SS, Ibarburu GH, et al
    Effect of combination pioglitazone with sodium-glucose cotransporter-2 inhibitors or glucagon-like peptide-1 receptor agonists on outcomes in type 2 diabetes: A systematic review, meta-analysis, and real-world study from an international federated dat
    Diabetes Obes Metab. 2024 Apr 1. doi: 10.1111/dom.15576.
    >> Share

  46. KANBAY M, Copur S, Topcu AU, Guldan M, et al
    An update review of post-transplant diabetes mellitus: Concept, risk factors, clinical implications and management.
    Diabetes Obes Metab. 2024 Apr 1. doi: 10.1111/dom.15575.
    >> Share

  47. HODGSON A, Gillies CL, Highton P, Haddon L, et al
    Risk of lower extremity amputation in patients with type 2 diabetes mellitus and peripheral arterial disease receiving sodium-glucose cotransporter-2 inhibitors versus other medications: A systematic review and meta-analysis of observational cohort st
    Diabetes Obes Metab. 2024 Apr 1. doi: 10.1111/dom.15571.
    >> Share

    March 2024

  48. Correction to 'In people with type 2 diabetes, sarcopenia is associated with the incidence of cardiovascular disease: A prospective cohort study from the UK Biobank'.
    Diabetes Obes Metab. 2024 Mar 27. doi: 10.1111/dom.15591.
    >> Share

  49. SUZUKI Y, Kaneko H, Nagasawa H, Okada A, et al
    Comparison of estimated glomerular filtration rate change with sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists among people with diabetes: A propensity-score matching study.
    Diabetes Obes Metab. 2024 Mar 26. doi: 10.1111/dom.15561.
    >> Share

  50. CARIOU B, Linge J, Neeland IJ, Dahlqvist Leinhard O, et al
    Effect of tirzepatide on body fat distribution pattern in people with type 2 diabetes.
    Diabetes Obes Metab. 2024 Mar 26. doi: 10.1111/dom.15566.
    >> Share

  51. ZHANG Y, Yang D, Jia Q, Yan J, et al
    The effect of glucagon-like peptide-1 receptor agonists on cardiac function and structure in patients with or without type 2 diabetes mellitus: An updated systematic review and meta-analysis.
    Diabetes Obes Metab. 2024 Mar 26. doi: 10.1111/dom.15557.
    >> Share

  52. BELL DSH, Jerkins T
    The potential for improved outcomes in the prevention and therapy of diabetic kidney disease through 'stacking' of drugs from different classes.
    Diabetes Obes Metab. 2024 Mar 22. doi: 10.1111/dom.15559.
    >> Share

  53. RODBARD HW, Barnard-Kelly K, Pfeiffer AFH, Mauersberger C, et al
    Practical strategies to manage obesity in type 2 diabetes.
    Diabetes Obes Metab. 2024 Mar 21. doi: 10.1111/dom.15556.
    >> Share

  54. RIVERA FB, Lumbang GNO, Gaid DRM, Cruz LLA, et al
    Glucagon-like peptide-1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta-analysis and meta-regression.
    Diabetes Obes Metab. 2024 Mar 20. doi: 10.1111/dom.15529.
    >> Share

  55. DEN BROK EJ, Svensson CH, Panagiotou M, van Greevenbroek MMJ, et al
    The effect of bolus advisors on glycaemic parameters in adults with diabetes on intensive insulin therapy: A systematic review with meta-analysis.
    Diabetes Obes Metab. 2024 Mar 19. doi: 10.1111/dom.15521.
    >> Share

  56. BORNSTEIN SR, de Zeeuw D, Heerspink HJL, Schulze F, et al
    Aldosterone synthase inhibitor (BI 690517) therapy for people with diabetes and albuminuric chronic kidney disease: A multicentre, randomized, double-blind, placebo-controlled, Phase I trial.
    Diabetes Obes Metab. 2024 Mar 18. doi: 10.1111/dom.15518.
    >> Share

  57. SHI C, Tan Y, Hu S, Qin Y, et al
    Effectiveness and safety of once-weekly subcutaneous semaglutide versus other glucose-lowering agents in real-world patients with type 2 diabetes: A retrospective, observational post-marketing study.
    Diabetes Obes Metab. 2024 Mar 18. doi: 10.1111/dom.15552.
    >> Share

  58. PENG M, He S, Wang J, An Y, et al
    Efficacy of 1-hour postload plasma glucose as a suitable measurement in predicting type 2 diabetes and diabetes-related complications: A post hoc analysis of the 30-year follow-up of the Da Qing IGT and Diabetes Study.
    Diabetes Obes Metab. 2024 Mar 15. doi: 10.1111/dom.15547.
    >> Share

  59. LAU D, Pearson GJ, Raggi P, Klarenbach S, et al
    Personalizing cardiovascular risk: Coronary artery calcium scans to improve statin use in adults with type 2 diabetes can be cost-effective in select individuals.
    Diabetes Obes Metab. 2024 Mar 15. doi: 10.1111/dom.15558.
    >> Share

  60. FADINI GP, Bonora BM, Ghiani M, Anichini R, et al
    Oral or injectable semaglutide for the management of type 2 diabetes in routine care: A multicentre observational study comparing matched cohorts.
    Diabetes Obes Metab. 2024 Mar 13. doi: 10.1111/dom.15554.
    >> Share

  61. JAIN AB, Reichert SM, Amadid H, Braae UC, et al
    Use of once-daily oral semaglutide and associated clinical outcomes among adults with type 2 diabetes in routine clinical practice in Canada: A multicentre, prospective real-world study (PIONEER REAL Canada).
    Diabetes Obes Metab. 2024 Mar 11. doi: 10.1111/dom.15493.
    >> Share

  62. NYSTROM T, Andersson Franko M, Ludvigsson J, Lind M, et al
    Overweight or obesity, weight variability and the risk of retinopathy in type 1 diabetes.
    Diabetes Obes Metab. 2024 Mar 11. doi: 10.1111/dom.15545.
    >> Share

  63. ZHAO H, Wu Y, Xie Y, Li Y, et al
    Hydrogel dressings for diabetic foot ulcer: A systematic review and meta-analysis.
    Diabetes Obes Metab. 2024 Mar 11. doi: 10.1111/dom.15544.
    >> Share

  64. DOMAZET SL, Olesen TB, Stidsen JV, Svensson CK, et al
    Low-grade inflammation in persons with recently diagnosed type 2 diabetes: The role of abdominal adiposity and putative mediators.
    Diabetes Obes Metab. 2024 Mar 11. doi: 10.1111/dom.15514.
    >> Share

  65. HELMINK MAG, Hageman SHJ, Eliasson B, Sattar N, et al
    Lifetime and 10-year cardiovascular risk prediction in individuals with type 1 diabetes: The LIFE-T1D model.
    Diabetes Obes Metab. 2024 Mar 8. doi: 10.1111/dom.15531.
    >> Share

  66. SOHN TS, Han KA, Kim Y, Lee BW, et al
    A 52-week efficacy and safety study of enavogliflozin versus dapagliflozin as an add-on to metformin in patients with type 2 diabetes mellitus: ENHANCE-M extension study.
    Diabetes Obes Metab. 2024 Mar 8. doi: 10.1111/dom.15537.
    >> Share

  67. POPOVIC DS, Patoulias D, Karakasis P, Koufakis T, et al
    Effect of tirzepatide on the risk of diabetic retinopathy in type 2 diabetes.
    Diabetes Obes Metab. 2024 Mar 8. doi: 10.1111/dom.15535.
    >> Share

  68. YANG J, Shangguan Q, Xie G, Yang M, et al
    Sex-specific associations between haemoglobin glycation index and the risk of cardiovascular and all-cause mortality in individuals with pre-diabetes and diabetes: A large prospective cohort study.
    Diabetes Obes Metab. 2024 Mar 7. doi: 10.1111/dom.15541.
    >> Share

  69. IVERSEN E, Christensen KM, Walls AB, Eickhoff MK, et al
    Performance of new and panel CKD-EPI equations in European adults with type 2 diabetes.
    Diabetes Obes Metab. 2024 Mar 6. doi: 10.1111/dom.15536.
    >> Share

  70. HUANG Y, Wang S, Cai C, Huang X, et al
    Retinal vascular density as a potential biomarker of diabetic cerebral small vessel disease.
    Diabetes Obes Metab. 2024 Mar 4. doi: 10.1111/dom.15492.
    >> Share

  71. TURNER LV, Riddell MC
    Pre-dinner walks may be superior to post-dinner walks for glucose time in range in adults with type 1 diabetes on hybrid closed-loop insulin delivery systems.
    Diabetes Obes Metab. 2024 Mar 4. doi: 10.1111/dom.15532.
    >> Share

  72. HOYT JA, Cozzi E, D'Alessio DA, Thompson CC, et al
    A look at duodenal mucosal resurfacing: Rationale for targeting the duodenum in type 2 diabetes.
    Diabetes Obes Metab. 2024 Mar 4. doi: 10.1111/dom.15533.
    >> Share

  73. BATDORF HM, Lawes LL, Cassagne GA, Fontenot MS, et al
    Accelerated onset of diabetes in non-obese diabetic mice fed a refined high-fat diet.
    Diabetes Obes Metab. 2024 Mar 4. doi: 10.1111/dom.15522.
    >> Share

  74. ALI S, Baig S, Wanninayake S, da Silva Xavier G, et al
    Glucagon-like peptide-1 analogues in monogenic syndromic obesity: Real-world data from a large cohort of Alstrom syndrome patients.
    Diabetes Obes Metab. 2024;26:989-996.
    >> Share

  75. AL-SOFIANI ME, Petrovski G, Al Shaikh A, Alguwaihes A, et al
    The MiniMed 780G automated insulin delivery system adapts to substantial changes in daily routine: Lessons from real world users during Ramadan.
    Diabetes Obes Metab. 2024;26:937-949.
    >> Share

  76. WU J, Zhou R, Zhang Q, Zhang Q, et al
    Safety, pharmacokinetics and pharmacodynamics of HRS-7535, a novel oral small molecule glucagon-like peptide-1 receptor agonist, in healthy participants: A phase 1, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose, and
    Diabetes Obes Metab. 2024;26:901-910.
    >> Share

  77. HUANG X, Dannya E, Liu X, Yu Y, et al
    Effect of sodium-glucose cotransporter-2 inhibitors on myocardial infarction incidence: A systematic review and meta-analysis of randomized controlled trials and cohort studies.
    Diabetes Obes Metab. 2024;26:1040-1049.
    >> Share

  78. MARITSCH M, Foll S, Lehmann V, Styger N, et al
    Smartwatches for non-invasive hypoglycaemia detection during cognitive and psychomotor stress.
    Diabetes Obes Metab. 2024;26:1133-1136.
    >> Share

  79. SILVERII GA, Monami M, Gallo M, Ragni A, et al
    Glucagon-like peptide-1 receptor agonists and risk of thyroid cancer: A systematic review and meta-analysis of randomized controlled trials.
    Diabetes Obes Metab. 2024;26:891-900.
    >> Share

  80. ALKABBANI W, Maxwell CJ, Marrie RA, Tyas SL, et al
    Insulin, hypoglycaemia and dementia: A causal mediation analysis showcasing challenges and potential opportunities.
    Diabetes Obes Metab. 2024;26:1120-1124.
    >> Share

  81. LEE YJ, Lee SH, You SC, Lee YH, et al
    Moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with metabolic syndrome and atherosclerotic cardiovascular disease: A post-hoc analysis of the RACING trial.
    Diabetes Obes Metab. 2024;26:829-839.
    >> Share

  82. REDDY M, Oliver N
    The role of real-time continuous glucose monitoring in diabetes management and how it should link to integrated personalized diabetes management.
    Diabetes Obes Metab. 2024;26 Suppl 1:46-56.
    >> Share

    February 2024
  83. LIM S, Lee SH, Min KW, Lee CB, et al
    A multicentre, double-blind, placebo-controlled, randomized, parallel comparison, phase 3 trial to evaluate the efficacy and safety of pioglitazone add-on therapy in type 2 diabetic patients treated with metformin and dapagliflozin.
    Diabetes Obes Metab. 2024 Feb 29. doi: 10.1111/dom.15526.
    >> Share

  84. VARGAS KG, Rutten T, Siemes B, Brockmeyer M, et al
    Assessing the potential for precision medicine in body weight reduction with regard to type 2 diabetes mellitus therapies: A meta-regression analysis of 120 randomized controlled trials.
    Diabetes Obes Metab. 2024 Feb 29. doi: 10.1111/dom.15519.
    >> Share

  85. WILLIG MR, Stinson EJ, Looker HC, Piaggi P, et al
    Insulin resistance before type 2 diabetes onset is associated with increased risk of albuminuria after diabetes onset: A prospective cohort study.
    Diabetes Obes Metab. 2024 Feb 28. doi: 10.1111/dom.15505.
    >> Share

  86. SWIFT C, Frazer M, Gronroos NN, Sargent A, et al
    Real-world glycated haemoglobin changes among type 2 diabetes mellitus patients treated with a maintenance dose of 7 mg or 14 mg of oral semaglutide.
    Diabetes Obes Metab. 2024 Feb 28. doi: 10.1111/dom.15516.
    >> Share

  87. BONNET F, Balkau B, Lambert O, Diawara Y, et al
    The number of nephroprotection targets attained is associated with cardiorenal outcomes and mortality in patients with diabetic kidney disease. The CKD-REIN cohort study.
    Diabetes Obes Metab. 2024 Feb 28. doi: 10.1111/dom.15507.
    >> Share

  88. ZHAO Y, Han M, Qie R, Zhang Y, et al
    Associations of body mass index trajectory, waist circumference trajectory, or both with type 2 diabetes mellitus risk in Chinese adults: The China-PAR project.
    Diabetes Obes Metab. 2024 Feb 28. doi: 10.1111/dom.15508.
    >> Share

  89. IIJIMA H, Gouda M, Hida H, Mori-Anai K, et al
    Renal outcomes with sodium-glucose cotransporter 2 inhibitors in Japanese people with grade 3 chronic kidney disease and type 2 diabetes: Analysis of medical administrative databases.
    Diabetes Obes Metab. 2024 Feb 27. doi: 10.1111/dom.15461.
    >> Share

  90. KUNUTSOR SK, Balasubramanian VG, Zaccardi F, Gillies CL, et al
    Glycaemic control and macrovascular and microvascular outcomes: A systematic review and meta-analysis of trials investigating intensive glucose-lowering strategies in people with type 2 diabetes.
    Diabetes Obes Metab. 2024 Feb 26. doi: 10.1111/dom.15511.
    >> Share

  91. SHAO X, Lu J, Tao R, Wu L, et al
    Clinically relevant stratification of patients with type 2 diabetes by using continuous glucose monitoring data.
    Diabetes Obes Metab. 2024 Feb 26. doi: 10.1111/dom.15512.
    >> Share

  92. SHEN W, Cai L, Wang B, Li J, et al
    Associations of a proinflammatory diet, habitual salt intake, and the onset of type 2 diabetes: A prospective cohort study from the UK Biobank.
    Diabetes Obes Metab. 2024 Feb 26. doi: 10.1111/dom.15517.
    >> Share

  93. MESQUITA LA, Spiazzi BF, Piccoli GF, Nogara DA, et al
    Does metformin reduce the risk of cancer in obesity and diabetes? A systematic review and meta-analysis.
    Diabetes Obes Metab. 2024 Feb 23. doi: 10.1111/dom.15509.
    >> Share

  94. WAN EYF, Xu W, Mok AHY, Chin WY, et al
    Evaluating different low-density lipoprotein cholesterol thresholds to initiate statin for prevention of cardiovascular diseases in patients with type 2 diabetes mellitus: A target trial emulation study.
    Diabetes Obes Metab. 2024 Feb 21. doi: 10.1111/dom.15503.
    >> Share

  95. GOMEZ-PERALTA F, Chico Ballesteros A, Marco Martinez A, Perez Corral B, et al
    Insulin glargine 300 U/ml versus insulin degludec 100 U/ml improves nocturnal glycaemic control and variability in type 1 diabetes under routine clinical practice: A glucodensities-based post hoc analysis of the OneCare study.
    Diabetes Obes Metab. 2024 Feb 20. doi: 10.1111/dom.15496.
    >> Share

  96. KUNUTSOR SK, Zaccardi F, Balasubramanian VG, Gillies CL, et al
    Glycaemic control and macrovascular and microvascular outcomes in type 2 diabetes: Systematic review and meta-analysis of cardiovascular outcome trials of novel glucose-lowering agents.
    Diabetes Obes Metab. 2024 Feb 20. doi: 10.1111/dom.15500.
    >> Share

  97. HOVELMANN U, Engberg S, Heise T, Kristensen NR, et al
    Pharmacokinetic and pharmacodynamic properties of once-weekly insulin icodec in individuals with type 1 diabetes.
    Diabetes Obes Metab. 2024 Feb 20. doi: 10.1111/dom.15510.
    >> Share

  98. MISHRIKY BM, Cummings DM, Fu Y, Halladay JR, et al
    Comparative analysis of hospitalization risk for incident heart failure in non-Hispanic Black versus non-Hispanic White individuals with type 2 diabetes on empagliflozin (Empa-AA): Insights from real-world data.
    Diabetes Obes Metab. 2024 Feb 15. doi: 10.1111/dom.15499.
    >> Share

  99. HIRONAKA J, Okada H, Minamida M, Kondo Y, et al
    Impact of an online nutrition management application service on glycaemic management in individuals with diabetes: A propensity-score-matched retrospective cohort study.
    Diabetes Obes Metab. 2024 Feb 14. doi: 10.1111/dom.15487.
    >> Share

  100. JACOBSEN JR, Westergaard LM, Fosbol EL, Kristensen SL, et al
    Association of carpal tunnel syndrome with incident diabetes.
    Diabetes Obes Metab. 2024 Feb 14. doi: 10.1111/dom.15482.
    >> Share

  101. GULDEMOND N
    What is meant by 'integrated personalized diabetes management': A view into the future and what success should look like.
    Diabetes Obes Metab. 2024 Feb 8. doi: 10.1111/dom.15476.
    >> Share

  102. FADINI GP, Buzzetti R, Pitocco D, Tortato E, et al
    IDegLira for the real-world treatment of type 2 diabetes in Italy. Final results from the REX observational study.
    Diabetes Obes Metab. 2024 Feb 8. doi: 10.1111/dom.15486.
    >> Share

  103. MARUHASHI T, Tanaka A, Takahashi K, Higashi Y, et al
    Erythropoiesis and estimated fluid volume regulation following initiation of ipragliflozin treatment in patients with type 2 diabetes mellitus and chronic kidney disease: A post-hoc analysis of the PROCEED trial.
    Diabetes Obes Metab. 2024 Feb 7. doi: 10.1111/dom.15481.
    >> Share

  104. HERMANNS N, Kulzer B, Ehrmann D
    Person-reported outcomes in diabetes care: What are they and why are they so important?
    Diabetes Obes Metab. 2024 Feb 4. doi: 10.1111/dom.15471.
    >> Share

  105. FENG L, Chen C, Guo Q, Chen L, et al
    Improvement of early-phase insulin secretion is an independent factor for achieving glycaemic control: A pooled analysis of SEED and DAWN study.
    Diabetes Obes Metab. 2024;26:745-753.
    >> Share

  106. CUI C, Cao F, Kong II, Wu Q, et al
    A model-informed approach to accelerate the clinical development of cofrogliptin (HSK7653), a novel ultralong-acting dipeptidyl peptidase-4 inhibitor.
    Diabetes Obes Metab. 2024;26:592-601.
    >> Share

  107. CRATER GD, Lalonde K, Ravenelle F, Harvey M, et al
    Effects of CB1R inverse agonist, INV-202, in patients with features of metabolic syndrome. A randomized, placebo-controlled, double-blind phase 1b study.
    Diabetes Obes Metab. 2024;26:642-649.
    >> Share

  108. ROSENSTOCK J, Cariou B, Eliasson J, Frappin G, et al
    Greater time spent with HbA1c less than 7.0% with oral semaglutide versus oral comparators: An exploratory analysis of the PIONEER studies.
    Diabetes Obes Metab. 2024;26:532-539.
    >> Share

  109. LIEVERSE TTGF, Puchades MJ, Mulder UDJ, Provenzano M, et al
    Glomerular and tubular effects of dapagliflozin, eplerenone and their combination in patients with chronic kidney disease: A post-hoc analysis of the ROTATE-3 study.
    Diabetes Obes Metab. 2024;26:576-582.
    >> Share

  110. WEN WL, Lee YJ, Hwu DW, Chang YH, et al
    Age- and gender-adjusted estimated glomerular filtration rate definition reveals hyperfiltration as a risk factor for renal function deterioration in type 2 diabetes.
    Diabetes Obes Metab. 2024 Feb 1. doi: 10.1111/dom.15465.
    >> Share

  111. DE KLERK JA, Bijkerk R, Beulens JWJ, van Zonneveld AJ, et al
    Branched-chain amino acid levels are inversely associated with incident and prevalent chronic kidney disease in people with type 2 diabetes.
    Diabetes Obes Metab. 2024 Feb 1. doi: 10.1111/dom.15475.
    >> Share

  112. LIU Y, Yu S, Feng W, Mo H, et al
    A meta-analysis of diabetes risk prediction models applied to prediabetes screening.
    Diabetes Obes Metab. 2024 Feb 1. doi: 10.1111/dom.15457.
    >> Share

  113. MA J, Liu M, Wang R, Du L, et al
    Efficacy and safety of tirzepatide in people with type 2 diabetes by baseline body mass index: An exploratory subgroup analysis of SURPASS-AP-Combo.
    Diabetes Obes Metab. 2024 Feb 1. doi: 10.1111/dom.15446.
    >> Share

    January 2024
  114. JIAO T, Kianmehr H, Lin Y, Li P, et al
    Some patients with type 2 diabetes may benefit from intensive glycaemic and blood pressure control: A post-hoc machine learning analysis of ACCORD trial data.
    Diabetes Obes Metab. 2024 Jan 31. doi: 10.1111/dom.15453.
    >> Share

  115. ZHANG Y, Jiong OX, Tang S, Tang YC, et al
    Comparison of prediction models for cardiovascular and mortality risk in people with type 2 diabetes: An external validation in 23 685 adults included in the UK Biobank.
    Diabetes Obes Metab. 2024 Jan 31. doi: 10.1111/dom.15474.
    >> Share

  116. MADDALONI E, Naciu AM, Mignogna C, Galiero R, et al
    Saxagliptin/dapagliflozin is non-inferior to insulin glargine in terms of beta-cell function in subjects with latent autoimmune diabetes in adults: A 12-month, randomized, comparator-controlled pilot study.
    Diabetes Obes Metab. 2024 Jan 31. doi: 10.1111/dom.15469.
    >> Share

  117. EBEKOZIEN O, Fantasia K, Farrokhi F, Sabharwal A, et al
    Technology and health inequities in diabetes care: How do we widen access to underserved populations and utilize technology to improve outcomes for all?
    Diabetes Obes Metab. 2024 Jan 31. doi: 10.1111/dom.15470.
    >> Share

  118. JAFAR A, Pasqua MR
    Postprandial glucose-management strategies in type 1 diabetes: Current approaches and prospects with precision medicine and artificial intelligence.
    Diabetes Obes Metab. 2024 Jan 23. doi: 10.1111/dom.15463.
    >> Share

  119. HOWELL CR, Zhu S, Malla G, Carson G, et al
    Defining diabetes status using medication groups in Medicare data: Trends in prescribing diabetes medications to patients without a diabetes diagnosis over time.
    Diabetes Obes Metab. 2024 Jan 22. doi: 10.1111/dom.15450.
    >> Share

  120. REZNIK Y, Bonnemaison E, Fagherazzi G, Renard E, et al
    The use of an automated insulin delivery system is associated with a reduction in diabetes distress and improvement in quality of life in people with type 1 diabetes.
    Diabetes Obes Metab. 2024 Jan 22. doi: 10.1111/dom.15462.
    >> Share

  121. NAKAMURA Y, Horie I, Kitamura T, Kusunoki Y, et al
    Glucagon secretion and its association with glycaemic control and ketogenesis during sodium-glucose cotransporter 2 inhibition by ipragliflozin in people with type 1 diabetes: Results from the multicentre, open-label, prospective study.
    Diabetes Obes Metab. 2024 Jan 22. doi: 10.1111/dom.15458.
    >> Share

  122. ISHIBASHI R, Inaba Y, Koshizaka M, Takatsuna Y, et al
    Sodium-glucose co-transporter 2 inhibitor therapy reduces the administration frequency of anti-vascular endothelial growth factor agents in patients with diabetic macular oedema with a history of anti-vascular endothelial growth factor agent use: A co
    Diabetes Obes Metab. 2024 Jan 19. doi: 10.1111/dom.15454.
    >> Share

  123. LONGO M, Caruso P, Scappaticcio L, Maiorino MI, et al
    Two years with GIOIA 'Effects of gliflozins and gliptins on markers of cardiovascular damage in type 2 diabetes': A prospective, multicentre, quasi-experimental study on sodium-glucose cotransporter 2 and dipeptidyl peptidase-4 inhibitors in diabetes
    Diabetes Obes Metab. 2024 Jan 17. doi: 10.1111/dom.15451.
    >> Share

  124. REBORDOSA C, Thomsen RW, Tave AK, Madsen M, et al
    Liver, renal, genitourinary and diabetic ketoacidosis risks among new users of empagliflozin versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: Post-authorization safety study based on multinational cohorts.
    Diabetes Obes Metab. 2024 Jan 17. doi: 10.1111/dom.15429.
    >> Share

  125. WANG X, Ma H, Li X, Liang Z, et al
    Risk factor control and incident cardiovascular disease in patients with diabetes: Sex-specific relations.
    Diabetes Obes Metab. 2024 Jan 16. doi: 10.1111/dom.15443.
    >> Share

  126. DE VRIES SAG, Sas TCJ, Bak JCG, Mul D, et al
    Socio-economic disparities in hospital care among Dutch patients with diabetes mellitus.
    Diabetes Obes Metab. 2024 Jan 16. doi: 10.1111/dom.15440.
    >> Share

  127. SAMUELS SL, Chajecki A, Hu P, Kayser M, et al
    Real-world use of glucagon-like peptide-1 receptor agonists in youth with type 2 diabetes is associated with short-term improvements in HbA1c.
    Diabetes Obes Metab. 2024 Jan 16. doi: 10.1111/dom.15430.
    >> Share

  128. MICHALOPOULOU M, Jebb SA, MacKillop LH, Dyson P, et al
    REduced-Carbohydrate intervention for managing Obesity and Reduction of gestational Diabetes (RECORD): A randomized controlled feasibility trial.
    Diabetes Obes Metab. 2024 Jan 16. doi: 10.1111/dom.15442.
    >> Share


  129. Correction to 'Societal health and economic burden of cardiovascular diseases in the population with type 2 diabetes in Qatar. A 10-year forecasting model'.
    Diabetes Obes Metab. 2024 Jan 16. doi: 10.1111/dom.15452.
    >> Share

  130. SSEMMONDO E, Deshmukh H, Wilmot EG, Adeleke KA, et al
    Effect of intermittently scanned continuous glucose monitoring in people with diabetes with a psychosocial indication for initiation.
    Diabetes Obes Metab. 2024 Jan 16. doi: 10.1111/dom.15435.
    >> Share

  131. SLOAN L, Cheng AYY, Escalada J, Haluzik M, et al
    The role of basal insulins in the treatment of people with type 2 diabetes and chronic kidney disease: A narrative review.
    Diabetes Obes Metab. 2024 Jan 15. doi: 10.1111/dom.15425.
    >> Share

  132. MUNTIS FR, Crandell JL, Evenson KR, Maahs DM, et al
    Pre-exercise protein intake is associated with reduced time in hypoglycaemia among adolescents with type 1 diabetes.
    Diabetes Obes Metab. 2024 Jan 15. doi: 10.1111/dom.15438.
    >> Share

  133. WANG W, Guo X, Zhang C, Ning T, et al
    Prusogliptin (DBPR108) monotherapy in treatment-naive patients with type 2 diabetes: A randomized, double-blind, active and placebo-controlled, phase 3 study.
    Diabetes Obes Metab. 2024 Jan 15. doi: 10.1111/dom.15433.
    >> Share

  134. SHIVAM V, Gillies CL, Goff LM, Zaccardi F, et al
    Taste perception genomics in gestational diabetes mellitus: A systematic review.
    Diabetes Obes Metab. 2024 Jan 9. doi: 10.1111/dom.15449.
    >> Share

  135. SHETTY S, Suvarna R
    Efficacy and safety of once-weekly insulin icodec in type 2 diabetes: A meta-analysis of ONWARDS phase 3 randomized controlled trials.
    Diabetes Obes Metab. 2024 Jan 8. doi: 10.1111/dom.15408.
    >> Share

  136. HENSON J, Tziannou A, Rowlands AV, Edwardson CL, et al
    Twenty-four-hour physical behaviour profiles across type 2 diabetes mellitus subtypes.
    Diabetes Obes Metab. 2024 Jan 8. doi: 10.1111/dom.15437.
    >> Share

  137. RHEE JJ, Han J, Montez-Rath ME, Chertow GM, et al
    Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes and mild/moderate chronic kidney disease.
    Diabetes Obes Metab. 2024 Jan 8. doi: 10.1111/dom.15427.
    >> Share

  138. TONG G, Lu S, Kuang H, Li Y, et al
    Effect of baseline characteristics on the efficacy of dulaglutide added to basal insulin in Chinese patients with type 2 diabetes: A subgroup analysis of AWARD-CHN3.
    Diabetes Obes Metab. 2024 Jan 7. doi: 10.1111/dom.15416.
    >> Share

  139. MARIGLIANO M, Piona C, Mancioppi V, Morotti E, et al
    Glucose sensor with predictive alarm for hypoglycaemia: Improved glycaemic control in adolescents with type 1 diabetes.
    Diabetes Obes Metab. 2024 Jan 4. doi: 10.1111/dom.15432.
    >> Share

  140. YANG W, Guo X, Lauand F, Li L, et al
    Effects of age and disease duration on the efficacy and safety of iGlarLixi in Asian people with type 2 diabetes: A post hoc analysis of the LixiLan-O-AP and LixiLan-L-CN trials.
    Diabetes Obes Metab. 2024 Jan 3. doi: 10.1111/dom.15414.
    >> Share

  141. YU L, Wang J, Gong Q, An Y, et al
    Influence of a diet and/or exercise intervention on long-term mortality and vascular complications in people with impaired glucose tolerance: Da Qing Diabetes Prevention Outcome study.
    Diabetes Obes Metab. 2024 Jan 2. doi: 10.1111/dom.15413.
    >> Share

  142. DESHMUKH H, Adeleke K, Wilmot EG, Folwell A, et al
    Clinical features of type 1 diabetes in older adults and the impact of intermittently scanned continuous glucose monitoring: An Association of British Clinical Diabetologists (ABCD) study.
    Diabetes Obes Metab. 2024 Jan 2. doi: 10.1111/dom.15434.
    >> Share

  143. KIM T, Campbell DB, Au F, Ronksley PE, et al
    Patterns of metformin use and glycated haemoglobin trends among patients with newly diagnosed type 2 diabetes in Alberta, Canada.
    Diabetes Obes Metab. 2024 Jan 2. doi: 10.1111/dom.15419.
    >> Share

  144. HANKOSKY ER, Wang H, Neff LM, Kan H, et al
    Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with obesity or overweight: SURMOUNT-1 post hoc analysis.
    Diabetes Obes Metab. 2024;26:319-328.
    >> Share

  145. ZHU Y, Wang Q, Dai H, Hou T, et al
    Sex-specific causality of MRI-derived body compositions on glycaemic traits: Mendelian randomization and observational study.
    Diabetes Obes Metab. 2024;26:373-384.
    >> Share

  146. ROSENSTOCK J, Lee CJ, Fernandez Lando L, Liu M, et al
    Impact on glycated haemoglobin and body weight changes after stopping tirzepatide for 4 weeks in the SURPASS-1 monotherapy trial.
    Diabetes Obes Metab. 2024;26:396-399.
    >> Share

  147. DIALLO A, Carlos-Bolumbu M, Galtier F
    Is composite cardiovascular death or hospitalization for heart failure a valid surrogate for mortality in patients treated with sodium-glucose cotransporter 2 inhibitors? A correlation meta-analysis.
    Diabetes Obes Metab. 2024;26:392-395.
    >> Share

  148. TANDAY N, Tarasov AI, Moffett RC, Flatt PR, et al
    Pancreatic islet cell plasticity: Pathogenic or therapeutically exploitable?
    Diabetes Obes Metab. 2024;26:16-31.
    >> Share

  149. DAI H, Hou T, Wang Q, Zhu Z, et al
    The effect of metformin on urate metabolism: Findings from observational and Mendelian randomization analyses.
    Diabetes Obes Metab. 2024;26:242-250.
    >> Share

  150. CHEN J, Feng X, Zhou X, Li Y, et al
    Role of the tripartite motif-containing (TRIM) family of proteins in insulin resistance and related disorders.
    Diabetes Obes Metab. 2024;26:3-15.
    >> Share

    December 2023
  151. MORENO-PEREZ O, Reyes-Garcia R, Modrego-Pardo I, Doulatram-Gamgaram VK, et al
    Real-world effectiveness and safety of oral semaglutide in people living with type 2 diabetes: A nationwide multicentre retrospective observational study (ENDO(2) S-RWD).
    Diabetes Obes Metab. 2023 Dec 27. doi: 10.1111/dom.15431.
    >> Share

  152. AZIZ F, Sternad C, Sourij C, Knoll L, et al
    Glycated haemoglobin, HOMA2-B, C-peptide to glucose ratio and type 2 diabetes clusters as predictors for therapy failure in individuals with type 2 diabetes without insulin therapy: A registry analysis.
    Diabetes Obes Metab. 2023 Dec 27. doi: 10.1111/dom.15409.
    >> Share

  153. MCMURRAY JJV, Solomon SD, Lock JP, Massaro JM, et al
    Meta-analysis of risk of major adverse cardiovascular events in adults with type 2 diabetes treated with bexagliflozin.
    Diabetes Obes Metab. 2023 Dec 27. doi: 10.1111/dom.15394.
    >> Share

  154. LEI M, Ling P, Ni Y, Chen D, et al
    The efficacy of glucose-responsive insulin and glucagon delivery on exercise-induced hypoglycaemia among adults with type 1 diabetes mellitus: A meta-analysis of randomized controlled trials.
    Diabetes Obes Metab. 2023 Dec 27. doi: 10.1111/dom.15422.
    >> Share

  155. ABDELGANI S, Khattab A, Adams J, Baskoy G, et al
    The impact of increased hepatic glucose production caused by empagliflozin on plasma glucose concentration in individuals with type 2 diabetes and nondiabetic individuals.
    Diabetes Obes Metab. 2023 Dec 22. doi: 10.1111/dom.15404.
    >> Share

  156. YE M, Vena JE, Shen-Tu G, Johnson JA, et al
    Reduced incidence of diabetes during the COVID-19 pandemic in Alberta: A time-segmented longitudinal study of Alberta's Tomorrow Project.
    Diabetes Obes Metab. 2023 Dec 22. doi: 10.1111/dom.15420.
    >> Share

  157. MEHMOOD S, Ye C, Hanley AJ, Connelly PW, et al
    Impact of the diagnosis of gestational diabetes on maternal physical activity after pregnancy.
    Diabetes Obes Metab. 2023 Dec 20. doi: 10.1111/dom.15415.
    >> Share

  158. KARAKASIS P, Patoulias D, Fragakis N, Klisic A, et al
    Effect of tirzepatide on albuminuria levels and renal function in patients with type 2 diabetes mellitus: A systematic review and multilevel meta-analysis.
    Diabetes Obes Metab. 2023 Dec 20. doi: 10.1111/dom.15410.
    >> Share

  159. GERSTEIN HC, Mian R, Ramasundarahettige C, Branch KRH, et al
    Cardiovascular and renal outcomes with varying degrees of kidney disease in high-risk people with type 2 diabetes: An epidemiological analysis of data from the AMPLITUDE-O trial.
    Diabetes Obes Metab. 2023 Dec 20. doi: 10.1111/dom.15417.
    >> Share

  160. TSUR N, Pollack R, Frankel M, Tsur A, et al
    Future diabetes risk can be predicted by the number of abnormal oral glucose tolerance test values during pregnancy.
    Diabetes Obes Metab. 2023 Dec 19. doi: 10.1111/dom.15406.
    >> Share

  161. LI Y, Cheng Z, Lu W, Li P, et al
    Efficacy of noiiglutide injection on body weight in obese Chinese adults without diabetes: A multicentre, randomized, double-blind, placebo-controlled, phase 2 trial.
    Diabetes Obes Metab. 2023 Dec 17. doi: 10.1111/dom.15407.
    >> Share

  162. YATES T, Biddle GJH, Henson J, Edwardson CL, et al
    Impact of weight loss and weight gain trajectories on body composition in a population at high risk of type 2 diabetes: A prospective cohort analysis.
    Diabetes Obes Metab. 2023 Dec 14. doi: 10.1111/dom.15400.
    >> Share

  163. TAKAHASHI H, Asakawa K, Kosakai Y, Lee T, et al
    Comparative effectiveness of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors on liver function in patients with type 2 diabetes in Japan: A real-world data analysis.
    Diabetes Obes Metab. 2023 Dec 12. doi: 10.1111/dom.15399.
    >> Share

  164. MUNSHI M, Ritzel R, Jude EB, Dex T, et al
    Advancing type 2 diabetes therapy with iGlarLixi in older people: Pooled analysis of four randomized controlled trials.
    Diabetes Obes Metab. 2023 Dec 11. doi: 10.1111/dom.15377.
    >> Share

  165. STROMBOTNE KL, Lum J, Pizer SD, Figueroa S, et al
    Clinical effectiveness and cost-impact after 2 years of a ketogenic diet and virtual coaching intervention for patients with diabetes.
    Diabetes Obes Metab. 2023 Dec 11. doi: 10.1111/dom.15401.
    >> Share

  166. KOBO O, Cavender MA, Jensen TJ, Kuhlman AB, et al
    Once-weekly semaglutide reduces the risk of cardiovascular events in people with type 2 diabetes and polyvascular disease: A post hoc analysis.
    Diabetes Obes Metab. 2023 Dec 11. doi: 10.1111/dom.15396.
    >> Share

  167. DAVIS TME, Davis WA
    An assessment of factors contributing to the decline in risk of stroke complicating type 2 diabetes: The Fremantle Diabetes Study.
    Diabetes Obes Metab. 2023 Dec 11. doi: 10.1111/dom.15391.
    >> Share

  168. DRENTHEN LCA, Ajie M, Teerenstra S, Abbink EJ, et al
    Impact of sedentary behaviour on glucose concentration in people with type 1 diabetes.
    Diabetes Obes Metab. 2023 Dec 11. doi: 10.1111/dom.15397.
    >> Share

  169. WANG X, He C, Wu N, Tian Y, et al
    Establishment and validation of a prediction model for gestational diabetes.
    Diabetes Obes Metab. 2023 Dec 11. doi: 10.1111/dom.15356.
    >> Share

  170. MIKLOSZ A, Chabowski A
    Efficacy of adipose-derived mesenchymal stem cell therapy in the treatment of chronic micro- and macrovascular complications of diabetes.
    Diabetes Obes Metab. 2023 Dec 11. doi: 10.1111/dom.15375.
    >> Share

  171. FURUSAWA S, Nomoto H, Yokoyama H, Suzuki Y, et al
    Glycaemic control efficacy of switching from dipeptidyl peptidase-4 inhibitors to oral semaglutide in subjects with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 2 study).
    Diabetes Obes Metab. 2023 Dec 11. doi: 10.1111/dom.15393.
    >> Share

  172. CHOE HJ, Oh HR, Bu D, An N, et al
    Evaluation of the efficacy of a combination of dapagliflozin and lobeglitazone on glucose concentrations and body fat in patients with type 2 diabetes: Location-F study.
    Diabetes Obes Metab. 2023 Dec 11. doi: 10.1111/dom.15388.
    >> Share

  173. LEE KS, Lee YH, Lee SG
    Alanine to glycine ratio is a novel predictive biomarker for type 2 diabetes mellitus.
    Diabetes Obes Metab. 2023 Dec 11. doi: 10.1111/dom.15395.
    >> Share

  174. WEN Q, Chowdhury AI, Aydin B, Shekha M, et al
    Metformin restores prohormone processing enzymes and normalizes aberrations in secretion of proinsulin and insulin in palmitate-exposed human islets.
    Diabetes Obes Metab. 2023;25:3757-3765.
    >> Share

  175. SOHN M, Frias JP, Lim S
    Cardiovascular efficacy and safety of antidiabetic agents: A network meta-analysis of randomized controlled trials.
    Diabetes Obes Metab. 2023;25:3560-3577.
    >> Share

  176. TAYLOR SI, Cherng HR, Shahidzadeh Yazdi Z, Montasser ME, et al
    Pharmacogenetics of sodium-glucose co-transporter-2 inhibitors: Validation of a sex-agnostic pharmacodynamic biomarker.
    Diabetes Obes Metab. 2023;25:3512-3520.
    >> Share

  177. TONDA K, Iwabuchi Y, Shiga T, Owaki Y, et al
    Impact of patient characteristic factors on the dynamics of liver glucose metabolism: Evaluation of multiparametric imaging with dynamic whole-body (18) F-fluorodeoxyglucose-positron emission tomography.
    Diabetes Obes Metab. 2023;25:3521-3528.
    >> Share

  178. ALKABBANI W, Shah BR, Zongo A, Eurich DT, et al
    Post-initiation predictors of discontinuation of the sodium-glucose cotransporter-2 inhibitors: A comparative cohort study from the United Kingdom.
    Diabetes Obes Metab. 2023;25:3490-3500.
    >> Share

    November 2023
  179. EISSING T, Goulooze SC, van den Berg P, van Noort M, et al
    Pharmacokinetics and pharmacodynamics of finerenone in patients with chronic kidney disease and type 2 diabetes: Insights based on FIGARO-DKD and FIDELIO-DKD.
    Diabetes Obes Metab. 2023 Nov 30. doi: 10.1111/dom.15387.
    >> Share

  180. CHEN X, Hou X, Gao J, Yu X, et al
    Ethnic disparities in cardiovascular and renal responses to canagliflozin between Asian and White patients with type 2 diabetes mellitus: A post hoc analysis of the CANVAS Program.
    Diabetes Obes Metab. 2023 Nov 30. doi: 10.1111/dom.15380.
    >> Share

  181. BANTOUNOU MA, Sardellis P, Thuemmler R, Black Boada D, et al
    Effect of the dual sodium-glucose co-transporter-1 and -2 inhibitor sotagliflozin on renal outcomes in type 1 diabetes and type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
    Diabetes Obes Metab. 2023 Nov 29. doi: 10.1111/dom.15364.
    >> Share

  182. IGWEOKPALA S, Sule NO, Douros A, Yu OHY, et al
    Incretin-based drugs and the risk of diabetic retinopathy among individuals with type 2 diabetes: A systematic review and meta-analysis of observational studies.
    Diabetes Obes Metab. 2023 Nov 29. doi: 10.1111/dom.15367.
    >> Share

  183. GOLDENBERG RM
    A comment on tirzepatide versus glucagon-like peptide-1 receptor agonists and heart rate with regard to 'Impact of a dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist tirzepatide on heart rate among patients with t
    Diabetes Obes Metab. 2023 Nov 28. doi: 10.1111/dom.15381.
    >> Share

  184. QIN W, Yang J, Deng C, Ruan Q, et al
    Efficacy and safety of semaglutide 2.4 mg for weight loss in overweight or obese adults without diabetes: An updated systematic review and meta-analysis including the 2-year STEP 5 trial.
    Diabetes Obes Metab. 2023 Nov 28. doi: 10.1111/dom.15386.
    >> Share

  185. WANG H, He S, Wang J, An Y, et al
    Does high-normal blood pressure lead to excess cardiovascular disease events and deaths in Chinese people? A post-hoc analysis of the 30-year follow-up of the Da Qing IGT and Diabetes Study.
    Diabetes Obes Metab. 2023 Nov 27. doi: 10.1111/dom.15379.
    >> Share

  186. PRATT E
    Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes.
    Diabetes Obes Metab. 2023 Nov 23. doi: 10.1111/dom.15372.
    >> Share

  187. LIU D, Li N, Zhou Y, Wang M, et al
    Sex-specific associations between skeletal muscle mass and incident diabetes: A population-based cohort study.
    Diabetes Obes Metab. 2023 Nov 23. doi: 10.1111/dom.15373.
    >> Share

  188. FUJITA KK, Ye F, Collister D, Klarenbach S, et al
    Sodium-glucose co-transporter-2 inhibitors are associated with kidney benefits at all degrees of albuminuria: A retrospective cohort study of adults with diabetes.
    Diabetes Obes Metab. 2023 Nov 23. doi: 10.1111/dom.15361.
    >> Share

  189. YU C, Wang Y, Zhang B, Xu X, et al
    Associations between complexity of glucose time series and cognitive function in adults with type 2 diabetes.
    Diabetes Obes Metab. 2023 Nov 23. doi: 10.1111/dom.15376.
    >> Share

  190. MATHER KJ, Coskun T, Pratt EJ, Milicevic Z, et al
    Improvements in post-challenge lipid response following tirzepatide treatment in patients with type 2 diabetes.
    Diabetes Obes Metab. 2023 Nov 21. doi: 10.1111/dom.15365.
    >> Share

  191. ZIMMER RT, Birnbaumer P, Sternad C, Zunner BEM, et al
    Impact of a 4-week intensive track and field training intervention on glycaemia in adolescents with type 1 diabetes: The ChilDFiT1 study.
    Diabetes Obes Metab. 2023 Nov 20. doi: 10.1111/dom.15352.
    >> Share

  192. THABIT H, Boughton C, Mubita W, Rubio J, et al
    Impact of hybrid closed-loop insulin delivery on cardiac rhythm in older adults with type 1 diabetes: A post hoc analysis of trial data.
    Diabetes Obes Metab. 2023 Nov 20. doi: 10.1111/dom.15366.
    >> Share

  193. FAN Y, Xia M, Yan H, Li X, et al
    Efficacy of beinaglutide in the treatment of hepatic steatosis in type 2 diabetes patients with nonalcoholic fatty liver disease: A randomized, open-label, controlled trial.
    Diabetes Obes Metab. 2023 Nov 17. doi: 10.1111/dom.15359.
    >> Share

  194. SAITO Y, Tanaka A, Imai T, Miura SI, et al
    Factors associated with the uric acid-lowering effects of sodium-glucose cotransporter-2 inhibition in patients with type 2 diabetes: Insights from the randomized PROTECT trial.
    Diabetes Obes Metab. 2023 Nov 14. doi: 10.1111/dom.15368.
    >> Share

  195. LI X, Zhang W, Bi Y, Chen J, et al
    Non-alcoholic fatty liver disease is associated with brain function disruption in type 2 diabetes patients without cognitive impairment.
    Diabetes Obes Metab. 2023 Nov 14. doi: 10.1111/dom.15354.
    >> Share

  196. ZHOU L, Su W, Wang Y, Zhang Y, et al
    FOXO1 reduces STAT3 activation and causes impaired mitochondrial quality control in diabetic cardiomyopathy.
    Diabetes Obes Metab. 2023 Nov 14. doi: 10.1111/dom.15369.
    >> Share

  197. WEN X, Yang H, Yang M, Tao W, et al
    Factors that determine glucose variability, defined by the coefficient of variation in continuous glucose monitoring values, in a Chinese population with type 2 diabetes.
    Diabetes Obes Metab. 2023 Nov 12. doi: 10.1111/dom.15350.
    >> Share

  198. LEI M, Chen D, Ling P, Wang C, et al
    Effect of artificial pancreas system use on glycaemic control among pregnant women with type 1 diabetes mellitus: A meta-analysis of randomized controlled trials.
    Diabetes Obes Metab. 2023 Nov 12. doi: 10.1111/dom.15357.
    >> Share

  199. KIM J, Kim B, Kim MK, Baek KH, et al
    Weight change in patients with new-onset type 2 diabetes mellitus and its association with remission: Comprehensive real-world data.
    Diabetes Obes Metab. 2023 Nov 8. doi: 10.1111/dom.15345.
    >> Share

  200. LIU W, Zhang D, Wang R, Chen J, et al
    Global trends in the burden of chronic kidney disease attributable to type 2 diabetes: An age-period-cohort analysis.
    Diabetes Obes Metab. 2023 Nov 7. doi: 10.1111/dom.15349.
    >> Share

  201. HELLMAN J, Hartvig NV, Kaas A, Moller JB, et al
    Associations of bolus insulin injection frequency and smart pen engagement with glycaemic control in people living with type 1 diabetes.
    Diabetes Obes Metab. 2023 Nov 5. doi: 10.1111/dom.15316.
    >> Share

  202. REZNIK Y, Carvalho M, Fendri S, Prevost G, et al
    Should people with type 2 diabetes treated by multiple daily insulin injections with home health care support be switched to hybrid closed-loop? The CLOSE AP+ randomized controlled trial.
    Diabetes Obes Metab. 2023 Nov 3. doi: 10.1111/dom.15351.
    >> Share

  203. UEMURA T, Nishimoto M, Eriguchi M, Tamaki H, et al
    Utility of serum beta2-microglobulin for prediction of kidney outcome among patients with biopsy-proven diabetic nephropathy.
    Diabetes Obes Metab. 2023 Nov 3. doi: 10.1111/dom.15347.
    >> Share

  204. JIANG P, Sun N, Yang W, Xiao L, et al
    Development of a novel Fc fusion protein dual glucagon-like peptide-1 and gastric inhibitory polypeptide receptor agonists.
    Diabetes Obes Metab. 2023;25:3356-3365.
    >> Share

  205. GASBJERG LS, Rosenkilde MM, Meier JJ, Holst JJ, et al
    The importance of glucose-dependent insulinotropic polypeptide receptor activation for the effects of tirzepatide.
    Diabetes Obes Metab. 2023;25:3079-3092.
    >> Share

  206. SANZ-GONZALEZ A, Cozar-Castellano I, Broca C, Sabatier J, et al
    Pharmacological activation of insulin-degrading enzyme improves insulin secretion and glucose tolerance in diet-induced obese mice.
    Diabetes Obes Metab. 2023;25:3268-3278.
    >> Share

  207. RANGLANI S, Ward J, Sattar N, Strawbridge RJ, et al
    Testing for associations between HbA1c levels, polygenic risk and brain health in UK Biobank (N = 39 283).
    Diabetes Obes Metab. 2023;25:3136-3143.
    >> Share

  208. STRATHE A, Horn DB, Larsen MS, Rubino D, et al
    A model-based approach to predict individual weight loss with semaglutide in people with overweight or obesity.
    Diabetes Obes Metab. 2023;25:3171-3180.
    >> Share

  209. MADDALONI E, Carlone A, Pitocco D, Leanza G, et al
    Glycated haemoglobin in the first year after diagnosis of type 1 diabetes is an independent risk factor for diabetic retinopathy: The IMDIAB 25 years follow-up study.
    Diabetes Obes Metab. 2023;25:3415-3419.
    >> Share

    October 2023
  210. HENRY Z, Villar Fimbel S, Bendelac N, Perge K, et al
    Beneficial effects of automated insulin delivery over one-year follow-up in real life for youths and adults with type 1 diabetes irrespective of patient characteristics.
    Diabetes Obes Metab. 2023 Oct 31. doi: 10.1111/dom.15344.
    >> Share

  211. SOLIS-HERRERA C, Triplitt C
    Non-steroidal mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes.
    Diabetes Obes Metab. 2023 Oct 27. doi: 10.1111/dom.15327.
    >> Share

  212. BOONPOR J, Pell JP, Ho FK, Celis-Morales C, et al
    In people with type 2 diabetes, sarcopenia is associated with the incidence of cardiovascular disease: A prospective cohort study from the UK Biobank.
    Diabetes Obes Metab. 2023 Oct 26. doi: 10.1111/dom.15338.
    >> Share

  213. SHARMA A, Marques P, Neuen BL, Fletcher RA, et al
    Timing of statistical benefit of canagliflozin in patients with type 2 diabetes for cardiovascular and heart failure outcomes: Insights from the CANVAS Program and CREDENCE trial.
    Diabetes Obes Metab. 2023 Oct 26. doi: 10.1111/dom.15340.
    >> Share

  214. SHAH VN, Al-Karadsheh A, Barnes C, Mandry J, et al
    Pharmacokinetic similarity of switching SAR341402 insulin aspart biosimilar and NovoLog insulin aspart versus continuous use of NovoLog in adults with type 1 diabetes: The GEMELLI X trial.
    Diabetes Obes Metab. 2023 Oct 25. doi: 10.1111/dom.15341.
    >> Share

  215. KIM JH, Lyu YS, Kim MK, Kim SY, et al
    Repeated detection of non-alcoholic fatty liver disease increases the incidence risk of type 2 diabetes in young adults.
    Diabetes Obes Metab. 2023 Oct 23. doi: 10.1111/dom.15304.
    >> Share

  216. SCARAMUZZA AE, Marigliano M, Bonfanti R, Cherubini V, et al
    Implementing Control-IQ technology after a virtual educational camp in children and adolescents with type 1 diabetes: Does time in range plateau over 1 year?
    Diabetes Obes Metab. 2023 Oct 23. doi: 10.1111/dom.15343.
    >> Share

  217. MA J, Yan X, Feng Q, Liu W, et al
    Ultra-rapid lispro improved postprandial glucose control compared to insulin lispro in predominantly Chinese patients with type 1 diabetes: A prospective, randomized, double-blind phase 3 study.
    Diabetes Obes Metab. 2023 Oct 23. doi: 10.1111/dom.15317.
    >> Share

  218. DIALLO A, Villard O, Carlos-Bolumbu M, Renard E, et al
    Effects of hypoglycaemic agents on reducing surrogate metabolic parameters for the prevention of cardiovascular events and death in patients with type 2 diabetes: A systematic review and meta-analysis.
    Diabetes Obes Metab. 2023 Oct 23. doi: 10.1111/dom.15335.
    >> Share

  219. BODIS K, Breuer S, Crepzia-Pevzner A, Zaharia OP, et al
    Impact of physical fitness and exercise training on subcutaneous adipose tissue beiging markers in humans with and without diabetes and a high-fat diet-fed mouse model.
    Diabetes Obes Metab. 2023 Oct 23. doi: 10.1111/dom.15322.
    >> Share

  220. KUATE DEFO A, Bakula V, Pisaturo A, Labos C, et al
    Diabetes, antidiabetic medications and risk of dementia: A systematic umbrella review and meta-analysis.
    Diabetes Obes Metab. 2023 Oct 23. doi: 10.1111/dom.15331.
    >> Share

  221. ZUCCHINI S, Ripoli C, Cherubini V, Coccioli MS, et al
    Nasal glucagon is safe and effective in children and adolescents with type 1 diabetes: A real-world prospective cohort study.
    Diabetes Obes Metab. 2023 Oct 22. doi: 10.1111/dom.15330.
    >> Share

  222. NIU S, Alkhuzam KA, Guan D, Jiao T, et al
    5-Year simulation of diabetes-related complications in people treated with tirzepatide or semaglutide versus insulin glargine.
    Diabetes Obes Metab. 2023 Oct 22. doi: 10.1111/dom.15332.
    >> Share

  223. LANDGRAF W, Owens DR, Frier BM, Bolli GB, et al
    Treatment responses to basal insulin glargine 300 U/ml and glargine 100 U/ml in newly defined subphenotypes of type 2 diabetes: A post hoc analysis of the EDITION 3 randomized clinical trial.
    Diabetes Obes Metab. 2023 Oct 20. doi: 10.1111/dom.15336.
    >> Share

  224. YANG Y, He L, Liu P, Wang J, et al
    Impact of a dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist tirzepatide on heart rate among patients with type 2 diabetes: A systematic review and pairwise and network meta-analysis.
    Diabetes Obes Metab. 2023 Oct 20. doi: 10.1111/dom.15342.
    >> Share

  225. SHABNAM S, Abner S, Gillies CL, Davies MJ, et al
    Effect of delay in treatment intensification in people with type 2 diabetes and suboptimal glycaemia after basal insulin initiation: A real-world observational study.
    Diabetes Obes Metab. 2023 Oct 19. doi: 10.1111/dom.15337.
    >> Share

  226. TACK W, De Cock AM, Dirinck EL, Bastijns S, et al
    Pathophysiological interactions between sarcopenia and type 2 diabetes: A two-way street influencing diagnosis and therapeutic options.
    Diabetes Obes Metab. 2023 Oct 18. doi: 10.1111/dom.15321.
    >> Share

  227. PATEL H, Khunti K, Rodbard HW, Bajaj HS, et al
    Gastrointestinal adverse events and weight reduction in people with type 2 diabetes treated with tirzepatide in the SURPASS clinical trials.
    Diabetes Obes Metab. 2023 Oct 18. doi: 10.1111/dom.15333.
    >> Share

  228. FOGHSGAARD S, Vedtofte L, Andersen ES, Bahne E, et al
    Liraglutide treatment for the prevention of glucose tolerance deterioration in women with prior gestational diabetes mellitus: A 52-week randomized controlled clinical trial.
    Diabetes Obes Metab. 2023 Oct 17. doi: 10.1111/dom.15306.
    >> Share

  229. ABUSHANAB D, Al-Badriyeh D, Marquina C, Liew D, et al
    Societal health and economic burden of cardiovascular diseases in the population with type 2 diabetes in Qatar. A 10-year forecasting model.
    Diabetes Obes Metab. 2023 Oct 16. doi: 10.1111/dom.15299.
    >> Share

  230. TSUKAMOTO S, Tanaka S, Yamada T, Uneda K, et al
    Effect of tirzepatide on glycaemic control and weight loss compared with other glucagon-like peptide-1 receptor agonists in Japanese patients with type 2 diabetes mellitus.
    Diabetes Obes Metab. 2023 Oct 12. doi: 10.1111/dom.15312.
    >> Share

  231. NESTI L, Pugliese NR, Santoni L, Armenia S, et al
    Distinct effects of type 2 diabetes and obesity on cardiopulmonary performance.
    Diabetes Obes Metab. 2023 Oct 12. doi: 10.1111/dom.15324.
    >> Share

  232. GOHLKE B, Reschke F, Lanzinger S, Boettcher C, et al
    Time trends towards earlier puberty in boys and girls with type 1 diabetes: Insights from the German Diabetes Prospective Follow-up (DPV) registry, 2000 to 2021.
    Diabetes Obes Metab. 2023 Oct 12. doi: 10.1111/dom.15315.
    >> Share

  233. LU J, Ying Z, Wang P, Fu M, et al
    Effects of continuous glucose monitoring on glycaemic control in type 2 diabetes: A systematic review and network meta-analysis of randomized controlled trials.
    Diabetes Obes Metab. 2023 Oct 12. doi: 10.1111/dom.15328.
    >> Share

  234. LEE HA, Park H
    Metabolically healthy obese individuals are still at high risk for diabetes: Application of the marginal structural model.
    Diabetes Obes Metab. 2023 Oct 12. doi: 10.1111/dom.15329.
    >> Share

  235. XIANG AH, Lin JC, Chow T, Martinez MP, et al
    Types of diabetes during pregnancy and risk of depression and anxiety in offspring from childhood to young adulthood.
    Diabetes Obes Metab. 2023 Oct 12. doi: 10.1111/dom.15308.
    >> Share

  236. JI L, Ahmann AJ, Ahren B, Capehorn MS, et al
    Proportion of participants with type 2 diabetes achieving a metabolic composite endpoint with once-weekly semaglutide treatment versus comparators: Post hoc pooled analysis from SUSTAIN 1-5, 7-10 and SUSTAIN China.
    Diabetes Obes Metab. 2023 Oct 12. doi: 10.1111/dom.15309.
    >> Share

  237. PERAKAKIS N, Bornstein SR, Birkenfeld AL, Linkermann A, et al
    Efficacy of finerenone in patients with type 2 diabetes, chronic kidney disease and altered markers of liver steatosis and fibrosis: A FIDELITY subgroup analysis.
    Diabetes Obes Metab. 2023 Oct 10. doi: 10.1111/dom.15305.
    >> Share

  238. LEOHR J, Dellva MA, LaBell E, Coutant DE, et al
    Ultra rapid lispro (Lyumjev(R)) shortens time to recovery from hyperglycaemia compared to Humalog(R) in individuals with type 1 diabetes on continuous subcutaneous insulin infusion.
    Diabetes Obes Metab. 2023 Oct 9. doi: 10.1111/dom.15307.
    >> Share

  239. YUAN K, Wu B, Zeng R, Zhou F, et al
    Construction and validation of a nomogram for predicting diabetes remission at 3 months after bariatric surgery in patients with obesity combined with type 2 diabetes mellitus.
    Diabetes Obes Metab. 2023 Oct 9. doi: 10.1111/dom.15303.
    >> Share

  240. KLIIM-HANSEN V, Johansson KS, Gasbjerg LS, Jimenez-Solem E, et al
    The impact of type 2 diabetes and glycaemic control on mortality and clinical outcomes in hospitalized patients with COVID-19 in the capital region of Denmark.
    Diabetes Obes Metab. 2023 Oct 5. doi: 10.1111/dom.15302.
    >> Share

  241. DAVIS TME, Davis W
    The relationship between glycated haemoglobin and blood glucose-lowering treatment trajectories in type 2 diabetes: The Fremantle Diabetes Study Phase II.
    Diabetes Obes Metab. 2023 Oct 5. doi: 10.1111/dom.15314.
    >> Share

  242. OSONOI T, Oura T, Hirase T
    Glycaemic control, body weight, and safety of tirzepatide versus dulaglutide by baseline glycated haemoglobin level in Japanese patients with type 2 diabetes: A subgroup analysis of the SURPASS J-mono study.
    Diabetes Obes Metab. 2023 Oct 4. doi: 10.1111/dom.15296.
    >> Share

  243. GUAN D, Lewis MO, Li P, Zhang Y, et al
    Incremental burden on health-related quality of life, health service utilization and direct medical expenditures associated with cognitive impairment among non-institutionalized people with diabetes aged 65 years and older.
    Diabetes Obes Metab. 2023 Oct 3. doi: 10.1111/dom.15313.
    >> Share

  244. AVGERINOS I, Karagiannis T, Matthews DR, Tsapas A, et al
    Effects of sodium-glucose co-transporter-2 inhibitors by background cardiovascular medications: A systematic review and meta-analysis.
    Diabetes Obes Metab. 2023;25:3020-3029.
    >> Share

  245. DOI Y, Hamano T, Yamaguchi S, Sakaguchi Y, et al
    Mediators between canagliflozin and renoprotection vary depending on patient characteristics: Insights from the CREDENCE trial.
    Diabetes Obes Metab. 2023;25:2944-2953.
    >> Share

  246. DWYER KM, Figtree P, Gupta A
    Therapeutic carbohydrate restriction and sodium-glucose transporter 2 inhibitors in chronic kidney disease: A potentially powerful combination.
    Diabetes Obes Metab. 2023;25:2791-2794.
    >> Share

  247. SONG SH, Frier BM
    Severe hypoglycaemia in adults presenting to a hospital emergency department: Clinical characteristics, comorbidities, and mortality outcomes.
    Diabetes Obes Metab. 2023;25:2824-2834.
    >> Share

  248. ZOU X, Luo Y, Huang Q, Zhu Z, et al
    Differential effect of interventions in patients with prediabetes stratified by a machine learning-based diabetes progression prediction model.
    Diabetes Obes Metab. 2023 Oct 1. doi: 10.1111/dom.15291.
    >> Share

    September 2023
  249. CHRISTENSEN M, Laugesen ELG, Bibby BM, Hansen KW, et al
    The glycaemic roller coaster phenomenon in type 1 diabetes.
    Diabetes Obes Metab. 2023 Sep 28. doi: 10.1111/dom.15297.
    >> Share

  250. HARRIS SB, Mohammedi K, Bertolini M, Carlyle M, et al
    Patient and physician perspectives and experiences of basal insulin titration in type 2 diabetes in the United States: Cross-sectional surveys.
    Diabetes Obes Metab. 2023 Sep 25. doi: 10.1111/dom.15240.
    >> Share

  251. DO QD, Haskova A, Radovnicka L, Konecna J, et al
    Comparison of Control-IQ and open-source AndroidAPS automated insulin delivery systems in adults with type 1 diabetes: The CODIAC study.
    Diabetes Obes Metab. 2023 Sep 25. doi: 10.1111/dom.15289.
    >> Share

  252. HONG T, Sun F, Wang Q, Chen X, et al
    Global burden of diabetes mellitus from 1990 to 2019 attributable to dietary factors: An analysis of the Global Burden of Disease Study 2019.
    Diabetes Obes Metab. 2023 Sep 25. doi: 10.1111/dom.15290.
    >> Share

  253. RADEMAKER D, van der Wel AWT, van Eekelen R, Voormolen DN, et al
    Continuous glucose monitoring metrics and pregnancy outcomes in insulin-treated diabetes: A post-hoc analysis of the GlucoMOMS trial.
    Diabetes Obes Metab. 2023 Sep 21. doi: 10.1111/dom.15276.
    >> Share

  254. BEA S, Son H, Bae JH, Cho SW, et al
    Risk of thyroid cancer associated with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: A population-based cohort study.
    Diabetes Obes Metab. 2023 Sep 21. doi: 10.1111/dom.15292.
    >> Share

  255. WAN EYF, Mathur S, Zhang R, Lam AHY, et al
    Long-term effects of coronavirus disease 2019 on diabetes complications and mortality in people with diabetes: Two cohorts in the UK and Hong Kong.
    Diabetes Obes Metab. 2023 Sep 21. doi: 10.1111/dom.15279.
    >> Share

  256. WANG W, Yan X, Cheng Z, Zhang Q, et al
    Efficacy and safety of adding once-weekly dulaglutide to basal insulin for inadequately controlled type 2 diabetes in Chinese patients (AWARD-CHN3): A randomized, double-blind, placebo-controlled, phase III trial.
    Diabetes Obes Metab. 2023 Sep 21. doi: 10.1111/dom.15263.
    >> Share

  257. SUGIMOTO T, Tokuda H, Miura H, Kawashima S, et al
    Longitudinal association of continuous glucose monitoring-derived metrics with cognitive decline in older adults with type 2 diabetes: A 1-year prospective observational study.
    Diabetes Obes Metab. 2023 Sep 21. doi: 10.1111/dom.15275.
    >> Share

  258. SHAO Y, Shi L, Nauman E, Price-Haywood E, et al
    Telehealth use and its impact on clinical outcomes in patients with type 2 diabetes during the COVID-19 pandemic.
    Diabetes Obes Metab. 2023 Sep 19. doi: 10.1111/dom.15293.
    >> Share

  259. DAVIS TME, Maxwell S, Chan C, Keen HI, et al
    The effect of empagliflozin and fenofibrate therapies, alone and in combination, on the serum urate concentration in hyperuricaemic type 2 diabetes.
    Diabetes Obes Metab. 2023 Sep 19. doi: 10.1111/dom.15295.
    >> Share

  260. JI L, Lu J, Gao L, Yan X, et al
    A randomized, double-blind, placebo controlled, phase 3 trial to evaluate the efficacy and safety of cetagliptin added to ongoing metformin therapy in patients with uncontrolled type 2 diabetes with metformin monotherapy.
    Diabetes Obes Metab. 2023 Sep 19. doi: 10.1111/dom.15274.
    >> Share

  261. DRENTHEN LCA, Ajie M, Bakker EA, Abbink EJ, et al
    Daily unstructured physical activity affects mean glucose, occurrence of hypoglycaemia and glucose variability in people with type 1 diabetes.
    Diabetes Obes Metab. 2023 Sep 18. doi: 10.1111/dom.15277.
    >> Share

  262. DAVIES MJ, Alibegovic AC, Kelkar P, Braae UC, et al
    Glycaemic control and weight outcomes after adding or switching to biphasic insulin aspart 30/70 in people with type 2 diabetes mellitus previously treated with basal-bolus insulin in UK clinical practice.
    Diabetes Obes Metab. 2023 Sep 18. doi: 10.1111/dom.15278.
    >> Share

  263. STEDMAN M, Robinson A, Dunn G, Meza-Torres B, et al
    Diabetes foot complications and standardized mortality rate in type 2 diabetes.
    Diabetes Obes Metab. 2023 Sep 18. doi: 10.1111/dom.15260.
    >> Share

  264. SIVALINGAM S, Wasehuus VS, Rotbain Curovic V, Blond MB, et al
    Albuminuria-lowering effect of adding semaglutide on top of empagliflozin in individuals with type 2 diabetes: A randomized and placebo-controlled study.
    Diabetes Obes Metab. 2023 Sep 18. doi: 10.1111/dom.15287.
    >> Share

  265. WANG J, Liu H, Yue G, Deng Y, et al
    Human placenta-derived mesenchymal stem cells ameliorate diabetic kidney disease by modulating the T helper 17 cell/ regulatory T-cell balance through the programmed death 1 / programmed death-ligand 1 pathway.
    Diabetes Obes Metab. 2023 Sep 18. doi: 10.1111/dom.15282.
    >> Share

  266. WILLIAMS KJ, Bashan E, Kruse C, Sritharan S, et al
    Time in range in patients with type 2 diabetes who are long-term users of d-Nav(R), an artificial intelligence-driven technology for autonomous titration of insulin dosing.
    Diabetes Obes Metab. 2023 Sep 18. doi: 10.1111/dom.15280.
    >> Share

  267. NADKARNI GN, Stapleton S, Takale D, Edwards K, et al
    Derivation and independent validation of kidneyintelX.dkd: A prognostic test for the assessment of diabetic kidney disease progression.
    Diabetes Obes Metab. 2023 Sep 18. doi: 10.1111/dom.15273.
    >> Share

  268. MARK-WAGSTAFF C, Deshmukh H, Wilmot EG, Walker N, et al
    Intermittently scanned continuous glucose monitoring and hypoglycaemia awareness in drivers with diabetes: Insights from the Association of British Clinical Diabetologists Nationwide audit.
    Diabetes Obes Metab. 2023 Sep 17. doi: 10.1111/dom.15283.
    >> Share

  269. BOYE KS, Lebrec J, Dib A, Heitmann E, et al
    The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Final patient-reported outcomes at 24 months.
    Diabetes Obes Metab. 2023 Sep 15. doi: 10.1111/dom.15145.
    >> Share

  270. RATZKI-LEEWING A, Black JE, Kahkoska AR, Ryan BL, et al
    Severe (level 3) hypoglycaemia occurrence in a real-world cohort of adults with type 1 or 2 diabetes mellitus (iNPHORM, United States).
    Diabetes Obes Metab. 2023 Sep 13. doi: 10.1111/dom.15268.
    >> Share

  271. GIORGINO F, Guerci B, Fuchtenbusch M, Lebrec J, et al
    The real-world observational prospective study of health outcomes with dulaglutide and liraglutide in patients with type 2 diabetes (TROPHIES): Final, 24-month analysis of time to first significant treatment change, treatment persistence and clinical
    Diabetes Obes Metab. 2023 Sep 12. doi: 10.1111/dom.15244.
    >> Share

  272. HANKOSKY ER, Wang H, Neff LM, Kan H, et al
    Tirzepatide reduces the predicted risk of developing type 2 diabetes in people with obesity or overweight: Post hoc analysis of the SURMOUNT-1 trial.
    Diabetes Obes Metab. 2023 Sep 12. doi: 10.1111/dom.15269.
    >> Share

  273. BRANDTS J, Tittel SR, Bramlage P, Danne T, et al
    Low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol in type 1 diabetes and type 2 diabetes: Lipid goal attainment in a large German-Austrian diabetes registry.
    Diabetes Obes Metab. 2023 Sep 11. doi: 10.1111/dom.15264.
    >> Share

  274. PIEBER TR, Asong M, Fluhr G, Holler V, et al
    Pharmacokinetic and pharmacodynamic properties of once-weekly insulin icodec in individuals with type 2 diabetes.
    Diabetes Obes Metab. 2023 Sep 11. doi: 10.1111/dom.15266.
    >> Share

  275. YU J, Sweeting AN, Gianacas C, Houston L, et al
    The effects of canagliflozin in type 2 diabetes in subgroups defined by population-specific body mass index: Insights from the CANVAS Program and CREDENCE trial.
    Diabetes Obes Metab. 2023 Sep 6. doi: 10.1111/dom.15267.
    >> Share

  276. KARAKASIS P, Patoulias D, Pamporis K, Popovic DS, et al
    Efficacy and safety of once-weekly versus once-daily basal insulin analogues in the treatment of type 2 diabetes mellitus: A systematic review and meta-analysis.
    Diabetes Obes Metab. 2023 Sep 5. doi: 10.1111/dom.15259.
    >> Share

  277. RAJEEV SP, Roberts CA, Brown E, Sprung VS, et al
    No evidence of compensatory changes in energy balance, despite reductions in body weight and liver fat, during dapagliflozin treatment in type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled, cross-over trial (ENERGIZE).
    Diabetes Obes Metab. 2023 Sep 5. doi: 10.1111/dom.15257.
    >> Share

  278. NAKAJIMA H, Okada H, Yoshimura Y, Tanaka T, et al
    Younger patients and low c-peptide immunoreactivity index but not nutritional states affect fasting blood ketone levels in Japanese with type 1 diabetes after sodium-glucose cotransporter 2 inhibitor administration.
    Diabetes Obes Metab. 2023 Sep 5. doi: 10.1111/dom.15262.
    >> Share

  279. JI L, Lu J, Gao L, Ying C, et al
    Efficacy and safety of cetagliptin as monotherapy in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled phase 3 trial.
    Diabetes Obes Metab. 2023 Sep 3. doi: 10.1111/dom.15261.
    >> Share

  280. FINEMAN MS, Bryant CLN, Colbert K, Jozefiak TH, et al
    First-in-human study of a pharmacological duodenal exclusion therapy shows reduced postprandial glucose and insulin and increased bile acid and gut hormone concentrations.
    Diabetes Obes Metab. 2023;25:2447-2456.
    >> Share

  281. PRATT E, Ma X, Liu R, Robins D, et al
    Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants.
    Diabetes Obes Metab. 2023;25:2634-2641.
    >> Share

  282. LE ROUX CW, Hankosky ER, Wang D, Malik R, et al
    Tirzepatide 10 and 15 mg compared with semaglutide 2.4 mg for the treatment of obesity: An indirect treatment comparison.
    Diabetes Obes Metab. 2023;25:2626-2633.
    >> Share

  283. BANERJEE M, Pal R, Maisnam I, Chowdhury S, et al
    Serum uric acid lowering and effects of sodium-glucose cotransporter-2 inhibitors on gout: A meta-analysis and meta-regression of randomized controlled trials.
    Diabetes Obes Metab. 2023;25:2697-2703.
    >> Share

  284. SHIN W, Hompesch M, Byeon J, Kang S, et al
    Safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of the novel long-acting glucagon analogue HM15136 in overweight and obese patients with co-morbidities.
    Diabetes Obes Metab. 2023;25:2723-2733.
    >> Share

  285. URVA S, O'Farrell L, Du Y, Loh MT, et al
    The novel GIP, GLP-1 and glucagon receptor agonist retatrutide delays gastric emptying.
    Diabetes Obes Metab. 2023;25:2784-2788.
    >> Share

  286. KUNZLER J, Zuger T, Stettler C, Laimer MW, et al
    Comparing the technical reliability and insulin dosing of a "do-it-yourself artificial pancreas" with a commercial hybrid closed-loop system in a "shadow-mode" scenario: An exploratory study.
    Diabetes Obes Metab. 2023;25:2780-2783.
    >> Share

  287. GRADINARIU V, Ard J, van Dam RM
    Effects of dietary quality, physical activity and weight loss on glucose homeostasis in persons with and without prediabetes in the PREMIER trial.
    Diabetes Obes Metab. 2023;25:2714-2722.
    >> Share

  288. MEDSCI KKF, Schnecke V, Haase CL, Harder-Lauridsen NM, et al
    Weight change and risk of obesity-related complications: A retrospective population-based cohort study of a UK primary care database.
    Diabetes Obes Metab. 2023;25:2669-2679.
    >> Share

  289. TAYLOR SI, Montasser ME, Yuen AH, Fan H, et al
    Acute pharmacodynamic responses to exenatide: Drug-induced increases in insulin secretion and glucose effectiveness.
    Diabetes Obes Metab. 2023;25:2586-2594.
    >> Share

  290. CASTANEDA J, Arrieta A, van den Heuvel T, Cohen O, et al
    The significance of coefficient of variation as a measure of hypoglycaemia risk and glycaemic control in real world users of the automated insulin delivery MiniMed 780G system.
    Diabetes Obes Metab. 2023;25:2545-2552.
    >> Share

  291. KEIDAI Y, Yoshiji S, Hasebe M, Minamino H, et al
    Stabilization of kidney function and reduction in heart failure events with sodium-glucose co-transporter 2 inhibitors: A meta-analysis and meta-regression analysis.
    Diabetes Obes Metab. 2023;25:2505-2513.
    >> Share

  292. WU H, Liu X, Jiang W, Hu C, et al
    The rest-activity rhythm, genetic susceptibility and risk of type 2 diabetes: A prospective study in UK Biobank.
    Diabetes Obes Metab. 2023 Sep 1. doi: 10.1111/dom.15236.
    >> Share

    August 2023
  293. KIMURA T, Katakura Y, Shimoda M, Kawasaki F, et al
    Comparison of clinical efficacy and safety of weekly glucagon-like peptide-1 receptor agonists dulaglutide and semaglutide in Japanese patients with type 2 diabetes: Randomized, parallel-group, multicentre, open-label trial (COMING study).
    Diabetes Obes Metab. 2023 Aug 30. doi: 10.1111/dom.15258.
    >> Share

  294. CAMPBELL MD, Alobaid AM, Hopkins M, Dempsey PC, et al
    Interrupting prolonged sitting with frequent short bouts of light-intensity activity in people with type 1 diabetes improves glycaemic control without increasing hypoglycaemia: The SIT-LESS randomised controlled trial.
    Diabetes Obes Metab. 2023 Aug 25. doi: 10.1111/dom.15254.
    >> Share

  295. YABE D, Shiki K, Homma G, Meinicke T, et al
    Efficacy and safety of the sodium-glucose co-transporter-2 inhibitor empagliflozin in elderly Japanese adults (>/=65 years) with type 2 diabetes: A randomized, double-blind, placebo-controlled, 52-week clinical trial (EMPA-ELDERLY).
    Diabetes Obes Metab. 2023 Aug 25. doi: 10.1111/dom.15249.
    >> Share

  296. GUO L, Li L, Yu Q, Wang N, et al
    Safety and effectiveness of dulaglutide in Chinese adults with type 2 diabetes mellitus in a real-world setting: A prospective, observational post-marketing study.
    Diabetes Obes Metab. 2023 Aug 23. doi: 10.1111/dom.15252.
    >> Share

  297. MOLLO A, Vlacho B, Gratacos M, Mata-Cases M, et al
    A multicomponent health care intervention is associated with improved glycaemic control in subjects with poorly controlled type 2 diabetes compared with routine care: The INTEGRA study.
    Diabetes Obes Metab. 2023 Aug 22. doi: 10.1111/dom.15250.
    >> Share

  298. CHE M, Xia Z, Jiang D, Wang Y, et al
    Impact of sarcosine on diabetic retinopathy: Findings based on weighted gene co-expression network analysis and machine learning techniques.
    Diabetes Obes Metab. 2023 Aug 22. doi: 10.1111/dom.15243.
    >> Share

  299. LIU Y, Wang J, Xu F, Zhang S, et al
    A J-shaped relationship between ketones and the risk of diabetic kidney disease in patients with type 2 diabetes: New insights from a cross-sectional study.
    Diabetes Obes Metab. 2023 Aug 22. doi: 10.1111/dom.15231.
    >> Share


  300. Correction to "Patient perspectives and experiences with basal insulin titration in type 2 diabetes in the United States: A cross-sectional survey".
    Diabetes Obes Metab. 2023 Aug 17. doi: 10.1111/dom.15253.
    >> Share

  301. MULLER A, Moser O, Sternad C, Aziz F, et al
    Effects of 8 weeks of aerobic endurance training on functional capacity and metabolic variables in people with type 1 diabetes: A secondary outcome analysis of the ULTRAFLEXI-1 study.
    Diabetes Obes Metab. 2023 Aug 14. doi: 10.1111/dom.15245.
    >> Share

  302. MCINNES N, Hall S, Lochnan HA, Harris SB, et al
    Diabetes remission and relapse following an intensive metabolic intervention combining insulin glargine/lixisenatide, metformin and lifestyle approaches: Results of a randomised controlled trial.
    Diabetes Obes Metab. 2023 Aug 14. doi: 10.1111/dom.15234.
    >> Share

  303. ASHRAF MT, Ahmed Rizvi SH, Kashif MAB, Shakeel Khan MK, et al
    Efficacy of anti-CD3 monoclonal antibodies in delaying the progression of recent-onset type 1 diabetes mellitus: A systematic review, meta-analyses and meta-regression.
    Diabetes Obes Metab. 2023 Aug 14. doi: 10.1111/dom.15237.
    >> Share

  304. HALS IK, Balasuriya C, Casas R, Ludvigsson J, et al
    A 1-year pilot study of intralymphatic injections of GAD-alum in individuals with latent autoimmune diabetes in adults (LADA) with signs of high immunity: No safety concerns and resemblance to juvenile type 1 diabetes.
    Diabetes Obes Metab. 2023 Aug 14. doi: 10.1111/dom.15239.
    >> Share

  305. HEERSPINK HJL, Vart P, Jongs N, Neuen BL, et al
    Estimated lifetime benefit of novel pharmacological therapies in patients with type 2 diabetes and chronic kidney disease: A joint analysis of randomized controlled clinical trials.
    Diabetes Obes Metab. 2023 Aug 14. doi: 10.1111/dom.15232.
    >> Share

  306. EDD SN, Castaneda J, Choudhary P, Kolassa R, et al
    Twelve-month results of the ADAPT randomized controlled trial: Reproducibility and sustainability of advanced hybrid closed-loop therapy outcomes versus conventional therapy in adults with type 1 diabetes.
    Diabetes Obes Metab. 2023 Aug 8. doi: 10.1111/dom.15217.
    >> Share

  307. ISAKSEN AA, Sandbaek A, Skriver MV, Bjerg L, et al
    Glucose-lowering drug use in migrants and native Danes with type 2 diabetes: Disparities in combination therapy and drug types.
    Diabetes Obes Metab. 2023 Aug 7. doi: 10.1111/dom.15230.
    >> Share

  308. BELL DSH, Jerkins T
    In praise of pioglitazone: An economically efficacious therapy for type 2 diabetes and other manifestations of the metabolic syndrome.
    Diabetes Obes Metab. 2023 Aug 3. doi: 10.1111/dom.15222.
    >> Share

  309. NIEUWLAND AJ, Waibel FWA, Flury A, Lisy M, et al
    Initial antibiotic therapy for postoperative moderate or severe diabetic foot infections: Broad versus narrow spectrum, empirical versus targeted.
    Diabetes Obes Metab. 2023 Aug 2. doi: 10.1111/dom.15228.
    >> Share

  310. KAN M, Fu H, Xu Y, Yue Z, et al
    Effects of once-weekly glucagon-like peptide-1 receptor agonists on type 2 diabetes mellitus complicated with coronary artery disease: Potential role of the renin-angiotensin system.
    Diabetes Obes Metab. 2023 Aug 2. doi: 10.1111/dom.15219.
    >> Share

  311. MANNUCCI E, Silverii GA
    Cardiovascular prevention with glucose-lowering drugs in type 2 diabetes: An evidence-based approach to the categories of primary and secondary prevention.
    Diabetes Obes Metab. 2023 Aug 2. doi: 10.1111/dom.15226.
    >> Share

  312. HOOGENDOORN M, Galekop M, van Baal P
    The lifetime health and economic burden of obesity in five European countries: what is the potential impact of prevention?
    Diabetes Obes Metab. 2023;25:2351-2361.
    >> Share

  313. SILVER HJ, Olson D, Mayfield D, Wright P, et al
    Effect of the glucagon-like peptide-1 receptor agonist liraglutide, compared to caloric restriction, on appetite, dietary intake, body fat distribution and cardiometabolic biomarkers: A randomized trial in adults with obesity and prediabetes.
    Diabetes Obes Metab. 2023;25:2340-2350.
    >> Share

  314. SRIDHAR VS, Neuen BL, Fletcher RA, Slee A, et al
    Kidney protection with canagliflozin: A combined analysis of the randomized CANVAS program and CREDENCE trials.
    Diabetes Obes Metab. 2023;25:2331-2339.
    >> Share

  315. SEN T, Curovic VR, Jongs N, Laverman GD, et al
    Effects of albuminuria-lowering treatments on inflammation markers: A post hoc analysis from the ROTATE trials.
    Diabetes Obes Metab. 2023;25:2413-2418.
    >> Share

  316. SMEIJER JD, Kohan DE, de Zeeuw D, Heerspink HJL, et al
    Diuretic medication and change in fluid retention biomarkers during treatment with the endothelin receptor antagonist atrasentan.
    Diabetes Obes Metab. 2023;25:2419-2422.
    >> Share

  317. BLUHER M, Aras M, Aronne LJ, Batterham RL, et al
    New insights into the treatment of obesity.
    Diabetes Obes Metab. 2023;25:2058-2072.
    >> Share

  318. GOH SY, Kosiborod MN, Lam CSP, Cavender MA, et al
    Lower risk of cardiovascular events and death associated with initiation of sodium-glucose cotransporter-2 inhibitors versus sulphonylureas: Analysis from the CVD-REAL 2 study.
    Diabetes Obes Metab. 2023;25:2402-2409.
    >> Share

  319. BJORNER JB, Larsen S, Lubker C, Holst-Hansen T, et al
    The improved health utility of once-weekly subcutaneous semaglutide 2.4 mg compared with placebo in the STEP 1-4 obesity trials.
    Diabetes Obes Metab. 2023;25:2142-2150.
    >> Share

  320. CUMMINGS C, Jiang A, Sheehan A, Ferraz-Bannitz R, et al
    Continuous glucose monitoring in patients with post-bariatric hypoglycaemia reduces hypoglycaemia and glycaemic variability.
    Diabetes Obes Metab. 2023;25:2191-2202.
    >> Share

    July 2023
  321. ROMADLON DS, Tu YK, Chen YC, Hasan F, et al
    Comparative efficacy of digitally assisted interventions for glycated haemoglobin levels among patients with type 2 diabetes: A systematic review and component network Meta-Analysis.
    Diabetes Obes Metab. 2023 Jul 31. doi: 10.1111/dom.15227.
    >> Share

  322. PARK S, Jeong HE, Bea S, Yu OHY, et al
    Safety of sodium-glucose co-transporter-2 inhibitors on amputation across categories of baseline cardiovascular disease and diuretics use in patients with type 2 diabetes.
    Diabetes Obes Metab. 2023 Jul 28. doi: 10.1111/dom.15221.
    >> Share

  323. VAN HULTEN V, Driessen JHM, Starup-Linde JK, Al-Mashhadi ZK, et al
    The associations of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as add-on to metformin with fracture risk in patients with type 2 diabetes mellitus.
    Diabetes Obes Metab. 2023 Jul 28. doi: 10.1111/dom.15220.
    >> Share

  324. LI R, Chen JX, Lu Q, Geng TT, et al
    Associations of lipoprotein subclasses with risk of all-cause and cardiovascular disease mortality in individuals with type 2 diabetes: A prospective cohort study.
    Diabetes Obes Metab. 2023 Jul 26. doi: 10.1111/dom.15224.
    >> Share

  325. BARRON E, Khunti K, Wright AK, Ashcroft DM, et al
    Impact of the COVID-19 pandemic on new diagnoses of type 2 diabetes in England.
    Diabetes Obes Metab. 2023 Jul 25. doi: 10.1111/dom.15223.
    >> Share

  326. UNSWORTH R, Avari P, Lett AM, Oliver N, et al
    Adaptive bolus calculators for people with type 1 diabetes: A systematic review.
    Diabetes Obes Metab. 2023 Jul 24. doi: 10.1111/dom.15204.
    >> Share

  327. VERHULST CEM, van Heck JIP, Fabricius TW, Stienstra R, et al
    Hypoglycaemia induces a sustained pro-inflammatory response in people with type 1 diabetes and healthy controls.
    Diabetes Obes Metab. 2023 Jul 24. doi: 10.1111/dom.15205.
    >> Share

  328. ISMAIL HM, Barua S, Wang J, Sabharwal A, et al
    Baseline leptin predicts response to metformin in adolescents with type 1 diabetes and increased body mass index.
    Diabetes Obes Metab. 2023 Jul 24. doi: 10.1111/dom.15218.
    >> Share

  329. AL MALKI F, El Damanhoury B, Othman A, Alghamdi Z, et al
    Evaluating the clinical effectiveness and safety of insulin glargine 300 U/mL in individuals with type 2 diabetes uncontrolled on basal insulin: A real-world evidence study from Saudi Arabia (EVOLUTION).
    Diabetes Obes Metab. 2023 Jul 24. doi: 10.1111/dom.15178.
    >> Share

  330. HUANG F, Ji X, Wang Z, Yin Y, et al
    Fat-to-muscle ratio is associated with insulin resistance and cardiometabolic disorders in adults with type 1 diabetes mellitus.
    Diabetes Obes Metab. 2023 Jul 17. doi: 10.1111/dom.15212.
    >> Share

  331. LIAO WL, Huang YN, Chang YW, Liu TY, et al
    Combining polygenic risk scores and human leukocyte antigen variants for personalized risk assessment of type 1 diabetes in the Taiwanese population.
    Diabetes Obes Metab. 2023 Jul 17. doi: 10.1111/dom.15187.
    >> Share

  332. RON I, Mdah R, Zemet R, Ulman RY, et al
    Adipose tissue-derived FABP4 mediates glucagon-stimulated hepatic glucose production in gestational diabetes.
    Diabetes Obes Metab. 2023 Jul 14. doi: 10.1111/dom.15214.
    >> Share

  333. ZHOU C, Dong C, Wang Q, Fu C, et al
    Healthy lifestyle and all-cause and cause-specific dementia in individuals with type 2 diabetes and the roles of diabetes duration and insulin use in UK Biobank cohort.
    Diabetes Obes Metab. 2023 Jul 12. doi: 10.1111/dom.15215.
    >> Share

  334. BASSAND JP, Virdone S, Camm AJ, Fox KAA, et al
    Oral anticoagulation across diabetic subtypes in patients with newly diagnosed atrial fibrillation: A report from the GARFIELD-AF registry.
    Diabetes Obes Metab. 2023 Jul 12. doi: 10.1111/dom.15202.
    >> Share

  335. KARAKUS KE, Shah VN, Klonoff D, Akturk HK, et al
    Changes in the glycaemia risk index and its association with other continuous glucose monitoring metrics after initiation of an automated insulin delivery system in adults with type 1 diabetes.
    Diabetes Obes Metab. 2023 Jul 10. doi: 10.1111/dom.15208.
    >> Share

  336. CHERNEY DZI, Bhatt DL, Szarek M, Sun F, et al
    Effect of sotagliflozin on albuminuria in patients with type 2 diabetes and chronic kidney disease.
    Diabetes Obes Metab. 2023 Jul 10. doi: 10.1111/dom.15203.
    >> Share

  337. WU Y, Cheng S, Gu H, Yang K, et al
    Variants within the LPL gene confer susceptility to diabetic kidney disease and rapid decline in kidney function in Chinese patients with type 2 diabetes.
    Diabetes Obes Metab. 2023 Jul 10. doi: 10.1111/dom.15199.
    >> Share

  338. FUJIHARA K, Khin L, Murai K, Yamazaki Y, et al
    Relationship between the magnitude of body mass index reductions and remission in patients with type 2 diabetes in real world settings: Analysis of nationwide patient registry in Japan (JDDM74).
    Diabetes Obes Metab. 2023 Jul 7. doi: 10.1111/dom.15206.
    >> Share

  339. ROTBAIN CUROVIC V, Houlind MB, Kroonen MYAM, Jongs N, et al
    Overall and inter-individual effect of four different drug classes on soluble urokinase plasminogen activator receptor in type 1 and type 2 diabetes.
    Diabetes Obes Metab. 2023 Jul 7. doi: 10.1111/dom.15209.
    >> Share

  340. HALVORSEN YD, Conery AL, Lock JP, Zhou W, et al
    Bexagliflozin as an adjunct to metformin for the treatment of type 2 diabetes in adults: A 24-week, randomized, double-blind, placebo-controlled trial.
    Diabetes Obes Metab. 2023 Jul 6. doi: 10.1111/dom.15192.
    >> Share

  341. NGUYEN BN, Mital S, Bugden S, Nguyen HV, et al
    Cost-effectiveness of canagliflozin and dapagliflozin for treatment of patients with chronic kidney disease and type 2 diabetes.
    Diabetes Obes Metab. 2023 Jul 6. doi: 10.1111/dom.15201.
    >> Share

  342. RATZKI-LEEWING AA, Black JE, Ryan BL, Zou G, et al
    Development and validation of a real-world model to predict 1-year Level 3 (severe) hypoglycaemia risk in adults with diabetes (the iNPHORM study, United States).
    Diabetes Obes Metab. 2023 Jul 6. doi: 10.1111/dom.15186.
    >> Share

  343. BELL DSH, McGill JB, Jerkins T
    Management of the 'wicked' combination of heart failure and chronic kidney disease in the patient with diabetes.
    Diabetes Obes Metab. 2023 Jul 6. doi: 10.1111/dom.15181.
    >> Share

  344. RIGATO M, Fadini GP, Avogaro A
    Safety of sodium-glucose cotransporter 2 inhibitors in elderly patients with type 2 diabetes: A meta-analysis of randomized controlled trials.
    Diabetes Obes Metab. 2023 Jul 4. doi: 10.1111/dom.15193.
    >> Share

  345. ROSSING P, Anker SD, Filippatos G, Pitt B, et al
    The impact of obesity on cardiovascular and kidney outcomes in patients with chronic kidney disease and type 2 diabetes treated with finerenone: Post hoc analysis of the FIDELITY study.
    Diabetes Obes Metab. 2023 Jul 4. doi: 10.1111/dom.15197.
    >> Share

  346. JURGENS M, Schou M, Hasbak P, Kjaer A, et al
    The effects of empagliflozin on measured glomerular filtration rate and estimated extracellular and plasma volumes in patients with type 2 diabetes.
    Diabetes Obes Metab. 2023 Jul 3. doi: 10.1111/dom.15183.
    >> Share

  347. ABRAHAMI D, D'Andrea E, Yin H, Kim SC, et al
    Contemporary trends in the utilization of second-line pharmacological therapies for type 2 diabetes in the United States and the United Kingdom.
    Diabetes Obes Metab. 2023 Jul 3. doi: 10.1111/dom.15196.
    >> Share

  348. GIORDA CB, Gnavi R, Tartaglino B, Favella L, et al
    An update on the incidence of type 1 diabetes during the COVID-19 pandemic years.
    Diabetes Obes Metab. 2023 Jul 3. doi: 10.1111/dom.15182.
    >> Share

  349. NICHOLAS SB, Daratha KB, Alicic RZ, Jones CR, et al
    Prescription of guideline-directed medical therapies in patients with diabetes and chronic kidney disease from the CURE-CKD Registry, 2019-2020.
    Diabetes Obes Metab. 2023 Jul 3. doi: 10.1111/dom.15194.
    >> Share

  350. CIARALDI TP, Boeder SC, Mudaliar SR, Giovannetti ER, et al
    Astaxanthin, a natural antioxidant, lowers cholesterol and markers of cardiovascular risk in individuals with prediabetes and dyslipidaemia.
    Diabetes Obes Metab. 2023;25:1985-1994.
    >> Share

  351. YI TW, Wong MMY, Neuen BL, Arnott C, et al
    Effects of canagliflozin on cardiovascular and kidney events in patients with chronic kidney disease with and without peripheral arterial disease: Integrated analysis from the CANVAS Program and CREDENCE trial.
    Diabetes Obes Metab. 2023;25:2043-2047.
    >> Share

  352. YAZAWA R, Ishida M, Balavarca Y, Hennige AM, et al
    A randomized Phase I study of the safety, tolerability, pharmacokinetics and pharmacodynamics of BI 456906, a dual glucagon receptor/glucagon-like peptide-1 receptor agonist, in healthy Japanese men with overweight/obesity.
    Diabetes Obes Metab. 2023;25:1973-1984.
    >> Share

  353. YILDIRIM SIMSIR I, Tuysuz B, Ozbek MN, Tanrikulu S, et al
    Clinical features of generalized lipodystrophy in Turkey: A cohort analysis.
    Diabetes Obes Metab. 2023;25:1950-1963.
    >> Share

  354. MCEWAN P, Foos V, Martin B, Chen J, et al
    Estimating the value of sodium-glucose cotransporter-2 inhibitors within the context of contemporary guidelines and the totality of evidence.
    Diabetes Obes Metab. 2023;25:1830-1838.
    >> Share

  355. JHUND PS
    Improving heart failure outcomes with sodium-glucose cotransporter 2 inhibitors in different patient groups.
    Diabetes Obes Metab. 2023;25 Suppl 3:26-32.
    >> Share

    June 2023
  356. LAURSEN JC, Rotbain Curovic V, Kroonen MYAM, Jongs N, et al
    Effects of baricitinib, empagliflozin, linagliptin and telmisartan on cardiovascular autonomic neuropathy in type 1 diabetes: An exploratory, randomized, open-label, crossover trial.
    Diabetes Obes Metab. 2023 Jun 29. doi: 10.1111/dom.15180.
    >> Share

  357. ZENG J, Gan S, Mi N, Liu Y, et al
    Diabetes remission in drug-naive patients with type 2 diabetes after dorzagliatin treatment: A prospective cohort study.
    Diabetes Obes Metab. 2023 Jun 29. doi: 10.1111/dom.15179.
    >> Share

  358. ZHAO L, Bidargaddi N, Vakulin A, Li W, et al
    A micro-randomized pilot study to examine the impact of just-in-time nudging on after-dinner snacking in adults with type 2 diabetes: A study protocol.
    Diabetes Obes Metab. 2023 Jun 29. doi: 10.1111/dom.15159.
    >> Share

  359. KOSHIZAKA M, Ishibashi R, Ishikawa K, Shoji M, et al
    Urinary alpha1 microglobulin level is useful for selecting sodium-glucose transporter 2 inhibitor or metformin for visceral fat reduction in patients with type 2 diabetes.
    Diabetes Obes Metab. 2023 Jun 29. doi: 10.1111/dom.15188.
    >> Share

  360. RILEY DR, Essa H, Austin P, Preston F, et al
    All-cause mortality and cardiovascular outcomes with sodium-glucose Co-transporter 2 inhibitors, glucagon-like peptide-1 receptor agonists and with combination therapy in people with type 2 diabetes.
    Diabetes Obes Metab. 2023 Jun 29. doi: 10.1111/dom.15185.
    >> Share

  361. SCHECHTER M, Melzer Cohen C, Zelter T, Yanuv I, et al
    Risk of hospitalization with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes lacking evidence of chronic kidney disease: Real-world data.
    Diabetes Obes Metab. 2023 Jun 29. doi: 10.1111/dom.15172.
    >> Share

  362. RETNAKARAN R, Pu J, Emery A, Kramer CK, et al
    Baseline determinants of remission of type 2 diabetes in response to short-term insulin-based therapy: The pivotal role of beta-cell function.
    Diabetes Obes Metab. 2023 Jun 28. doi: 10.1111/dom.15073.
    >> Share

  363. WANG Y, Lu J, Ni J, Wang M, et al
    Association between glycaemia risk index (GRI) and diabetic retinopathy in type 2 diabetes: A cohort study.
    Diabetes Obes Metab. 2023 Jun 23. doi: 10.1111/dom.15068.
    >> Share

  364. XUE P, Tan X, Benedict C
    Association of socioeconomic deprivation with sleep health in patients with type 2 diabetes.
    Diabetes Obes Metab. 2023 Jun 21. doi: 10.1111/dom.15190.
    >> Share

  365. SHAO Y, Shi L, Nauman E, Price-Haywood E, et al
    Trends and disparities in telehealth use among Louisiana Medicaid beneficiaries with type 2 diabetes.
    Diabetes Obes Metab. 2023 Jun 20. doi: 10.1111/dom.15155.
    >> Share

  366. PARK HK, Kim KA, Min KW, Sohn TS, et al
    Effects of dapagliflozin compared with glimepiride on body composition in Asian patients with type 2 diabetes inadequately controlled with metformin: The BEYOND study.
    Diabetes Obes Metab. 2023 Jun 20. doi: 10.1111/dom.15164.
    >> Share

  367. ASANO M, Sekikawa A, Sugeno M, Matsuoka O, et al
    Safety/tolerability, efficacy and pharmacokinetics of 600-mug cotadutide in Japanese type 2 diabetes patients with a body mass index of 25 kg/m(2) or higher: A phase I, randomized, double-blind, placebo-controlled study.
    Diabetes Obes Metab. 2023 Jun 19. doi: 10.1111/dom.15107.
    >> Share

  368. YU HJ, Ho M, Chau PH, Fong DYT, et al
    Trajectories of fasting glucose and glycated haemoglobin in obese and non-obese incident diabetes: Results from two large cohort studies.
    Diabetes Obes Metab. 2023 Jun 19. doi: 10.1111/dom.15173.
    >> Share

  369. DAVIES MJ, Alibegovic AC, Jensen AB, Munikrishnappa R, et al
    Real-world study of ethnic differences in glycaemic control and clinical characteristics among insulin-naive people with type 2 diabetes initiating biphasic insulin aspart 30/70: A retrospective, observational cohort study in England.
    Diabetes Obes Metab. 2023 Jun 19. doi: 10.1111/dom.15165.
    >> Share

  370. LIN Y, Shao H, Fonseca V, Anderson AH, et al
    A prediction model on incident chronic kidney disease among individuals with type 2 diabetes in the United States.
    Diabetes Obes Metab. 2023 Jun 19. doi: 10.1111/dom.15177.
    >> Share

  371. ALSHANNAQ H, Cogswell G, Pollock RF, Ahmed W, et al
    Cost-utility of real-time continuous glucose monitoring versus self-monitoring of blood glucose and intermittently scanned continuous glucose monitoring in people with type 1 diabetes receiving multiple daily insulin injections in Denmark.
    Diabetes Obes Metab. 2023 Jun 19. doi: 10.1111/dom.15158.
    >> Share

  372. ZUSI C, Csermely A, Rinaldi E, Bertoldo K, et al
    Crosstalk between genetic variability of adiponectin and leptin, glucose-insulin system and subclinical atherosclerosis in patients with newly diagnosed type 2 diabetes. The Verona Newly Diagnosed Type 2 Diabetes Study 14.
    Diabetes Obes Metab. 2023 Jun 19. doi: 10.1111/dom.15152.
    >> Share

  373. MARTINOT JB, Le-Dong NN, Borel AL, Tamisier R, et al
    Respiratory effort during sleep and the rate of prevalent type 2 diabetes in obstructive sleep apnoea.
    Diabetes Obes Metab. 2023 Jun 13. doi: 10.1111/dom.15169.
    >> Share

  374. RITZEL R, Ghosh S, Emral R, Malek R, et al
    Comparative efficacy and safety of Gla-300 versus IDegAsp in insulin-naive people with type 2 diabetes mellitus uncontrolled on oral anti-diabetics.
    Diabetes Obes Metab. 2023 Jun 13. doi: 10.1111/dom.15121.
    >> Share

  375. BEA S, Choi A, Kim JH, Cho YM, et al
    Risk of breakthrough SARS-CoV-2 infection and clinical outcomes among vaccinated patients with type 2 diabetes.
    Diabetes Obes Metab. 2023 Jun 13. doi: 10.1111/dom.15163.
    >> Share

  376. DEO SV, Al-Kindi S, Motairek I, Elgudin YE, et al
    Neighbourhood-level social deprivation and the risk of recurrent heart failure hospitalizations in type 2 diabetes.
    Diabetes Obes Metab. 2023 Jun 13. doi: 10.1111/dom.15174.
    >> Share

  377. COLLIER A, Curran C, Cameron L, Wild SH, et al
    Liver fibrosis markers and all cause mortality in people with type 2 diabetes: A population based study (The Ayrshire Diabetes Outcomes Cohort (ADOC) Study).
    Diabetes Obes Metab. 2023 Jun 13. doi: 10.1111/dom.15153.
    >> Share

  378. SAXENA AR, Frias JP, Gorman DN, Lopez RN, et al
    Tolerability, safety and pharmacodynamics of oral, small-molecule glucagon-like peptide-1 receptor agonist danuglipron for type 2 diabetes: A 12-week, randomized, placebo-controlled, Phase 2 study comparing different dose-escalation schemes.
    Diabetes Obes Metab. 2023 Jun 13. doi: 10.1111/dom.15168.
    >> Share

  379. ZHANG YN, Dai YJ, Cui Y, Wu Q, et al
    Diabetes, fasting blood glucose and the efficacy of remote ischaemic conditioning: A secondary analysis of the RICAMIS trial.
    Diabetes Obes Metab. 2023 Jun 8. doi: 10.1111/dom.15156.
    >> Share

  380. HEINRICH NS, Pedersen RP, Vestergaard MB, Lindberg U, et al
    Evaluation of the effects of ezetimibe on albuminuria and kidney fat in individuals with type 2 diabetes and chronic kidney disease.
    Diabetes Obes Metab. 2023 Jun 6. doi: 10.1111/dom.15146.
    >> Share

  381. DE LUCA M, Zese M, Bandini G, Chiappetta S, et al
    Metabolic bariatric surgery as a therapeutic option for patients with type 2 diabetes: A meta-analysis and network meta-analysis of randomized controlled trials.
    Diabetes Obes Metab. 2023 Jun 5. doi: 10.1111/dom.15117.
    >> Share

  382. GRASSI B, Gomez AM, Calliari LE, Franco D, et al
    Real-world performance of the MiniMed 780G advanced hybrid closed loop system in Latin America: Substantial improvement in glycaemic control with each technology iteration of the MiniMed automated insulin delivery system.
    Diabetes Obes Metab. 2023;25:1688-1697.
    >> Share

  383. NERILD HH, Bronden A, Gether IM, Hellmann PH, et al
    Liraglutide changes postprandial responses of gut hormones involved in the regulation of gallbladder motility.
    Diabetes Obes Metab. 2023;25:1632-1637.
    >> Share

  384. ROSENSTOCK J, Kolkailah AA, McGuire DK, Espeland MA, et al
    Incident and recurrent hypoglycaemia with linagliptin and glimepiride over a median of 6 years in the CAROLINA cardiovascular outcome trial.
    Diabetes Obes Metab. 2023;25:1453-1463.
    >> Share

  385. PRATT E, Ma X, Liu R, Robins D, et al
    Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes.
    Diabetes Obes Metab. 2023 Jun 1. doi: 10.1111/dom.15150.
    >> Share

    May 2023
  386. VAN WEENEN E, Banholzer N, Foll S, Zueger T, et al
    Glycaemic patterns of male professional athletes with type 1 diabetes during exercise, recovery and sleep: Retrospective, observational study over an entire competitive season.
    Diabetes Obes Metab. 2023 May 31. doi: 10.1111/dom.15147.
    >> Share

  387. HARTMANN B, Tittel SR, Gillesen A, Klarl B, et al
    Surfing the waves of the COVID-19 pandemic with diabetes mellitus: Analysis of changes in the diabetes therapy, metabolism and physical activity of 92 992 people living with type 1 or type 2 diabetes from the German DPV registry.
    Diabetes Obes Metab. 2023 May 31. doi: 10.1111/dom.15149.
    >> Share

  388. DELL'AQUILA K, Lee J, Wang SH, Alamuri TT, et al
    Incidence, characteristics, risk factors and outcomes of diabetic ketoacidosis in COVID-19 patients: Comparison with influenza and pre-pandemic data.
    Diabetes Obes Metab. 2023 May 30. doi: 10.1111/dom.15120.
    >> Share

  389. FRECHTEL G, Sauque-Reyna L, Choza-Romero R, Anguiano L, et al
    Advancing therapy in people with suboptimally controlled basal insulin-treated type 2 diabetes: Subanalysis of the SoliMix trial in participants in Latin American countries.
    Diabetes Obes Metab. 2023 May 30. doi: 10.1111/dom.15125.
    >> Share

  390. SU J, Li M, Wan X, Yu H, et al
    Associations of diabetes, prediabetes and diabetes duration with the risk of chronic obstructive pulmonary disease: A prospective UK Biobank study.
    Diabetes Obes Metab. 2023 May 29. doi: 10.1111/dom.15142.
    >> Share

  391. PUAR P, Ahmed S, Hibino M, Pasricha A, et al
    The association between anthropometric indicators of obesity and cardiac reverse remodelling with empagliflozin in patients with type 2 diabetes and coronary artery disease.
    Diabetes Obes Metab. 2023 May 29. doi: 10.1111/dom.15119.
    >> Share

  392. PEDERSEN SD, Giorgino F, Umpierrez G, Thieu VT, et al
    Relationship between body weight change and glycaemic control with tirzepatide treatment in people with type 2 diabetes: A post hoc assessment of the SURPASS clinical trial programme.
    Diabetes Obes Metab. 2023 May 29. doi: 10.1111/dom.15140.
    >> Share

  393. CHERNEY DZI, de Zeeuw D, Heerspink HJL, Cardona J, et al
    Safety, tolerability, pharmacodynamics and pharmacokinetics of the soluble guanylyl cyclase activator BI 685509 in patients with diabetic kidney disease: A randomized trial.
    Diabetes Obes Metab. 2023 May 25. doi: 10.1111/dom.15099.
    >> Share

  394. HAGELQVIST PG, Andersen A, Maytham K, Andreasen CR, et al
    Glycaemia and cardiac arrhythmias in people with type 1 diabetes: A prospective observational study.
    Diabetes Obes Metab. 2023 May 18. doi: 10.1111/dom.15108.
    >> Share

  395. YUAN L, Li-Gao R, Verhoeven A, van Eyk HJ, et al
    Altered high-density lipoprotein composition is associated with risk for complications in type 2 diabetes mellitus in South Asian descendants: A cross-sectional, case-control study on lipoprotein subclass profiling.
    Diabetes Obes Metab. 2023 May 18. doi: 10.1111/dom.15118.
    >> Share

  396. FORBES AK, Suckling RJ, Hinton W, Feher MD, et al
    Sodium-glucose cotransporter-2 inhibitors and kidney outcomes in real-world type 2 diabetes populations: A systematic review and meta-analysis of observational studies.
    Diabetes Obes Metab. 2023 May 18. doi: 10.1111/dom.15111.
    >> Share

  397. STAMATI A, Sotiriou G, Karagiannis T, Christoforidis A, et al
    Efficacy and safety of carbohydrate restriction in patients with type 1 diabetes: A systematic review and meta-analysis.
    Diabetes Obes Metab. 2023 May 18. doi: 10.1111/dom.15124.
    >> Share

  398. LAROSE S, Filliter C, Platt RW, Yu OHY, et al
    Long-acting insulin analogues and the risk of diabetic retinopathy among patients with type 2 diabetes: A population-based cohort study.
    Diabetes Obes Metab. 2023 May 11. doi: 10.1111/dom.15106.
    >> Share

  399. WU Y, Wang Z, Zhao Z, Song X, et al
    Bile acid metabolites in early pregnancy and risk of gestational diabetes mellitus: Results from a prospective cohort study.
    Diabetes Obes Metab. 2023 May 10. doi: 10.1111/dom.15104.
    >> Share

  400. KANG A, Smyth B, Neuen BL, Heerspink HJL, et al
    The sodium-glucose cotransporter-2 inhibitor canagliflozin does not increase risk of non-genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double
    Diabetes Obes Metab. 2023 May 10. doi: 10.1111/dom.15091.
    >> Share

  401. DE VRIES SAG, Bak JCG, Stangenberger VA, Wouters MWJM, et al
    Use of hospital care among Dutch diabetes patients.
    Diabetes Obes Metab. 2023 May 8. doi: 10.1111/dom.15105.
    >> Share

  402. FUJIHARA K, Khin L, Murai K, Yamazaki Y, et al
    Incidence and predictors of remission and relapse of type 2 diabetes mellitus in Japan: Analysis of a nationwide patient registry (JDDM73).
    Diabetes Obes Metab. 2023 May 8. doi: 10.1111/dom.15100.
    >> Share

  403. KOHAN DE, Liew A, Tang SCW, Barratt J, et al
    Effects of atrasentan on markers of liver function in patients with type 2 diabetes and chronic kidney disease.
    Diabetes Obes Metab. 2023 May 4. doi: 10.1111/dom.15103.
    >> Share

  404. MOSER O, Rafferty J, Eckstein ML, Aziz F, et al
    Impact of severe hypoglycaemia requiring hospitalization on mortality in people with type 1 diabetes: A national retrospective observational cohort study.
    Diabetes Obes Metab. 2023 May 4. doi: 10.1111/dom.15102.
    >> Share

  405. MADDALONI E, Cavallari I, La Porta Y, Appetecchia A, et al
    Impact of baseline kidney function on the effects of sodium-glucose co-transporter-2 inhibitors on kidney and heart failure outcomes: A systematic review and meta-analysis of randomized controlled trials.
    Diabetes Obes Metab. 2023;25:1341-1350.
    >> Share

  406. ARODA VR, Erhan U, Jelnes P, Meier JJ, et al
    Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes.
    Diabetes Obes Metab. 2023;25:1385-1397.
    >> Share

  407. NAUCK MA, Mirna AEA, Quast DR
    Meta-analysis of head-to-head clinical trials comparing incretin-based glucose-lowering medications and basal insulin: An update including recently developed glucagon-like peptide-1 (GLP-1) receptor agonists and the glucose-dependent insulinotropic po
    Diabetes Obes Metab. 2023;25:1361-1371.
    >> Share

  408. STARK R, Feehan J, Mousa A, Andrews ZB, et al
    Liver-expressed antimicrobial peptide 2 is associated with improved pancreatic insulin secretion in adults with overweight and obesity.
    Diabetes Obes Metab. 2023;25:1213-1220.
    >> Share

    April 2023
  409. VERMA S, Husain M, Madsen CM, Leiter LA, et al
    Neutrophil-lymphocyte ratio predicts cardiovascular events in people with type 2 diabetes: post hoc analysis of the SUSTAIN 6 and PIONEER 6 cardiovascular outcomes trials.
    Diabetes Obes Metab. 2023 Apr 12. doi: 10.1111/dom.15088.
    >> Share

  410. CHUNG SM, Moon JS, Hong JH, Hwang IC, et al
    Comparison of the effects of gemigliptin versus glimepiride on cardiac function in patients with type 2 diabetes uncontrolled with metformin: the Gemi-Heart study.
    Diabetes Obes Metab. 2023 Apr 12. doi: 10.1111/dom.15095.
    >> Share

  411. JENDLE J, Reznik Y
    Insulin Pump and Closed Loop Systems' Use in People Living with Diabetes: A Narrative Review of Clinical and Cost-Effectiveness to Enable Access to Technology and Meet the Need of Payers.
    Diabetes Obes Metab. 2023 Apr 12. doi: 10.1111/dom.15087.
    >> Share

  412. SHAN J, Xu Z
    Effect of multifactorial intensive treatment in patients with diabetic kidney disease: a meta-analysis with trial sequential analysis.
    Diabetes Obes Metab. 2023 Apr 12. doi: 10.1111/dom.15093.
    >> Share

  413. TAKUMA K, Fuchigami A, Shigiyama F, Kumashiro N, et al
    Comparison of the effects of sitagliptin and dapagliflozin on time in range in Japanese patients with type 2 diabetes stratified by body mass index: A sub-analysis of the DIVERSITY-CVR study.
    Diabetes Obes Metab. 2023 Apr 12. doi: 10.1111/dom.15089.
    >> Share

  414. LEE MMY, Sattar N
    A review of current key guidelines for managing high risk patients with diabetes and heart failure and future prospects.
    Diabetes Obes Metab. 2023 Apr 11. doi: 10.1111/dom.15085.
    >> Share

  415. JUNG Y, Ahn E, Park T, Hwang GS, et al
    Longitudinal study investigating serum metabolites and their association with type 2 diabetes risk in a Korean population.
    Diabetes Obes Metab. 2023 Apr 11. doi: 10.1111/dom.15084.
    >> Share

  416. VERMA S, David JP, Leiter LA, Michelsen MM, et al
    Semaglutide reduces risk of MACE consistently across baseline triglyceride levels in patients with type 2 diabetes: Post Hoc Analyses of SUSTAIN 6 and PIONEER 6 trials.
    Diabetes Obes Metab. 2023 Apr 4. doi: 10.1111/dom.15081.
    >> Share

  417. FIELD BCT, Ruan Y, Varnai KA, Davies J, et al
    A UK nationwide study of adults admitted to hospital with diabetic ketoacidosis or hyperosmolar hyperglycaemic state and COVID-19.
    Diabetes Obes Metab. 2023 Apr 4. doi: 10.1111/dom.15076.
    >> Share

  418. YANG YS, Min KW, Park SO, Kim KS, et al
    Efficacy and Safety of Monotherapy with Enavogliflozin in Korean Patients with Type 2 Diabetes Mellitus: Results of a 12-week, multi-center, randomized, double-blind, placebo-controlled, phase 2 trial.
    Diabetes Obes Metab. 2023 Apr 4. doi: 10.1111/dom.15080.
    >> Share

  419. ARODA VR, Frias JP, Ji L, Niemoeller E, et al
    Efficacy and Safety of Once-Weekly Efpeglenatide in People with Suboptimally Controlled Type 2 Diabetes: The AMPLITUDE-D, AMPLITUDE-L and AMPLITUDE-S Randomised Controlled Trials.
    Diabetes Obes Metab. 2023 Apr 4. doi: 10.1111/dom.15079.
    >> Share

  420. PEMBERTON JS, Wilmot EG, Barnard-Kelly K, Leelarathna L, et al
    CGM accuracy: Contrasting CE marking with the governmental controls of the USA (FDA) and Australia (TGA): A narrative review.
    Diabetes Obes Metab. 2023;25:916-939.
    >> Share

  421. YU JH, Kim REY, Park SY, Lee DY, et al
    Association of long-term hyperglycaemia and insulin resistance with brain atrophy and cognitive decline: A longitudinal cohort study.
    Diabetes Obes Metab. 2023;25:1091-1100.
    >> Share

  422. JUNGNIK A, Arrubla Martinez J, Plum-Morschel L, Kapitza C, et al
    Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon-like peptide-1 receptor agonist BI 456906.
    Diabetes Obes Metab. 2023;25:1011-1023.
    >> Share

  423. POTTEGARD A, Andersen JH, Sondergaard J, Thomsen RW, et al
    Changes in the use of glucose-lowering drugs: A Danish nationwide study.
    Diabetes Obes Metab. 2023;25:1002-1010.
    >> Share

  424. SBRACCIA P, Aberle J, Olsen AH, Rathor N, et al
    Investigating the potential non-authorized use of two different formulations of liraglutide in Europe: A real-world drug utilization study.
    Diabetes Obes Metab. 2023;25:985-991.
    >> Share

  425. KASTNER JR, Poettler T, Kopanz J, Hochfellner DA, et al
    Current insulin infusion set failure criteria may be too stringent for real-life settings and may skew infusion set failure outcomes in extended-wear infusion set studies.
    Diabetes Obes Metab. 2023;25:1106-1111.
    >> Share

  426. ALCORN C, Subarajan P, Kesari A, Lockhart M, et al
    Sodium-glucose cotransporter-2 inhibitor prescribing practices.
    Diabetes Obes Metab. 2023;25:1136-1139.
    >> Share

    March 2023
  427. QUINN LM, Swaby R, Tatovic D, Narendan P, et al
    What does the licensing of teplizumab mean for diabetes care?
    Diabetes Obes Metab. 2023 Mar 30. doi: 10.1111/dom.15071.
    >> Share

  428. NGUYEN C, Crowe CL, Kuti E, Narsipur N, et al
    Impact of pre-existing type 2 diabetes with and without cardiovascular disease on patients with COVID-19.
    Diabetes Obes Metab. 2023 Mar 30. doi: 10.1111/dom.15069.
    >> Share

  429. GUO X, Yang W, Zhang J, Dong X, et al
    iGlarLixi provides a higher derived time-in-range versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with type 2 diabetes: A post hoc analysis.
    Diabetes Obes Metab. 2023 Mar 30. doi: 10.1111/dom.15074.
    >> Share

  430. SEEGMILLER JC, Schmit DJ, Arends VL, Steffes MW, et al
    Assessment of Circulating Insulin Using Mass Spectrometry During Insulin Glargine Treatment in Type 2 Diabetes: Implications for Estimating Insulin Sensitivity and beta-cell Function.
    Diabetes Obes Metab. 2023 Mar 30. doi: 10.1111/dom.15072.
    >> Share

  431. ARONSON R, Biester T, Leohr J, Pollom R, et al
    Ultra rapid lispro showed greater reduction in postprandial glucose versus Humalog in children, adolescents, and adults with type 1 diabetes mellitus.
    Diabetes Obes Metab. 2023 Mar 27. doi: 10.1111/dom.15063.
    >> Share

  432. BOONPOR J, Parra-Soto S, Gore J, Talebi A, et al
    Association Between Walking Pace and Incident Type 2 Diabetes by Adiposity Levels - A Prospective Cohort Study from The UK Biobank.
    Diabetes Obes Metab. 2023 Mar 23. doi: 10.1111/dom.15053.
    >> Share

  433. JERKINS T, McGill JB, Bell DSH
    Heart Failure and Diabetes: Clinical significance and epidemiology of this two-way association.
    Diabetes Obes Metab. 2023 Mar 22. doi: 10.1111/dom.15062.
    >> Share

  434. BALINTESCU A, Lind M, Andersson Franko M, Oldner A, et al
    Glycemic control and sepsis risk in adults with type 1 diabetes.
    Diabetes Obes Metab. 2023 Mar 22. doi: 10.1111/dom.15060.
    >> Share

  435. EKANAYAKE P, Edelman S
    Identifying Those Patients with Type 2 Diabetes Who Might Benefit from Insulin Pump Therapy: Literature Review, Clinical Opportunities, Potential Benefits & Challenges.
    Diabetes Obes Metab. 2023 Mar 22. doi: 10.1111/dom.15059.
    >> Share

  436. MCGUIRE DK, Busui RP, Deanfield J, Inzucchi SE, et al
    Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: SOUL, a randomized trial, design and baseline characteristics.
    Diabetes Obes Metab. 2023 Mar 21. doi: 10.1111/dom.15058.
    >> Share

  437. TSOUKAS MA, Woo V, Tobe SW, Slee A, et al
    Cardiovascular and kidney outcomes with canagliflozin according to type 2 diabetes treatment targets at baseline: Data from the CANVAS Program and CREDENCE.
    Diabetes Obes Metab. 2023 Mar 21. doi: 10.1111/dom.15057.
    >> Share

  438. SIMON TG, Wexler DJ, Schneeweiss S, Patorno E, et al
    Antidiabetes Medication Initiation Trends in U.S. Adults with Cirrhosis and Type 2 Diabetes: A Nationwide Study.
    Diabetes Obes Metab. 2023 Mar 20. doi: 10.1111/dom.15052.
    >> Share

  439. KABTHYMER RH, Karim MN, Hodge AM, de Courten B, et al
    High cereal fibre but not total fibre is associated with a lower risk of type 2 diabetes: Evidence from Melbourne Collaborative Cohort Study.
    Diabetes Obes Metab. 2023 Mar 18. doi: 10.1111/dom.15054.
    >> Share

  440. PINTAUDI B, Gironi I, Meneghini E, Conti M, et al
    Advanced hybrid closed loop system use in elderly with type 1 diabetes: effectiveness and safety in a prospective, observational, one year follow-up real-world study.
    Diabetes Obes Metab. 2023 Mar 18. doi: 10.1111/dom.15055.
    >> Share

  441. KANG SM, Yun HM, Sohn M, Lim S, et al
    Vascular and metabolic effects of ipragliflozin versus sitagliptin in type 2 diabetes treated with sulfonylurea and metformin: IVS study.
    Diabetes Obes Metab. 2023 Mar 18. doi: 10.1111/dom.15056.
    >> Share

  442. PASQUALOTTO E, Maintinguer RDS, van de Sande-Lee S, Araujo GN, et al
    EFFICACY AND SAFETY OF BEXAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: A SYSTEMATIC REVIEW AND META-ANALYSIS.
    Diabetes Obes Metab. 2023 Mar 16. doi: 10.1111/dom.15051.
    >> Share

  443. BONGAERTS B, Kuss O, Bonnet F, Chen H, et al
    HbA(1c) trajectories over 3 years in people with type 2 diabetes starting second-line glucose-lowering therapy: The prospective global DISCOVER study.
    Diabetes Obes Metab. 2023 Mar 12. doi: 10.1111/dom.15050.
    >> Share

  444. MIYA A, Nakamura A, Suzuki Y, Nomoto H, et al
    Inverse association between glucose variability and body fat in type 2 diabetes with impaired endogenous insulin secretion using continuous glucose monitoring: a prospective observational study.
    Diabetes Obes Metab. 2023 Mar 12. doi: 10.1111/dom.15049.
    >> Share

  445. JI L
    Current challenges of diabetes and metabolic disorders in China.
    Diabetes Obes Metab. 2023 Mar 7. doi: 10.1111/dom.15048.
    >> Share

  446. STOUGAARD EB, Rossing P, Vistisen D, Banks P, et al
    Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, reduces the risk of cardiovascular and kidney disease as assessed by Steno T1 Risk Engine in adults with type 1 diabetes.
    Diabetes Obes Metab. 2023 Mar 5. doi: 10.1111/dom.15047.
    >> Share

  447. KWAK SH, Han KA, Kim KS, Yu JM, et al
    Efficacy and safety of enavogliflozin, a novel SGLT2 inhibitor, in Korean people with type 2 diabetes: a 24-week, multicentre, randomised, double-blind, placebo-controlled, phase III trial.
    Diabetes Obes Metab. 2023 Mar 5. doi: 10.1111/dom.15046.
    >> Share

  448. MOHAMMEDI K, Belhatem N, Berentzen TL, Catarig AM, et al
    Once-weekly semaglutide use in patients with type 2 diabetes: results from the SURE France multicentre, prospective, observational study.
    Diabetes Obes Metab. 2023 Mar 4. doi: 10.1111/dom.15045.
    >> Share

  449. IBALD-MULLI A, Seufert J, Grimsmann JM, Laimer M, et al
    Identification of Predictive Factors of Diabetic Ketoacidosis in Type 1 Diabetes Using a Subgroup Discovery Algorithm.
    Diabetes Obes Metab. 2023 Mar 3. doi: 10.1111/dom.15039.
    >> Share

  450. GUO X, Sang C, Tang R, Jiang C, et al
    Effects of glucagon-like peptide-1 receptor agonists on major coronary events in patients with type 2 diabetes.
    Diabetes Obes Metab. 2023 Mar 2. doi: 10.1111/dom.15043.
    >> Share

  451. JI L, Lu Y, Li Q, Fu L, et al
    Efficacy and safety of empagliflozin in combination with insulin in Chinese patients with type 2 diabetes and insufficient glycaemic control: A Phase III, randomised, double-blind, placebo-controlled, parallel study.
    Diabetes Obes Metab. 2023 Mar 2. doi: 10.1111/dom.15041.
    >> Share

  452. YANG M, Chen J, Yue J, He S, et al
    Liver fat is superior to visceral and pancreatic fat as a risk biomarker of impaired glucose regulation in overweight/obese subjects.
    Diabetes Obes Metab. 2023;25:716-725.
    >> Share

    February 2023
  453. ALAMURI TT, Mahesh S, Dell'Aquila K, Leong TJ, et al
    COVID-19 Associated Ketosis and Diabetic Ketoacidosis: A Rapid Review.
    Diabetes Obes Metab. 2023 Feb 28. doi: 10.1111/dom.15036.
    >> Share

  454. JUNG H, Tittel SR, Schloot NC, Heitmann E, et al
    Clinical characteristics, treatment patterns and persistence in individuals with T2D initiating a Glucagon-like-peptide 1 receptor agonists (GLP-1 RA): a retrospective analysis of the Diabetes Prospective Follow-Up (DPV) registry.
    Diabetes Obes Metab. 2023 Feb 28. doi: 10.1111/dom.15038.
    >> Share

  455. KJAERGAARD AD, Krakauer J, Krakauer N, Teumer A, et al
    Allometric body shape indices, type 2 diabetes and kidney function: A two-sample Mendelian randomization study.
    Diabetes Obes Metab. 2023 Feb 28. doi: 10.1111/dom.15037.
    >> Share

  456. YEGGALAM A, Liebich JA, Yu K, Shrestha E, et al
    Safety and efficacy of sodium glucose transport inhibitors in patients with kidney transplantation and diabetes mellitus.
    Diabetes Obes Metab. 2023 Feb 27. doi: 10.1111/dom.15035.
    >> Share

  457. ARNOLD SV, de Lemos JA, Zheng L, Rosenson RS, et al
    Use of optimal medical therapy in patients with diabetes and atherosclerotic cardiovascular disease: Insights from a prospective longitudinal cohort study.
    Diabetes Obes Metab. 2023 Feb 27. doi: 10.1111/dom.15032.
    >> Share

  458. VAN DER AART-VAN DER BEEK AB, Apperloo E, Jongs N, Rouw DB, et al
    Albuminuria lowering effect of dapagliflozin, exenatide and their combination in patients with type 2 diabetes: a randomized cross-over clinical study.
    Diabetes Obes Metab. 2023 Feb 26. doi: 10.1111/dom.15033.
    >> Share

  459. BEHARY P, Alessmii H, Miras AD, Tharakan G, et al
    Tripeptide gut hormone infusion does not alter food preferences or sweet taste function in volunteers with obesity and pre-diabetes/diabetes but promotes restraint eating: A secondary analysis of a randomised single-blind placebo-controlled study.
    Diabetes Obes Metab. 2023 Feb 22. doi: 10.1111/dom.15028.
    >> Share

  460. HARRIS SB, Levrat-Guillen F
    Use the FreeStyle Libre system and diabetes treatment progression in T2DM: Results from a retrospective cohort study using a Canadian private payer claims database.
    Diabetes Obes Metab. 2023 Feb 21. doi: 10.1111/dom.15025.
    >> Share

  461. LIN C, Zhu X, Jiao R, Cai X, et al
    Population attributable fractions of modifiable risk factors for microvascular complications of type 2 diabetes in China: an analysis using national cross-sectional data.
    Diabetes Obes Metab. 2023 Feb 21. doi: 10.1111/dom.15029.
    >> Share

  462. XIA Z, You W, Li Y, Li F, et al
    Association between residual islet beta-cell function and achieving the target of time in range in inpatients with T2DM undergoing anti-diabetic treatment: an observation study.
    Diabetes Obes Metab. 2023 Feb 21. doi: 10.1111/dom.15026.
    >> Share

  463. GUJA C, Kis JT, Haluzik M, Bonnemaire M, et al
    iGlarLixi (insulin glargine 100 U/mL plus lixisenatide) is effective and well-tolerated in people with uncontrolled type 2 diabetes regardless of age: A REALI pooled analysis of prospective real-world data.
    Diabetes Obes Metab. 2023 Feb 21. doi: 10.1111/dom.15027.
    >> Share

  464. GESUITA R, Rabbone I, Marconi V, De Sanctis L, et al
    Trends and Cyclic Variation in the Incidence of Childhood Type 1 Diabetes in Two Italian Regions Over 33 Years and During The Covid-19 Pandemic.
    Diabetes Obes Metab. 2023 Feb 21. doi: 10.1111/dom.15024.
    >> Share

  465. VILSBOLL T, Lindahl CO, Nielsen NF, Tikkanen CK, et al
    Real-world impact of once-weekly subcutaneous semaglutide after two years of follow-up: Results from a nationwide observational study in people with type 2 diabetes.
    Diabetes Obes Metab. 2023 Feb 21. doi: 10.1111/dom.15031.
    >> Share

  466. PALMER BF
    Change in albuminuria as a surrogate endpoint for cardiovascular and renal outcomes in patients with diabetes.
    Diabetes Obes Metab. 2023 Feb 21. doi: 10.1111/dom.15030.
    >> Share

  467. CHEN J, Fan L, Maughn K, Rey GG, et al
    Trajectory of Glycated Hemoglobin Over Time Among Type 2 Diabetes Patients with Obesity on U-100 Basal-Bolus Insulin Regimen Using Real-World Data.
    Diabetes Obes Metab. 2023 Feb 16. doi: 10.1111/dom.15022.
    >> Share

  468. PEPIN JL, Bailly S, Texereau JB, Sonnet E, et al
    Prevalence of sleep apnea in patients with type 1 diabetes and its association with comorbidities and diabetic complications: a French nationwide prospective study.
    Diabetes Obes Metab. 2023 Feb 15. doi: 10.1111/dom.15015.
    >> Share

  469. LEHMANN V, Zueger T, Maritsch M, Kraus M, et al
    Machine learning for non-invasive sensing of hypoglycemia while driving in people with diabetes.
    Diabetes Obes Metab. 2023 Feb 15. doi: 10.1111/dom.15021.
    >> Share

  470. NAPOLI R, Berra C, Catarig AM, Di Loreto C, et al
    Once-weekly semaglutide use in patients with type 2 diabetes: real-world data from the SURE Italy observational study.
    Diabetes Obes Metab. 2023 Feb 15. doi: 10.1111/dom.15020.
    >> Share

  471. TYE SC, Oshima M, Arnott C, Neuen BL, et al
    The importance of targeting multiple risk markers in patients with type 2 diabetes: a post-hoc study from the CANVAS program.
    Diabetes Obes Metab. 2023 Feb 13. doi: 10.1111/dom.15018.
    >> Share

  472. CHERNEY DZI, Ferrannini E, Umpierrez GE, Peters AL, et al
    Efficacy and Safety of Sotagliflozin in Patients With Type 2 Diabetes and Stage 3 Chronic Kidney Disease.
    Diabetes Obes Metab. 2023 Feb 13. doi: 10.1111/dom.15019.
    >> Share

  473. VERMA S, Sabbour H, Alamuddin N, Alawadi F, et al
    A cross-sectional study of the prevalence and clinical management of atherosclerotic cardiovascular diseases in patients with type 2 diabetes across the Middle East and Africa (PACT-MEA): study design and rationale.
    Diabetes Obes Metab. 2023 Feb 12. doi: 10.1111/dom.15011.
    >> Share

  474. LI X, Hou X, Zhang H, Qian X, et al
    The association between stress hyperglycemia and in-hospital cardiac events after coronary artery bypass grafting in patients without diabetes: A retrospective observational study of 5,450 patients.
    Diabetes Obes Metab. 2023 Feb 12. doi: 10.1111/dom.15013.
    >> Share

  475. ANDREASEN CR, Andersen A, Hagelqvist PG, Maytham K, et al
    Sustained QTc Prolongation During Recovery from Hypoglycemia in People with Type 1 Diabetes, Independently of Recovery to Hyper- or Euglycemia.
    Diabetes Obes Metab. 2023 Feb 8. doi: 10.1111/dom.15005.
    >> Share

  476. BENHAMOU PY, Adenis A, Lebbad H, Tourki Y, et al
    One year real-world performance of the DBLG1 closed-loop system: Data from 3706 adult users with type 1 diabetes in Germany.
    Diabetes Obes Metab. 2023 Feb 8. doi: 10.1111/dom.15008.
    >> Share

  477. NGUYEN BN, Nguyen L, Mital S, Bugden S, et al
    Comparative Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-Like Peptide 1 Receptor Agonists, and Nonsteroidal Mineralocorticoid Receptor Antagonists in Chronic Kidney Disease and Type 2 Diabetes: A Systematic Review and Network Meta-A
    Diabetes Obes Metab. 2023 Feb 8. doi: 10.1111/dom.15009.
    >> Share

  478. BROSEN JMB, Agesen RM, Kristensen PL, Alibegovic AC, et al
    Effect of insulin degludec versus insulin glargine U100 on nocturnal glycaemia assessed by plasma glucose profiles in people with type 1 diabetes prone to nocturnal severe hypoglycaemia.
    Diabetes Obes Metab. 2023 Feb 7. doi: 10.1111/dom.15003.
    >> Share

  479. HIRUMA S, Shigiyama F, Kumashiro N
    Empagliflozin versus sitagliptin for ameliorating intrahepatic lipid content and tissue-specific insulin sensitivity in patients with early-stage type 2 diabetes with nonalcoholic fatty liver disease: A prospective randomized study.
    Diabetes Obes Metab. 2023 Feb 7. doi: 10.1111/dom.15006.
    >> Share

  480. JOSHI SR, Singh G, Marwah A, Mittra S, et al
    Comparative clinical efficacy and safety of insulin glargine 300 U/mL (Toujeo) versus insulin glargine 100 U/mL in Type 2 and Type 1 diabetes mellitus: A systematic literature review and meta-analysis.
    Diabetes Obes Metab. 2023 Feb 6. doi: 10.1111/dom.15007.
    >> Share

  481. BELL DSH
    Detecting and treating the protean manifestations of diabetic autonomic neuropathy.
    Diabetes Obes Metab. 2023 Feb 6. doi: 10.1111/dom.15004.
    >> Share

  482. HOFFMAN EG, D'Souza NC, Aiken J, Atherley S, et al
    Effects of Somatostatin Receptor Type 2 Antagonism During Insulin-Induced Hypoglycaemia in Male Rats with Pre-Diabetes.
    Diabetes Obes Metab. 2023 Feb 3. doi: 10.1111/dom.15002.
    >> Share

  483. FAWZY AM, Rivera-Caravaca JM, Fauchier L, Lip GYH, et al
    Response to letter from Du et al. regarding article 'Sodium-glucose cotransporter-2 inhibitor use was associated with lower risks of stroke and cardiac arrest but not ventricular arrhythmias?'.
    Diabetes Obes Metab. 2023;25:630-633.
    >> Share

  484. RODBARD D
    Continuous glucose monitoring metrics (Mean Glucose, time above range and time in range) are superior to glycated haemoglobin for assessment of therapeutic efficacy.
    Diabetes Obes Metab. 2023;25:596-601.
    >> Share

  485. EVANS M, Anupindi VR, DeKoven M, de Laguiche E, et al
    Eight-year trends in obesity-related complications and health care cost progression in a US population with obesity: A retrospective cohort study.
    Diabetes Obes Metab. 2023;25:536-544.
    >> Share

  486. KOSIBOROD MN, Bhatta M, Davies M, Deanfield JE, et al
    Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses.
    Diabetes Obes Metab. 2023;25:468-478.
    >> Share

  487. DU L, Qin J, Zhang Y
    Sodium-glucose cotransporter-2 inhibitor use was associated with lower risks of stroke and cardiac arrest but not ventricular arrhythmias?
    Diabetes Obes Metab. 2023;25:628-629.
    >> Share

  488. ZACCARDI F, Tan PS, Coupland C, Shah BR, et al
    Ethnicity and risks of severe COVID-19 outcomes associated with glucose-lowering medications: A cohort study.
    Diabetes Obes Metab. 2023;25:611-617.
    >> Share

  489. ISLAM N, Reynier P, Douros A, Yu OHY, et al
    Sulfonylureas versus metformin and the risk of ventricular arrhythmias among people with type 2 diabetes: a population-based cohort study.
    Diabetes Obes Metab. 2023 Feb 1. doi: 10.1111/dom.15000.
    >> Share

  490. MCGILL JB, Agarwal R, Anker SD, Bakris GL, et al
    Effects of finerenone in persons with CKD and T2D are independent of HbA1c at baseline, HbA1c variability, diabetes duration and insulin use at baseline.
    Diabetes Obes Metab. 2023 Feb 1. doi: 10.1111/dom.14999.
    >> Share

  491. TAKAHASHI Y, Nomoto H, Yokoyama H, Takano Y, et al
    Improvement of glycemic control and treatment satisfaction by switching from liraglutide or dulaglutide to subcutaneous semaglutide in patients with type 2 diabetes: A multicenter, prospective, randomized, open-label, parallel-group comparison study (
    Diabetes Obes Metab. 2023 Feb 1. doi: 10.1111/dom.14998.
    >> Share

  492. FERREIRA JP, Saraiva F, Sharma A, Vasques-Novoa F, et al
    Glucagon-like peptide 1 receptor agonists in patients with type 2 diabetes with and without chronic heart failure: a meta-analysis of randomized placebo-controlled outcome trials.
    Diabetes Obes Metab. 2023 Feb 1. doi: 10.1111/dom.14997.
    >> Share

    January 2023
  493. GREEN JB, Merrill P, Lokhnygina Y, Mentz RJ, et al
    Sex differences in complications, care, and clinical outcomes of patients with type 2 diabetes in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).
    Diabetes Obes Metab. 2023 Jan 26. doi: 10.1111/dom.14993.
    >> Share

  494. QI QYD, Playfair J, Brown WA, Burton P, et al
    Long-term impact of weight loss for people with overweight but not obesity, and with type 2 diabetes: ten-year outcomes of a randomised trial of gastric band surgery.
    Diabetes Obes Metab. 2023 Jan 26. doi: 10.1111/dom.14992.
    >> Share

  495. DAR MS, Wanner C, Marx N, Ofstad AP, et al
    Cardiovascular outcomes trial data from EMPA-REG OUTCOME, CAROLINA, and CARMELINA: assessment of a novel staging system for type 2 diabetes.
    Diabetes Obes Metab. 2023 Jan 26. doi: 10.1111/dom.14989.
    >> Share

  496. OBEROI A, Giezenaar C, Rigda RS, Horowitz M, et al
    Effects of co-ingesting glucose and whey protein on blood glucose, plasma insulin and glucagon concentrations, and gastric emptying, in older men with and without type 2 diabetes.
    Diabetes Obes Metab. 2023 Jan 24. doi: 10.1111/dom.14983.
    >> Share

  497. VON ARX LB, Rachman J, Webb J, Casey C, et al
    Therapeutic inertia related to the injectable glucagon-like peptide-1 receptor agonists dulaglutide and semaglutide in patients with type 2 diabetes in UK primary care.
    Diabetes Obes Metab. 2023 Jan 24. doi: 10.1111/dom.14985.
    >> Share

  498. HELLER S, Battelino T, Bailey TS, Pieber TR, et al
    Integrated safety and efficacy analysis of dasiglucagon for treatment of severe hypoglycaemia in individuals with type 1 diabetes.
    Diabetes Obes Metab. 2023 Jan 24. doi: 10.1111/dom.14987.
    >> Share

  499. LUND LC, Jensen PH, Pottegard A, Andersen M, et al
    Identifying diabetogenic drugs using real world healthcare databases: a Danish and Australian symmetry analysis.
    Diabetes Obes Metab. 2023 Jan 22. doi: 10.1111/dom.14982.
    >> Share

  500. DI MOLFETTA S, Caruso I, Cignarelli A, Natalicchio A, et al
    Professional continuous glucose monitoring in patients with diabetes mellitus: a systematic review and meta-analysis.
    Diabetes Obes Metab. 2023 Jan 20. doi: 10.1111/dom.14981.
    >> Share

  501. KOSHINO A, Oshima M, Arnott C, Fletcher RA, et al
    Effects of canagliflozin on liver steatosis and fibrosis markers in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis of the CREDENCE trial.
    Diabetes Obes Metab. 2023 Jan 19. doi: 10.1111/dom.14978.
    >> Share

  502. VALENTINE WJ, Hoog M, Mody R, Belger M, et al
    Long-term cost-effectiveness analysis of tirzepatide versus semaglutide 1.0 mg for the management of type 2 diabetes in the US.
    Diabetes Obes Metab. 2023 Jan 18. doi: 10.1111/dom.14979.
    >> Share

  503. OULHAJ A, Aziz F, Suliman A, Iqbal N, et al
    Joint longitudinal and time-to-event modeling compared with standard Cox modeling in patients with type 2 diabetes with and without established cardiovascular disease: an analysis of the EXSCEL trial.
    Diabetes Obes Metab. 2023 Jan 12. doi: 10.1111/dom.14975.
    >> Share

  504. HARRIS SB, Mohammedi K, Bertolini M, White J, et al
    Patient perspectives and experiences with basal insulin titration in type 2 diabetes in the United States: a cross-sectional survey.
    Diabetes Obes Metab. 2023 Jan 12. doi: 10.1111/dom.14973.
    >> Share

  505. MORITA R, Tsukamoto S, Obata S, Yamada T, et al
    Effects of sodium-glucose cotransporter 2 inhibitors, mineralocorticoid receptor antagonists, and their combination on albuminuria in diabetic patients.
    Diabetes Obes Metab. 2023 Jan 12. doi: 10.1111/dom.14976.
    >> Share

  506. LAJARA R, Heller C, Pantalone KM, Lew E, et al
    iGlarLixi vs. premixed insulin initiation in adults with type 2 diabetes advancing from basal insulin therapy: SoliComplex real-world study.
    Diabetes Obes Metab. 2023 Jan 12. doi: 10.1111/dom.14974.
    >> Share

  507. ANDERSEN G, Eloy R, Famulla S, Heise T, et al
    A co-formulation of pramlintide and insulin A21G (ADO09) improves post-prandial glucose and short-term control of mean glucose, time in range, and body weight versus insulin aspart in adults with type 1 diabetes.
    Diabetes Obes Metab. 2023 Jan 12. doi: 10.1111/dom.14972.
    >> Share

  508. JI L, Jiang X, Hao Q, Cheng Z, et al
    Efficacy and Safety of Janagliflozin Monotherapy in Chinese Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Diet and Exercise: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Trial.
    Diabetes Obes Metab. 2023 Jan 3. doi: 10.1111/dom.14971.
    >> Share

  509. BLUHER M, Malhotra A, Bader G
    beta-cell function in treatment-naive patients with type 2 diabetes mellitus: Analyses of baseline data from 15 clinical trials.
    Diabetes Obes Metab. 2023 Jan 3. doi: 10.1111/dom.14969.
    >> Share

  510. LI Y, Yu D, Guo L, Mu Y, et al
    Efficacy and Safety of Basal-First Titration Order in Individuals with Type 2 Diabetes Receiving Short-Term Intensive Insulin Therapy: An Exploratory Analysis of BEYOND V.
    Diabetes Obes Metab. 2023 Jan 3. doi: 10.1111/dom.14970.
    >> Share

  511. FRIAS JP, Lee ML, Carter MM, Ebel ER, et al
    A Microbiome-targeting Fiber-enriched Nutritional Formula is Well Tolerated and Improves Quality of Life and Hemoglobin A1c in Type 2 Diabetes: A Double-Blind, Randomized, Placebo-Controlled Trial.
    Diabetes Obes Metab. 2023 Jan 3. doi: 10.1111/dom.14967.
    >> Share

  512. RETNAKARAN M, Viana LV, Kramer CK
    Lifestyle Intervention for the Prevention of Type 2 Diabetes in women with Prior Gestational Diabetes: A Systematic Review and Meta-analysis.
    Diabetes Obes Metab. 2023 Jan 3. doi: 10.1111/dom.14966.
    >> Share

  513. KIM JM, Bhatt DL, Dagogo-Jack S, Cherney DZI, et al
    Potential for Residual Cardiovascular Risk Reduction: Eligibility for Icosapent Ethyl in the VERTIS CV Population with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease.
    Diabetes Obes Metab. 2023 Jan 2. doi: 10.1111/dom.14965.
    >> Share

  514. HAGELQVIST PG, Andersen A, Maytham KB, Andreasen CR, et al
    Exercise-Related Hypoglycemia Induces QTc-Interval Prolongation in Individuals With Type 1 Diabetes.
    Diabetes Obes Metab. 2023 Jan 2. doi: 10.1111/dom.14964.
    >> Share

  515. BERGMANN NC, Davies MJ, Lingvay I, Knop FK, et al
    Semaglutide for the treatment of overweight and obesity: A review.
    Diabetes Obes Metab. 2023;25:18-35.
    >> Share

  516. NYSTROM T, Toresson Grip E, Gunnarsson J, Casajust P, et al
    Empagliflozin reduces cardiorenal events, healthcare resource use and mortality in Sweden compared to dipeptidyl peptidase-4 inhibitors: Real world evidence from the Nordic EMPRISE study.
    Diabetes Obes Metab. 2023;25:261-271.
    >> Share

    December 2022
  517. PACKER M
    Alleviation of Functional Iron Deficiency by SGLT2 Inhibition in Patients With Type 2 Diabetes.
    Diabetes Obes Metab. 2022 Dec 30. doi: 10.1111/dom.14963.
    >> Share

  518. MEIER JJ, Bardtrum L, Cheng AYY, Malling B, et al
    Body weight loss with oral semaglutide is mediated predominantly by effects other than gastrointestinal adverse events in patients with type 2 diabetes: a post hoc analysis.
    Diabetes Obes Metab. 2022 Dec 23. doi: 10.1111/dom.14957.
    >> Share

  519. LEE YH, Kim DM, Yu JM, Choi KM, et al
    Anagliptin twice-daily regimen improves glycemic variability in subjects with type 2 diabetes: Double-Blind, Randomized Controlled Trial.
    Diabetes Obes Metab. 2022 Dec 23. doi: 10.1111/dom.14959.
    >> Share

  520. ARONSON R, Brown RE, Chu L, Bajaj HS, et al
    IMpact of flash glucose Monitoring in pEople with type 2 Diabetes Inadequately controlled with non-insulin Antihyperglycemic ThErapy (IMMEDIATE): A Randomized Clinical Trial.
    Diabetes Obes Metab. 2022 Dec 22. doi: 10.1111/dom.14949.
    >> Share

  521. MOLLO A, Vlacho B, Gratacos M, Mata-Cases M, et al
    Impact of a Multicomponent Healthcare Intervention on Glycemic Control in Subjects with Poorly Controlled Type 2 Diabetes: The INTEGRA Study.
    Diabetes Obes Metab. 2022 Dec 22. doi: 10.1111/dom.14951.
    >> Share

  522. GERSTEIN HC, Wolsk E, Claggett B, Diaz R, et al
    Effect of Lixisenatide on Natriuretic Peptides in People With Type 2 Diabetes And Recent Acute Coronary Syndrome: The ELIXA Trial.
    Diabetes Obes Metab. 2022 Dec 22. doi: 10.1111/dom.14954.
    >> Share

  523. KIYOSUE A, Dunn JP, Cui X, Hickey A, et al
    Safety and efficacy analyses across age and body mass index subgroups in East Asian participants with type 2 diabetes in the phase 3 tirzepatide studies (SURPASS program).
    Diabetes Obes Metab. 2022 Dec 22. doi: 10.1111/dom.14952.
    >> Share

  524. RASALAM R, Abdo S, Deed G, O'Brien R, et al
    Early type 2 diabetes treatment intensification with glucagon-like peptide-1 receptor agonists in primary care: an Australian perspective on guidelines and the global evidence.
    Diabetes Obes Metab. 2022 Dec 21. doi: 10.1111/dom.14953.
    >> Share

  525. HEISE T, Chien J, Beals JM, Benson C, et al
    Pharmacokinetic and pharmacodynamic properties of the novel Basal Insulin Fc (BIF, insulin efsitora alfa), an insulin fusion protein in development for once-weekly dosing for the treatment of patients with diabetes mellitus.
    Diabetes Obes Metab. 2022 Dec 20. doi: 10.1111/dom.14956.
    >> Share

  526. SAXENA AR, Lyle SA, Khavandi K, Qiu R, et al
    A phase 2a, randomized, double-blind, placebo-controlled, 3-arm, parallel-group study to assess the efficacy, safety, tolerability, and pharmacodynamics of PF-06835919 in patients with nonalcoholic fatty liver disease and type 2 diabetes mellitus.
    Diabetes Obes Metab. 2022 Dec 14. doi: 10.1111/dom.14946.
    >> Share

  527. THABIT H, Mubita W, Rubio J, Karuppan M, et al
    Comparison of faster-acting aspart with insulin aspart under conditions mimicking under-estimation or missed meal boluses in type 1 diabetes using closed-loop insulin delivery.
    Diabetes Obes Metab. 2022 Dec 13. doi: 10.1111/dom.14942.
    >> Share

  528. LINGVAY I, Cheng AY, Levine JA, Gomez-Valderas E, et al
    Achievement of glycemic targets with weight loss and without hypoglycemia in type 2 diabetes with once-weekly GIP and GLP-1 receptor agonist tirzepatide: a post-hoc analysis of the SURPASS-1 to -5 studies.
    Diabetes Obes Metab. 2022 Dec 13. doi: 10.1111/dom.14943.
    >> Share

  529. KOLKAILAH AA, Lingvay I, Dobrecky-Mery I, Aharonovich A, et al
    Effects of Once-Weekly Subcutaneous Semaglutide on Coronary Artery Disease Outcomes in Patients with Type 2 Diabetes with or at High Risk for Cardiovascular Disease: Insights from the SUSTAIN-6 Trial.
    Diabetes Obes Metab. 2022 Dec 13. doi: 10.1111/dom.14941.
    >> Share

  530. AZURI J, Hammerman A, Aboalhasan E, Sluckis B, et al
    Tirzepatide vs. Semaglutide for Weight Loss In Patients With Type 2 Diabetes Mellitus - A Value For Money Analysis.
    Diabetes Obes Metab. 2022 Dec 12. doi: 10.1111/dom.14940.
    >> Share

  531. DELVECCHIO M, Galati A, Maffeis C, Passanisi S, et al
    Retrospective analysis of 24-month real-world glucose control for children and adolescents with type 1 diabetes using the MiniMed(TM) 670G insulin pump.
    Diabetes Obes Metab. 2022 Dec 12. doi: 10.1111/dom.14934.
    >> Share

  532. BRANDT-JACOBSEN NH, Jurgens M, Hasbak P, Gaede P, et al
    Reduction of cardiac adipose tissue volume with short-term empagliflozin treatment in patients with type 2 diabetes: a sub-study from the SIMPLE randomized clinical trial.
    Diabetes Obes Metab. 2022 Dec 9. doi: 10.1111/dom.14933.
    >> Share

  533. MCCARTHY OM, Birch Kristensen K, Christensen MB, Schmidt S, et al
    Metabolic and physiological responses to graded exercise testing in individuals with type 1 diabetes using insulin pump therapy.
    Diabetes Obes Metab. 2022 Dec 8. doi: 10.1111/dom.14938.
    >> Share

  534. THAMMAKOSOL K, Sriphrapradang C
    Effectiveness and Safety of Early Insulin Glargine Administration in Combination with Continuous Intravenous Insulin Infusion in Management of Diabetic Ketoacidosis: A Randomized Controlled Trial.
    Diabetes Obes Metab. 2022 Dec 7. doi: 10.1111/dom.14929.
    >> Share

  535. BIANZANO S, Rose S, Nordaby M, Plum-Morschel L, et al
    Safety, tolerability, pharmacodynamics and pharmacokinetics following once-daily doses of BI 187004, an inhibitor of 11 beta-hydroxysteroid dehydrogenase-1, over 28 days in patients with type 2 diabetes mellitus and overweight or obesity.
    Diabetes Obes Metab. 2022 Dec 7. doi: 10.1111/dom.14932.
    >> Share

  536. ZHAO Y, Zheng Y, Tian Y, Yu Q, et al
    Objective sleep characteristics and continuous glucose monitoring profiles of type 2 diabetes patients in real-life settings.
    Diabetes Obes Metab. 2022 Dec 7. doi: 10.1111/dom.14930.
    >> Share

  537. MATSUBAYASHI Y, Yoshida A, Suganami H, Oe M, et al
    Predictors of haemoglobin levels and of changes in these levels, focusing on anaemia and polycythaemia after administration of the sodium-glucose cotransporter-2 inhibitor tofogliflozin.
    Diabetes Obes Metab. 2022;24:2469-2473.
    >> Share

  538. KADOWAKI T, Maegawa H, Watada H, Yabe D, et al
    Interconnection between cardiovascular, renal and metabolic disorders: A narrative review with a focus on Japan.
    Diabetes Obes Metab. 2022;24:2283-2296.
    >> Share

  539. HUANG CJ, Wang WT, Sung SH, Chen CH, et al
    Revisiting 'intensive' blood glucose control: A causal directed acyclic graph-guided systematic review of randomized controlled trials.
    Diabetes Obes Metab. 2022;24:2341-2352.
    >> Share

  540. TANDAY N, Lafferty RA, Flatt PR, Irwin N, et al
    Beneficial metabolic effects of recurrent periods of beta-cell rest and stimulation using stable neuropeptide Y1 and glucagon-like peptide-1 receptor agonists.
    Diabetes Obes Metab. 2022;24:2353-2363.
    >> Share

  541. OTTO T, Diesing J, Borchert J, Heitmann E, et al
    Age-dependent prevalence of type 2 diabetes, cardiovascular risk profiles, and use of diabetes drugs in Germany using health claims data.
    Diabetes Obes Metab. 2022 Dec 1. doi: 10.1111/dom.14924.
    >> Share

    November 2022
  542. KRESS S, Bramlage P, Holl RW, Moller CD, et al
    Validation of a Risk Prediction Model for Early Chronic Kidney Disease in Patients with Type 2 Diabetes: Data from the German/Austrian DPV Registry.
    Diabetes Obes Metab. 2022 Nov 29. doi: 10.1111/dom.14925.
    >> Share

  543. ONO R, Furihata K, Ichikawa Y, Nakazuru Y, et al
    A phase 1 study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of danuglipron (PF-06882961), an oral small-molecule glucagon-like peptide-1 receptor agonist, in Japanese adults with type 2 diabetes mellitus.
    Diabetes Obes Metab. 2022 Nov 26. doi: 10.1111/dom.14928.
    >> Share

  544. YANG R, Bai J, Fang Z, Wang Y, et al
    Effects of Intensive Blood Pressure Lowering in Patients with Diabetes: A Pooled Analysis of the STEP and ACCORD-BP Randomized Trials.
    Diabetes Obes Metab. 2022 Nov 26. doi: 10.1111/dom.14927.
    >> Share

  545. GAO L, Cheng Z, Su B, Su X, et al
    Efficacy and Safety of Janagliflozin as Add-on Therapy to Metformin in Chinese Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Metformin Alone: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Trial.
    Diabetes Obes Metab. 2022 Nov 25. doi: 10.1111/dom.14926.
    >> Share

  546. CORBIN KD, Dagogo-Jack S, Cannon CP, Cherney DZI, et al
    Cardiorenal outcomes by indices of liver steatosis and fibrosis in individuals with type 2 diabetes and atherosclerotic cardiovascular disease - analyses from VERTIS CV, a randomized trial of the SGLT2 inhibitor ertugliflozin.
    Diabetes Obes Metab. 2022 Nov 17. doi: 10.1111/dom.14923.
    >> Share

  547. NEW RRC, Sukumar R, Chaudhari V, Bogus M, et al
    Safety and Efficacy of an Oral Insulin (Capsulin) in Patients with Early-Stage Type 2 Diabetes: A Dose-Ranging Phase IIb Study.
    Diabetes Obes Metab. 2022 Nov 15. doi: 10.1111/dom.14922.
    >> Share

  548. NILSSON K, Andersson E, Persson S, Karlsdotter K, et al
    Model-based predictions on health benefits and budget impact of implementing empagliflozin in people with type 2 diabetes and established cardiovascular disease.
    Diabetes Obes Metab. 2022 Nov 12. doi: 10.1111/dom.14921.
    >> Share

  549. PERSSON S, Nilsson K, Karlsdotter K, Skogsberg J, et al
    Burden of established cardiovascular disease in people with type 2 diabetes and matched controls: Hospital-based care, days absent from work, costs, and mortality.
    Diabetes Obes Metab. 2022 Nov 12. doi: 10.1111/dom.14919.
    >> Share

  550. WU MZ, Teng TK, Tay WT, Ren QW, et al
    Chronic kidney disease begets heart failure and vice versa; temporal associations between heart failure events in relation to incident chronic kidney disease in type 2 diabetes.
    Diabetes Obes Metab. 2022 Nov 8. doi: 10.1111/dom.14916.
    >> Share

  551. EVANS M, Berry S, Nazeri A, Malkin SJ, et al
    The challenges and pitfalls of incorporating evidence from cardiovascular outcomes trials in health economic modeling of type 2 diabetes.
    Diabetes Obes Metab. 2022 Nov 7. doi: 10.1111/dom.14917.
    >> Share

  552. THABIT H, Boughton C, Mubita W, Rubio J, et al
    Impact of the CamAPS FX hybrid closed-loop insulin delivery system on sleep traits in older adults with type 1 diabetes.
    Diabetes Obes Metab. 2022 Nov 6. doi: 10.1111/dom.14914.
    >> Share

  553. ROSSING P, Garweg JG, Anker SD, Osonoi T, et al
    Effect of finerenone on occurrence of vision-threatening complications in patients with non-proliferative diabetic retinopathy: pooled analysis of two studies using routine ophthalmological examinations from clinical trial participants (ReFineDR/DeFin
    Diabetes Obes Metab. 2022 Nov 4. doi: 10.1111/dom.14915.
    >> Share

  554. HAN Y, Hu H, Liu Y, Wang Z, et al
    Nomogram model and risk score to predict 5-year risk of progression from pre-diabetes to diabetes in Chinese adults: development and validation of a novel model.
    Diabetes Obes Metab. 2022 Nov 2. doi: 10.1111/dom.14910.
    >> Share

  555. LIU SC, Chuang SM, Wang CH, Chien MN, et al
    Comparison of two titration programs for adding insulin detemir to oral antidiabetic drugs in patients with poorly controlled type 2 diabetes mellitus.
    Diabetes Obes Metab. 2022 Nov 2. doi: 10.1111/dom.14912.
    >> Share

  556. KHUNTI K, Aroda VR, Bhatt DL, Bozkurt B, et al
    Re-examining the widespread policy of stopping sodium-glucose cotransporter-2 inhibitors during acute illness: A perspective based on the updated evidence.
    Diabetes Obes Metab. 2022;24:2071-2080.
    >> Share

  557. SNITKER S, Egebjerg C, Frederiksen M, Sparre T, et al
    Ease-of-use and acceptability of the novel semaglutide 2.4 mg single-dose pen-injector in people with overweight or obesity in the STEP 8 phase III trial.
    Diabetes Obes Metab. 2022;24:2273-2276.
    >> Share

  558. CASTANEDA J, Mathieu C, Aanstoot HJ, Arrieta A, et al
    Predictors of time in target glucose range in real-world users of the MiniMed 780G system.
    Diabetes Obes Metab. 2022;24:2212-2221.
    >> Share

  559. CHOI IY, Chang Y, Cho Y, Kang J, et al
    Prediabetes diagnosis is associated with the progression of coronary artery calcification: The Kangbuk Samsung Health Study.
    Diabetes Obes Metab. 2022;24:2118-2126.
    >> Share

  560. RIVELINE JP, Wojtusciszyn A, Guerci B, Alves C, et al
    Real world hypoglycaemia related to glucose variability and Flash glucose scan frequency assessed from global FreeStyle Libre data.
    Diabetes Obes Metab. 2022;24:2102-2107.
    >> Share

  561. JONES B, Burade V, Akalestou E, Manchanda Y, et al
    In vivo and in vitro characterization of GL0034, a novel long-acting glucagon-like peptide-1 receptor agonist.
    Diabetes Obes Metab. 2022;24:2090-2101.
    >> Share

    October 2022
  562. IGUDESMAN D, Crandell J, Corbin KD, Zaharieva DP, et al
    Weight Management in Young Adults with Type 1 Diabetes: The Advancing Care for Type 1 Diabetes and Obesity Network Sequential Multiple Assignment Randomized Trial Pilot Results.
    Diabetes Obes Metab. 2022 Oct 31. doi: 10.1111/dom.14911.
    >> Share

  563. HE F, Chen W, Xu W, Liu D, et al
    Safety and Efficacy of Liraglutide on Reducing Visceral and Ectopic Fat in Adults with or without Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis.
    Diabetes Obes Metab. 2022 Oct 31. doi: 10.1111/dom.14908.
    >> Share

  564. DU Y, Gao L, Xiao X, Hou X, et al
    A Multi-center, Randomized, Double-Blinded, Parallel, Active and Placebo-Controlled Phase 3 Clinical Study of the glucokinase activator PB-201 in Treatment-naive Patients with Type 2 Diabetes Mellitus: A Study Protocol.
    Diabetes Obes Metab. 2022 Oct 30. doi: 10.1111/dom.14909.
    >> Share

  565. HARPER R, Bashan E, Williams KJ, Sritharan S, et al
    Challenging the 50-50 rule for the basal-bolus insulin ratio in patients with type 2 diabetes who maintain stable glycemic control.
    Diabetes Obes Metab. 2022 Oct 30. doi: 10.1111/dom.14904.
    >> Share

  566. HOME PD, McCrimmon RJ, Rosenstock J, Bluher M, et al
    Findings for iGlarLixi vs BIAsp 30 confirmed in groups of people with type 2 diabetes with different biomedical characteristics.
    Diabetes Obes Metab. 2022 Oct 30. doi: 10.1111/dom.14907.
    >> Share

  567. MASHAYEKHI M, Beckman JA, Nian H, Garner EM, et al
    Comparative Effects of Weight Loss and Incretin-Based Therapies on Vascular Endothelial Function, Fibrinolysis, and Inflammation in Individuals with Obesity and Pre-Diabetes: A Randomized, Controlled Trial.
    Diabetes Obes Metab. 2022 Oct 28. doi: 10.1111/dom.14903.
    >> Share

  568. ELDOR R, Francis BH, Fleming A, Neutel J, et al
    Oral Insulin (ORMD-0801) in Type 2 Diabetes Mellitus: Dose-Finding 12-Week Randomized Placebo-Controlled Study.
    Diabetes Obes Metab. 2022 Oct 24. doi: 10.1111/dom.14901.
    >> Share

  569. BATTELINO T, Danne T, Edelman SV, Choudhary P, et al
    CGM-based Time-in-Range Using Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Type 1 Diabetes: The Head-to-Head Randomized Controlled InRange Trial.
    Diabetes Obes Metab. 2022 Oct 20. doi: 10.1111/dom.14898.
    >> Share

  570. AVGERINOS I, Karagiannis T, Liakos A, Tsapas A, et al
    Racial, ethnic and sex disparities among participants in cardiovascular outcomes trials in type 2 diabetes: A systematic review and descriptive analysis.
    Diabetes Obes Metab. 2022 Oct 19. doi: 10.1111/dom.14900.
    >> Share

  571. EVANS M, Chubb B, Malkin SJ, Berry S, et al
    Once-weekly semaglutide versus insulin aspart for the treatment of type 2 diabetes in the UK: A long-term cost-effectiveness analysis based on SUSTAIN 11.
    Diabetes Obes Metab. 2022 Oct 17. doi: 10.1111/dom.14892.
    >> Share

  572. LI P, Zhang P, Guan D, Guo J, et al
    Changes in racial and ethnic disparities in glucose-lowering drug utilization and HbA1c in US adults with diabetes: 2005-2018.
    Diabetes Obes Metab. 2022 Oct 17. doi: 10.1111/dom.14894.
    >> Share

  573. HINTON W, Ansari AS, Whyte MB, McGovern AP, et al
    Sodium-glucose co-transporter-2 (SGLT2) inhibitors in type 2 diabetes: are clinical trial benefits for heart failure reflected in real-world clinical practice? A systematic review and meta-analysis of observational studies.
    Diabetes Obes Metab. 2022 Oct 14. doi: 10.1111/dom.14893.
    >> Share

  574. HONG SN, Mak IL, Chin WY, Yu EYT, et al
    Age-specific associations between the number of comorbidities and all-cause mortality and public direct medical costs in patients with type 2 diabetes: a retrospective cohort study.
    Diabetes Obes Metab. 2022 Oct 7. doi: 10.1111/dom.14889.
    >> Share

  575. MANNUCCI E, Gallo M, Giaccari A, Candido R, et al
    Effects of glucose-lowering agents on cardiovascular and renal outcomes in subjects with type 2 diabetes: an updated meta-analysis of randomized controlled trials with external adjudication of events.
    Diabetes Obes Metab. 2022 Oct 7. doi: 10.1111/dom.14888.
    >> Share

  576. MOODY AJ, Molina-Wilkins M, Clarke GD, Merovci A, et al
    Pioglitazone Reduces Epicardial Fat and Improves Diastolic Function in Patients with Type 2 Diabetes.
    Diabetes Obes Metab. 2022 Oct 7. doi: 10.1111/dom.14885.
    >> Share

  577. LIU L, Yan F, Yan H, Wang Z, et al
    Impact of iron supplementation on gestational diabetes mellitus: a literature review.
    Diabetes Obes Metab. 2022 Oct 6. doi: 10.1111/dom.14886.
    >> Share

  578. CHEN Y, Wang Q, Xie Z, Huang G, et al
    The impact of family history of type 2 diabetes on the clinical heterogeneity in idiopathic type 1 diabetes.
    Diabetes Obes Metab. 2022 Oct 6. doi: 10.1111/dom.14884.
    >> Share

  579. BLEKEN OSTERGAARD H, Humphreys V, Hengeveld EM, Honore JB, et al
    Cardiovascular risk and lifetime benefit from preventive treatment in type 2 diabetes: a post hoc analysis of the CAPTURE study.
    Diabetes Obes Metab. 2022 Oct 5. doi: 10.1111/dom.14887.
    >> Share

  580. HU S, Gu S, Qi C, Wang S, et al
    Cost-Utility Analysis of Semaglutide for type 2 diabetes after its Addition to the National Medical Insurance System in China.
    Diabetes Obes Metab. 2022 Oct 4. doi: 10.1111/dom.14881.
    >> Share

  581. ROSSING P, Agarwal R, Anker SD, Filippatos G, et al
    Finerenone in patients across the spectrum of chronic kidney disease and type 2 diabetes by GLP-1RA use.
    Diabetes Obes Metab. 2022 Oct 4. doi: 10.1111/dom.14883.
    >> Share

  582. YAMAGUCHI S, Shimabukuro M, Tanaka A, Imai T, et al
    Canagliflozin reduces proteinuria by targeting hyperinsulinemia in diabetic patients with heart failure: a post-hoc analysis of the CANDLE trial.
    Diabetes Obes Metab. 2022 Oct 4. doi: 10.1111/dom.14876.
    >> Share

  583. YABE D, Kawamori D, Seino Y, Oura T, et al
    Change of pharmacodynamics parameters following once-weekly tirzepatide treatment versus dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono sub-study).
    Diabetes Obes Metab. 2022 Oct 2. doi: 10.1111/dom.14882.
    >> Share

  584. PROIETTI R, Lip GYH
    Sodium-glucose cotransporter 2 inhibitors: An additional management option for patients with atrial fibrillation?
    Diabetes Obes Metab. 2022;24:1897-1900.
    >> Share

  585. CHO SJ, Oh IS, Jeong HE, Cho YM, et al
    Long-term clinical outcomes of oral antidiabetic drugs as fixed-dose combinations: A nationwide retrospective cohort study.
    Diabetes Obes Metab. 2022;24:2051-2060.
    >> Share

  586. CHOUDHARY P, Kao K, Dunn TC, Brandner L, et al
    Glycaemic measures for 8914 adult FreeStyle Libre users during routine care, segmented by age group and observed changes during the COVID-19 pandemic.
    Diabetes Obes Metab. 2022;24:1976-1982.
    >> Share

  587. SEN T, Koshino A, Neal B, Bijlsma MJ, et al
    Mechanisms of action of the sodium-glucose cotransporter-2 (SGLT2) inhibitor canagliflozin on tubular inflammation and damage: A post hoc mediation analysis of the CANVAS trial.
    Diabetes Obes Metab. 2022;24:1950-1956.
    >> Share

  588. LIU N, Wang G, Liu C, Liu J, et al
    Non-alcoholic fatty liver disease and complications in type 1 and type 2 diabetes: A Mendelian randomization study.
    Diabetes Obes Metab. 2022 Oct 1. doi: 10.1111/dom.14877.
    >> Share

    September 2022
  589. HALVORSEN YD, Lock JP, Frias JP, Tinahones FJ, et al
    A 96-Week, Double-Blind, Randomized, Controlled Trial Comparing Bexagliflozin to Glimepiride as an Adjunct to Metformin for the Treatment of Type 2 Diabetes in Adults.
    Diabetes Obes Metab. 2022 Sep 30. doi: 10.1111/dom.14875.
    >> Share

  590. BIDULKA P, Mathur R, Lugo-Palacios DG, O'Neill S, et al
    Ethnic and socioeconomic disparities in initiation of second-line antidiabetic treatment in people with type 2 diabetes in England: a cross-sectional study.
    Diabetes Obes Metab. 2022 Sep 22. doi: 10.1111/dom.14874.
    >> Share

  591. PHILIS-TSIMIKAS A, Bajaj HS, Begtrup K, Cailleteau R, et al
    Rationale and design of the phase 3 development programme (ONWARDS 1-6 trials) investigating once-weekly insulin icodec in diabetes.
    Diabetes Obes Metab. 2022 Sep 15. doi: 10.1111/dom.14871.
    >> Share

  592. LU L, Wan B, Sun M
    Mendelian Randomization Identifies Age at Menarche as an Independent Causal Effect Factor for Gestational Diabetes Mellitus.
    Diabetes Obes Metab. 2022 Sep 14. doi: 10.1111/dom.14869.
    >> Share

  593. VARGAS-URICOECHEA H, Burga Nunez JL, Rosas Guzman J, Silva Gomez L, et al
    Real-World Effectiveness and Safety of Insulin Glargine 300 U/mL in Insulin-Naive People with Type 2 Diabetes in the Latin America Region: A Subgroup Analysis of the ATOS Study.
    Diabetes Obes Metab. 2022 Sep 14. doi: 10.1111/dom.14868.
    >> Share

  594. CHEN X, Jiang H, Li H, Kuang H, et al
    Saxagliptin combined with additional oral antihyperglycemic agents in drug-naive diabetic patients with high glycosylated hemoglobin: a 24-week, multicenter, randomized, open-label, active parallel-controlled group clinical trial in China (SUCCESS).
    Diabetes Obes Metab. 2022 Sep 13. doi: 10.1111/dom.14873.
    >> Share

  595. SCHOLTES RA, Mosterd CM, Hesp AC, Smits MM, et al
    Mechanisms underlying the blood pressure lowering effects of empagliflozin, losartan and their combination in people with type 2 diabetes: a secondary analysis of a randomized cross-over trial.
    Diabetes Obes Metab. 2022 Sep 11. doi: 10.1111/dom.14864.
    >> Share

  596. RAZAGHIZAD A, Sharma A, Ni J, Ferreira JP, et al
    External Validation and Extension of the TIMI Risk Score for Heart Failure in Diabetes for Patients with Recent Acute Coronary Syndrome: An Analysis of the EXAMINE Trial.
    Diabetes Obes Metab. 2022 Sep 9. doi: 10.1111/dom.14867.
    >> Share

  597. SUGIMOTO T, Tokuda H, Miura H, Kawashima S, et al
    Cross-sectional association of metrics derived from continuous glucose monitoring with cognitive performance in older adults with type 2 diabetes mellitus.
    Diabetes Obes Metab. 2022 Sep 9. doi: 10.1111/dom.14866.
    >> Share

  598. LIM LL, Lau ESH, Cheung JTK, Chan SP, et al
    Real world usage of sulphonylurea in Asian patients with type 2 diabetes using the Joint Asia Diabetes Evaluation (JADE) Register.
    Diabetes Obes Metab. 2022 Sep 9. doi: 10.1111/dom.14865.
    >> Share

  599. HIROTA Y, Xu Y, Yamamoto A, Matsuoka A, et al
    Type 1 diabetes iron-deficiency anemia case report and the clinical relevance of RBC lifespan adjusted A1C.
    Diabetes Obes Metab. 2022 Sep 7. doi: 10.1111/dom.14860.
    >> Share

  600. NESTI L, Pugliese NR, Chiriaco M, Trico D, et al
    Epicardial adipose tissue thickness is associated with reduced peak oxygen consumption and systolic reserve in patients with type 2 diabetes and normal heart function.
    Diabetes Obes Metab. 2022 Sep 6. doi: 10.1111/dom.14861.
    >> Share

  601. SOURIJ C, Aziz F, Kojzar H, Obermayer AM, et al
    SARS-CoV-2S antibody level decline is more pronounced after second vaccination but response to the third COVID-19 vaccination is similar in people with type 1 and type 2 diabetes compared to healthy controls - the prospective COVAC-DM cohort study.
    Diabetes Obes Metab. 2022 Sep 4. doi: 10.1111/dom.14855.
    >> Share

  602. DIALLO A, Carlos-Bolumbu M, Renard E, Galtier F, et al
    Large Effect Size in Composite Kidney Outcomes than in Majors Cardiovascular Events of SGLT2 inhibitors compared with GLP-1 RAs: A Pooled Analysis of Type 2 Diabetes Trials.
    Diabetes Obes Metab. 2022 Sep 3. doi: 10.1111/dom.14859.
    >> Share

  603. LING S, Zaccardi F, Vlacho B, Li P, et al
    All-cause and cardiorenal mortality in 6 million adults with and without type 2 diabetes: a comparative, trend analysis in Canada, Spain, and the UK.
    Diabetes Obes Metab. 2022 Sep 3. doi: 10.1111/dom.14856.
    >> Share

  604. FUKUSHIMA T, Chubachi S, Namkoong H, Asakura T, et al
    Clinical significance of pre-diabetes, undiagnosed diabetes, and diagnosed diabetes on clinical outcomes in COVID-19: Integrative analysis from the Japan COVID-19 Task Force.
    Diabetes Obes Metab. 2022 Sep 3. doi: 10.1111/dom.14857.
    >> Share

  605. SUBRAMANIAN A, Gokhale K, Sainsbury C, Nirantharakumar K, et al
    Sodium/glucose co-transporter-2 inhibitors and the risk of gout in patients with type 2 diabetes mellitus a propensity score matched, new user design study with an active comparator in IQVIA Medical Research Data - UK.
    Diabetes Obes Metab. 2022 Sep 2. doi: 10.1111/dom.14858.
    >> Share

  606. HEISE T, Piras de Oliveira C, Juneja R, Ribeiro A, et al
    What is the value of faster acting prandial insulin? Focus on ultra rapid lispro.
    Diabetes Obes Metab. 2022;24:1689-1701.
    >> Share

  607. ABDUL-GHANI T, Puckett C, Migahid O, Abdelgani S, et al
    Type 2 diabetes subgroups and response to glucose-lowering therapy: Results from the EDICT and Qatar studies.
    Diabetes Obes Metab. 2022;24:1810-1818.
    >> Share

  608. FRANEK E, Gerstein HC, Riddle MC, Nicolay C, et al
    Efficacy and safety outcomes of dulaglutide by baseline HbA1c: A post hoc analysis of the REWIND trial.
    Diabetes Obes Metab. 2022;24:1753-1761.
    >> Share

    August 2022
  609. FAWZY AM, Rivera-Caravaca JM, Underhill P, Fauchier L, et al
    Incident heart failure, arrhythmias and cardiovascular outcomes with sodium glucose co-transporter 2 (SGLT2) inhibitor use in diabetic patients: Insights from a global federated electronic medical record database.
    Diabetes Obes Metab. 2022 Aug 31. doi: 10.1111/dom.14854.
    >> Share

  610. MOON SJ, Kim KS, Lee WJ, Lee MY, et al
    Efficacy of intermittent short-term use of a real-time continuous glucose monitoring system in non-insulin-treated patients with type 2 diabetes: a randomized controlled trial.
    Diabetes Obes Metab. 2022 Aug 28. doi: 10.1111/dom.14852.
    >> Share

  611. WADWA RP, Laffel LM, Franco DR, Dellva MA, et al
    Efficacy and safety of ultra rapid lispro (URLi) versus Lispro in children and adolescents with type 1 diabetes: PRONTO-Peds.
    Diabetes Obes Metab. 2022 Aug 24. doi: 10.1111/dom.14849.
    >> Share

  612. WU Z, Lebbar M, Taleb N, Legault L, et al
    Comparing dual-hormone and single-hormone automated insulin delivery systems on nocturnal glucose management among children and adolescents with type 1 diabetes: a pooled analysis.
    Diabetes Obes Metab. 2022 Aug 23. doi: 10.1111/dom.14850.
    >> Share

  613. MCCRIMMON RJ, Home P, Cheng A, Giorgino F, et al
    Hypoglycaemia events with iGlarLixi versus premix biphasic insulin aspart 30 (BIAsp 30) in people with type 2 diabetes advancing from basal insulin: An analysis of the SoliMix trial.
    Diabetes Obes Metab. 2022 Aug 23. doi: 10.1111/dom.14825.
    >> Share

  614. POLONSKY WH, Giorgino F, Rosenstock J, Whitmire K, et al
    Improved patient-reported outcomes with iGlarLixi versus premix BIAsp 30 in people with type 2 diabetes in the SoliMix trial.
    Diabetes Obes Metab. 2022 Aug 23. doi: 10.1111/dom.14822.
    >> Share

  615. CHEN L, Sun S, Gao Y, Ran X, et al
    Global mortality of diabetic foot ulcer: a systematic review and meta-analysis of observational studies.
    Diabetes Obes Metab. 2022 Aug 20. doi: 10.1111/dom.14840.
    >> Share

  616. HADJADJ S, Saulnier PJ, Ruan Y, Zhu X, et al
    Associations of microvascular complications with all-cause death in patients with diabetes and COVID-19: the CORONADO, ABCD Covid-19 audit and AMERICADO study groups.
    Diabetes Obes Metab. 2022 Aug 20. doi: 10.1111/dom.14845.
    >> Share

  617. MCCRIMMON RJ, Cheng AYY, Galstyan G, Djaballah K, et al
    iGlarLixi versus basal plus Rapid-Acting insulin in adults with type 2 diabetes advancing from basal insulin therapy: The SoliSimplify Real-World study.
    Diabetes Obes Metab. 2022 Aug 19. doi: 10.1111/dom.14844.
    >> Share

  618. CHARBONNEL BH, Chen H, Cid-Ruzafa J, Cooper A, et al
    Treatment patterns and glycated haemoglobin levels over 36 months in individuals with type 2 diabetes initiating second-line glucose-lowering therapy: The global DISCOVER study.
    Diabetes Obes Metab. 2022 Aug 19. doi: 10.1111/dom.14842.
    >> Share

  619. PIERI B, Deshmukh H, Wilmot EG, Choudhary P, et al
    Impaired awareness of hypoglycaemia; prevalence and associated factors before and after FreeStyle Libre use in the Association of British Clinical Diabetologists (ABCD) audit.
    Diabetes Obes Metab. 2022 Aug 18. doi: 10.1111/dom.14841.
    >> Share

  620. VAZEOU A, Tittel SR, Kordonouri O, Birkebaek NH, et al
    Increased prevalence of cardiovascular risk factors in children and adolescents with type 1 diabetes and hypertension: The SWEET international database.
    Diabetes Obes Metab. 2022 Aug 18. doi: 10.1111/dom.14834.
    >> Share

  621. WHARTON W, Anderson A, Hayden KM, Carmichael OT, et al
    Effect of renin-angiotensin system antihypertensive medication use on cognitive function in diabetes mellitus with obesity or overweight: An ancillary study to the Action for Health in Diabetes (Look AHEAD) trial.
    Diabetes Obes Metab. 2022 Aug 16. doi: 10.1111/dom.14838.
    >> Share

  622. RABBONE I, Pozzi E, Savastio S, Luca G, et al
    A comparison of the effectiveness and safety of insulin glargine 300 U/ml vs. 100 U/ml in children and adolescents with newly diagnosed type 1 diabetes: a retrospective, observational , short-term study.
    Diabetes Obes Metab. 2022 Aug 15. doi: 10.1111/dom.14839.
    >> Share

  623. PARRY-STRONG A, Wright-McNaughton M, Weatherall M, Hall RM, et al
    Very low carbohydrate (ketogenic) diets in type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
    Diabetes Obes Metab. 2022 Aug 15. doi: 10.1111/dom.14837.
    >> Share

  624. NUNES JC, Yu J, Arnott C, Jardine MJ, et al
    CANAGLIFLOZIN, MENTAL HEALTH ADVERSE EVENTS, AND DIABETES: EXPLORATORY ANALYSIS OF THE CREDENCE TRIAL AND CANVAS PROGRAM.
    Diabetes Obes Metab. 2022 Aug 8. doi: 10.1111/dom.14832.
    >> Share

  625. DE BLOCK C, Bailey C, Wysham C, Hemmingway A, et al
    Tirzepatide for the treatment of adults with type 2 diabetes: an endocrine perspective.
    Diabetes Obes Metab. 2022 Aug 5. doi: 10.1111/dom.14831.
    >> Share

  626. ARODA VR, Eckel RH
    Reconsidering the role of glycemic control on cardiovascular disease risk in type 2 diabetes: A 21(st) century assessment.
    Diabetes Obes Metab. 2022 Aug 5. doi: 10.1111/dom.14830.
    >> Share

  627. SANG M, Xie C, Qiu S, Wang X, et al
    Cholecystectomy is associated with dysglycaemia: Cross-sectional and prospective analyses.
    Diabetes Obes Metab. 2022;24:1656-1660.
    >> Share

  628. CORBETT JP, Hsu L, Brown SA, Kollar L, et al
    Smartwatch gesture-based meal reminders improve glycaemic control.
    Diabetes Obes Metab. 2022;24:1667-1670.
    >> Share

  629. HUMMEL J, Machann J, Dannecker C, Kullmann S, et al
    Eight weeks of empagliflozin does not affect pancreatic fat content and insulin secretion in people with prediabetes.
    Diabetes Obes Metab. 2022;24:1661-1666.
    >> Share

  630. WILDING JPH, Batterham RL, Davies M, Van Gaal LF, et al
    Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.
    Diabetes Obes Metab. 2022;24:1553-1564.
    >> Share

  631. NANDAKUMAR M, Moin ASM, Ramanjaneya M, Qaissi AA, et al
    Severe iatrogenic hypoglycaemia modulates the fibroblast growth factor protein response.
    Diabetes Obes Metab. 2022;24:1483-1497.
    >> Share

    July 2022
  632. GUERCI B, Giorgino F, Sapin H, Boye K, et al
    The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Patient Disposition, Clinical Characteristics, and Treatment Persistence at 12 Months.
    Diabetes Obes Metab. 2022 Jul 25. doi: 10.1111/dom.14823.
    >> Share

  633. YAHANG L, Xu H, Li J, Yang Y, et al
    Separate and joint effect of visit-to-visit glycemic variability and mean glucose level on all-cause mortality in patients with type 2 diabetes: a population-based cohort study.
    Diabetes Obes Metab. 2022 Jul 25. doi: 10.1111/dom.14826.
    >> Share

  634. XU Y, Oriot P, Dunn TC, Hermans MP, et al
    Evaluation of continuous glucose monitoring-derived person-specific HbA1c in the presence and absence of complications in type 1 diabetes.
    Diabetes Obes Metab. 2022 Jul 25. doi: 10.1111/dom.14824.
    >> Share

  635. SUCCURRO E, Vizza P, Papa A, Miceli S, et al
    Effects of 26-week treatment with empagliflozin versus glimepiride on myocardial glucose metabolic rate in patients with type 2 diabetes: the randomized, open-label, active-controlled crossover FIORE trial.
    Diabetes Obes Metab. 2022 Jul 15. doi: 10.1111/dom.14816.
    >> Share

  636. HOOD KK, Garcia-Willingham N, Hanes S, Tanenbaum ML, et al
    Lived experience of CamAPS FX closed loop system in youth with type 1 diabetes and their parents.
    Diabetes Obes Metab. 2022 Jul 15. doi: 10.1111/dom.14815.
    >> Share

  637. SIRVENT P, Chavanelle V, Otero YF, Bargetto M, et al
    TOTUM-63, a plant-based polyphenol-rich extract, improves glycemic control in subjects with prediabetes or early stage newly-diagnosed type 2 diabetes in a randomized, double-blind, placebo-controlled trial.
    Diabetes Obes Metab. 2022 Jul 15. doi: 10.1111/dom.14817.
    >> Share

  638. MACDONALD CJ, Frenoy P, Boutron-Ruault MC
    Response to Boonpor et al: Types of diet, obesity, and incident type 2 diabetes: Findings from the UK Biobank prospective cohort study.
    Diabetes Obes Metab. 2022 Jul 11. doi: 10.1111/dom.14813.
    >> Share

  639. LIN Y, Shao H, Shi L, Anderson AH, et al
    Predicting incident heart failure among patients with type 2 diabetes mellitus: the DM-CURE risk score.
    Diabetes Obes Metab. 2022 Jul 8. doi: 10.1111/dom.14806.
    >> Share

  640. XU J, Ling H, Geng J, Huang Y, et al
    Efficacy and safety of DBPR108 (prusogliptin) as an add-on to metformin therapy in patients with type 2 diabetes mellitus: A 24-week, multi-center, randomized, double-blind, placebo-controlled, superiority, phase III clinical trial.
    Diabetes Obes Metab. 2022 Jul 6. doi: 10.1111/dom.14810.
    >> Share

  641. GRIMSMANN JM, Tittel SR, Bramlage P, Mayer B, et al
    Disease heterogeneity of adult diabetes based on routine clinical parameters at diagnosis: Results from the German/Austrian DPV registry.
    Diabetes Obes Metab. 2022 Jul 6. doi: 10.1111/dom.14812.
    >> Share

  642. AMBERY P, Eryd SA, Jenkins-Jones S, Heywood B, et al
    The absolute risk of incident type 2 diabetes following exposure to systemic corticosteroids in selected steroid-related and phenotypic groups.
    Diabetes Obes Metab. 2022 Jul 6. doi: 10.1111/dom.14808.
    >> Share

  643. ARRIETA A, Battelino T, Scaramuzza AE, Da Silva J, et al
    Comparison of MiniMed 780G system performance in users aged younger and older than 15 years: Evidence from 12 870 real-world users.
    Diabetes Obes Metab. 2022;24:1370-1379.
    >> Share

  644. VON DEM BERGE T, Remus K, Biester S, Reschke F, et al
    In-home use of a hybrid closed loop achieves time-in-range targets in preschoolers and school children: Results from a randomized, controlled, crossover trial.
    Diabetes Obes Metab. 2022;24:1319-1327.
    >> Share

  645. ARODA VR, Bauer R, Christiansen E, Haluzik M, et al
    Efficacy and safety of oral semaglutide by subgroups of patient characteristics in the PIONEER phase 3 programme.
    Diabetes Obes Metab. 2022;24:1338-1350.
    >> Share

  646. CRABTREE TSJ, Adamson K, Reid H, Barnes D, et al
    Injectable semaglutide and reductions in HbA1c and weight in the real world in people switched from alternative glucagon-like peptide-1 receptor agonists.
    Diabetes Obes Metab. 2022;24:1398-1401.
    >> Share

  647. AGARWAL R, Hauske SJ, Wheeler DC, Doi K, et al
    Empagliflozin and incidence of events consistent with acute kidney injury: Pooled safety analysis in more than 15 000 individuals.
    Diabetes Obes Metab. 2022;24:1390-1393.
    >> Share

  648. MENG Q, Chepurny OG, Leech CA, Pruekprasert N, et al
    The alpha-7 nicotinic acetylcholine receptor agonist GTS-21 engages the glucagon-like peptide-1 incretin hormone axis to lower levels of blood glucose in db/db mice.
    Diabetes Obes Metab. 2022;24:1255-1266.
    >> Share

  649. DAGOGO-JACK S, Cannon CP, Cherney DZI, Cosentino F, et al
    Cardiorenal outcomes with ertugliflozin assessed according to baseline glucose-lowering agent: An analysis from VERTIS CV.
    Diabetes Obes Metab. 2022;24:1245-1254.
    >> Share

    June 2022
  650. YUAN X, Guo X, Zhang J, Dong X, et al
    Improved glycaemic control and weight benefit with iGlarLixi versus insulin glargine 100 U/mL in Chinese people with type 2 diabetes advancing their therapy from basal insulin plus oral antihyperglycaemic drugs: results from the LixiLan-L-CN randomize
    Diabetes Obes Metab. 2022 Jun 28. doi: 10.1111/dom.14803.
    >> Share

  651. BRUNETTI VC, Yu OHY, Platt RW, Filion KB, et al
    The Association of Long-Acting Insulin Analogue Use Versus Neutral Protamine Hagedorn Insulin Use With Major Adverse Cardiovascular Events Among Individuals With Type 2 Diabetes: A Population-Based Cohort Study.
    Diabetes Obes Metab. 2022 Jun 21. doi: 10.1111/dom.14802.
    >> Share

  652. YANG S, Zhao L, Mi Y, He W, et al
    Effects of sodium-glucose cotransporter 2 inhibitors and aldosterone antagonists, in addition to renin-angiotensin system antagonists on major adverse kidney outcomes in patients with type 2 diabetes and chronic kidney disease: a systematic review and
    Diabetes Obes Metab. 2022 Jun 16. doi: 10.1111/dom.14801.
    >> Share

  653. TELL SS, Schafer M, Vigers T, Baumgartner AD, et al
    Bromocriptine Quick-Release as Adjunct Therapy in Youth and Adults with Type 1 Diabetes: A Randomized, Placebo-Controlled Crossover Study.
    Diabetes Obes Metab. 2022 Jun 16. doi: 10.1111/dom.14800.
    >> Share

  654. TOP WMC, Lehert P, Schalkwijk CG, Stehouwer CDA, et al
    Effect of metformin on arginine and dimethylarginines in patients with advanced type 2 diabetes: A post hoc analysis of a randomized trial.
    Diabetes Obes Metab. 2022 Jun 15. doi: 10.1111/dom.14784.
    >> Share

  655. ALI MK, Kadir MM, Gujral UP, Fatima S, et al
    Obesity associated metabolites in relation to type 2 diabetes risk: a Prospective Nested Case-Control Study of the CARRS Cohort.
    Diabetes Obes Metab. 2022 Jun 8. doi: 10.1111/dom.14788.
    >> Share

  656. WEWER ALBRECHTSEN NJ, Moller A, Martinussen C, Gluud LL, et al
    Acute effects on glucose tolerance by neprilysin inhibition in patients with type 2 diabetes.
    Diabetes Obes Metab. 2022 Jun 8. doi: 10.1111/dom.14789.
    >> Share

  657. SHAH A, Prasad M, Mark V, Holst JJ, et al
    GLP-1 effect on ss-cell function varies according to diabetes remission status after RYGB.
    Diabetes Obes Metab. 2022 Jun 8. doi: 10.1111/dom.14793.
    >> Share

  658. IDRIS I, Zhang R, Mamza JB, Ford M, et al
    Significant reduction in chronic kidney disease progression with sodium glucose co-transporter-2 inhibitors compared to dipeptidyl peptidase-4 inhibitors in adults with type 2 diabetes in UK clinical setting: An observational outcomes study based on i
    Diabetes Obes Metab. 2022 Jun 8. doi: 10.1111/dom.14799.
    >> Share

  659. CHIRIACO M, Sacchetta L, Forotti G, Leonetti S, et al
    Prognostic value of 24-hour ambulatory blood pressure patterns in diabetes: a 21-year longitudinal study.
    Diabetes Obes Metab. 2022 Jun 8. doi: 10.1111/dom.14798.
    >> Share

  660. MADDALONI E, Bolli GB, Frier BM, Little RR, et al
    C-peptide determination in the diagnosis of type of diabetes and its management: a clinical perspective.
    Diabetes Obes Metab. 2022 Jun 8. doi: 10.1111/dom.14785.
    >> Share

  661. KENG MJ, Leal J, Bowman L, Armitage J, et al
    Hospital costs associated with adverse events in people with diabetes in the UK.
    Diabetes Obes Metab. 2022 Jun 8. doi: 10.1111/dom.14796.
    >> Share

  662. HRAMIAK I, Gerstein HC, Leiter LA, Yale JF, et al
    Comparing a Daily vs. Weekly Titration Algorithm in People with Type 2 Diabetes Switching from Basal Insulin to iGlarLixi in the LixiLan ONE CAN Randomized Trial.
    Diabetes Obes Metab. 2022 Jun 7. doi: 10.1111/dom.14787.
    >> Share

  663. ANDREASEN CR, Andersen A, Hagelqvist PG, Lauritsen JV, et al
    Hypoglycaemia and rebound hyperglycaemia increase left ventricular systolic function in patients with type 1 diabetes.
    Diabetes Obes Metab. 2022 Jun 7. doi: 10.1111/dom.14790.
    >> Share

  664. PHAM TT, Chen X, Barron J, Hart R, et al
    Effectiveness, safety, and treatment adherence of biosimilar follow-on insulin in diabetes management.
    Diabetes Obes Metab. 2022 Jun 7. doi: 10.1111/dom.14786.
    >> Share

  665. CAO H, Liu T, Wang L, Ji Q, et al
    Comparative efficacy of novel antidiabetic drugs on cardiovascular and renal outcomes in patients with diabetic kidney disease: A systematic review and network meta-analysis.
    Diabetes Obes Metab. 2022 Jun 6. doi: 10.1111/dom.14702.
    >> Share

  666. KLEIN KR, Boeder SC, Freeman JLR, Dunn I, et al
    Impact of the hepatoselective glucokinase activator TTP399 on ketoacidosis during insulin withdrawal in people with type 1 diabetes.
    Diabetes Obes Metab. 2022 Jun 4. doi: 10.1111/dom.14697.
    >> Share

  667. SPENCE JD, Viscoli C, Kernan WN, Young LH, et al
    Efficacy of lower doses of pioglitazone after stroke or transient ischaemic attack in patients with insulin resistance.
    Diabetes Obes Metab. 2022;24:1150-1158.
    >> Share

  668. CHERNEY DZI, Cosentino F, Pratley RE, Dagogo-Jack S, et al
    The differential effects of ertugliflozin on glucosuria and natriuresis biomarkers: Prespecified analyses from VERTIS CV.
    Diabetes Obes Metab. 2022;24:1114-1122.
    >> Share

  669. BARRACLOUGH JY, Yu J, Figtree GA, Perkovic V, et al
    Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: Data from the CANVAS Program and CREDENCE trial.
    Diabetes Obes Metab. 2022;24:1072-1083.
    >> Share

  670. KAHL S, Ofstad AP, Zinman B, Wanner C, et al
    Effects of empagliflozin on markers of liver steatosis and fibrosis and their relationship to cardiorenal outcomes.
    Diabetes Obes Metab. 2022;24:1061-1071.
    >> Share

  671. SHEEHAN A, Goldfine A, Bajwa M, Wolfs D, et al
    Pramlintide for post-bariatric hypoglycaemia.
    Diabetes Obes Metab. 2022;24:1021-1028.
    >> Share

  672. YOSHIJI S, Minamino H, Tanaka D, Yamane S, et al
    Effects of glucagon-like peptide-1 receptor agonists on cardiovascular and renal outcomes: A meta-analysis and meta-regression analysis.
    Diabetes Obes Metab. 2022;24:1029-1037.
    >> Share

  673. PRATLEY RE, Gorst-Rasmussen A
    Indirect treatment comparisons: Choosing the right tool for the job.
    Diabetes Obes Metab. 2022;24:1180-1181.
    >> Share

  674. WAIJER SW, Provenzano M, Mulder S, Rossing P, et al
    Impact of random variation in albuminuria and estimated glomerular filtration rate on patient enrolment and duration of clinical trials in nephrology.
    Diabetes Obes Metab. 2022;24:983-990.
    >> Share

  675. PAN Q, Li Y, Wan H, Wang J, et al
    Efficacy and safety of a basal insulin + 2-3 oral antihyperglycaemic drugs regimen versus a twice-daily premixed insulin + metformin regimen after short-term intensive insulin therapy in individuals with type 2 diabetes: the multicentre, open-label, r
    Diabetes Obes Metab. 2022 Jun 1. doi: 10.1111/dom.14780.
    >> Share

    May 2022
  676. ZENG B, Jia H, Gao L, Yang Q, et al
    Dual-hormone artificial pancreas for glucose control in type 1 diabetes: a meta-analysis.
    Diabetes Obes Metab. 2022 May 31. doi: 10.1111/dom.14781.
    >> Share

  677. O'MAHONEY LL, Highton PJ, Kudlek L, Morgan J, et al
    The impact of the Covid-19 pandemic on glycaemic control in people with diabetes: a systematic review and meta-analysis.
    Diabetes Obes Metab. 2022 May 23. doi: 10.1111/dom.14771.
    >> Share

  678. SEGAR MW, Kolkailah AA, Frederich R, Pong A, et al
    Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes.
    Diabetes Obes Metab. 2022 May 23. doi: 10.1111/dom.14769.
    >> Share

  679. PANG H, Lin J, Luo S, Huang G, et al
    The missing heritability in type 1 diabetes mellitus.
    Diabetes Obes Metab. 2022 May 23. doi: 10.1111/dom.14777.
    >> Share

  680. VADHER K, Patel H, Mody R, Levine JA, et al
    Efficacy of tirzepatide 5, 10, and 15 mg versus semaglutide 2 mg in patients with type 2 diabetes: an adjusted indirect treatment comparison.
    Diabetes Obes Metab. 2022 May 19. doi: 10.1111/dom.14775.
    >> Share

  681. YUAN D, Sharma H, Krishnan A, Vangaveti VN, et al
    Effect of glucagon-like peptide 1 receptor agonists on albuminuria in adult patients with type 2 diabetes mellitus: A Systematic Review and Meta-Analysis.
    Diabetes Obes Metab. 2022 May 19. doi: 10.1111/dom.14776.
    >> Share

  682. LI C, Yu J, Hockham C, Perkovic V, et al
    Canagliflozin and Atrial Fibrillation in Type 2 Diabetes Mellitus: A secondary analysis from the CANVAS Program and CREDENCE trials and meta-analysis.
    Diabetes Obes Metab. 2022 May 19. doi: 10.1111/dom.14772.
    >> Share

  683. PIEMONTI L, Keymeulen B, Gillard P, Linn T, et al
    Ladarixin, an inhibitor of IL-8 receptors CXCR1 and CXCR2, in new-onset type 1 diabetes: a multicenter, randomized, double-blind, placebo-controlled trial.
    Diabetes Obes Metab. 2022 May 19. doi: 10.1111/dom.14770.
    >> Share

  684. RYANG S, Kim SS, Bae JC, Han JM, et al
    A Double-blind, Randomized Controlled Trial on Glucose-lowering Effects and Safety of Adding 0.25 or 0.5 mg Lobeglitazone in Type 2 Diabetes Patients with Inadequate Control on Metformin and DPP-4 Inhibitor Therapy: REFIND Study.
    Diabetes Obes Metab. 2022 May 17. doi: 10.1111/dom.14766.
    >> Share

  685. COX DA, Wang H, Nicolay C, Bethel MA, et al
    Effect of expanded dulaglutide weekly doses (3.0 mg and 4.5 mg) on cardiovascular disease risk factors in participants with type 2 diabetes at increased cardiovascular disease risk: a post hoc analysis of the AWARD-11 study.
    Diabetes Obes Metab. 2022 May 11. doi: 10.1111/dom.14762.
    >> Share

  686. KELLERER M, Kaltoft MS, Lawson J, Nielsen LL, et al
    Effect of once-weekly semaglutide versus thrice-daily insulin aspart, both as add-on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): a randomized, open-label, multinational, phase 3b trial.
    Diabetes Obes Metab. 2022 May 11. doi: 10.1111/dom.14765.
    >> Share

  687. WEINSTOCK RS, Bode BW, Garg SK, Klonoff DC, et al
    Reduced Hypoglycemia Using Liver Targeted Insulin in Persons with Type 1 Diabetes.
    Diabetes Obes Metab. 2022 May 11. doi: 10.1111/dom.14761.
    >> Share

  688. HEJJAJI V, Gorgojo-Martinez JJ, Tang F, Garnelo JB, et al
    Factors Associated with Weight Loss in People with Overweight or Obesity Living with Type 2 Diabetes Mellitus: Insights from the Global DISCOVER Study.
    Diabetes Obes Metab. 2022 May 11. doi: 10.1111/dom.14745.
    >> Share

  689. XU Y, Bergenstal RM, Dunn TC, Ram Y, et al
    Inter-individual Variability in Average Glucose-HbA1c Relationship in type 1 diabetes and Implications for Clinical Practice.
    Diabetes Obes Metab. 2022 May 11. doi: 10.1111/dom.14763.
    >> Share

  690. AL-SALAMEH A, Wiernsperger N, Cariou B, Lalau JD, et al
    A comment on metformin and COVID-19 with regard to "Metformin use is associated with a decrease in the risk of hospitalization and mortality in COVID-19 patients with diabetes: A population-based study in Lombardy".
    Diabetes Obes Metab. 2022 May 11. doi: 10.1111/dom.14746.
    >> Share

  691. GARVEY WT, Umpierrez GE, Dunn JP, Kwan AYM, et al
    Weighing the evidence for weight management in individuals with type 2 diabetes.
    Diabetes Obes Metab. 2022 May 11. doi: 10.1111/dom.14764.
    >> Share

  692. BELL DSH
    Metformin induced vitamin B12 deficiency can cause or worsen distal symmetrical, autonomic and cardiac neuropathy in the patient with diabetes.
    Diabetes Obes Metab. 2022 May 2. doi: 10.1111/dom.14734.
    >> Share

  693. YADAV Y, Dunagan K, Khot R, Venkatesh SK, et al
    Inhibition of 11beta-Hydroxysteroid dehydrogenase-1 with AZD4017 in patients with nonalcoholic steatohepatitis or nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled, phase II study.
    Diabetes Obes Metab. 2022;24:881-890.
    >> Share

  694. NUYUJUKIAN DS, Newell MS, Zhou JJ, Koska J, et al
    Baseline blood pressure modifies the role of blood pressure variability in mortality: Results from the ACCORD trial.
    Diabetes Obes Metab. 2022;24:951-955.
    >> Share

  695. CHERTOW GM, Vart P, Jongs N, Langkilde AM, et al
    Quetelet (body mass) index and effects of dapagliflozin in chronic kidney disease.
    Diabetes Obes Metab. 2022;24:827-837.
    >> Share

  696. BENSIGNOR MO, Wolf JM, Rudser KD, Kelly AS, et al
    Glucagon-like peptide-1 receptor agonist prescribing patterns in adolescents with type 2 diabetes.
    Diabetes Obes Metab. 2022 May 1. doi: 10.1111/dom.14681.
    >> Share

  697. DONG YH, Chang CH, Lin JW, Yang WS, et al
    Comparative cardiovascular effectiveness of glucagon-like peptide-1 receptor agonists versus sodium glucose cotransporter 2 inhibitors in patients with type 2 diabetes: a population-based cohort study.
    Diabetes Obes Metab. 2022 May 1. doi: 10.1111/dom.14741.
    >> Share

  698. MIYAMOTO S, Heerspink HJL, de Zeeuw D, Toyoda M, et al
    Rationale, Design and Baseline Characteristics of the Effect of Canagliflozin in Type 2 Diabetic Patients with Microalbuminuria in Japanese Population (CANPIONE) study.
    Diabetes Obes Metab. 2022 May 1. doi: 10.1111/dom.14731.
    >> Share

  699. VAN RUITEN CC, Veltman DJ, Wijdeveld M, Ten Kulve JS, et al
    Combination therapy with exenatide decreases the dapagliflozin-induced changes in brain responses to anticipation and consumption of palatable food in patients with type 2 diabetes: a randomized controlled trial.
    Diabetes Obes Metab. 2022 May 1. doi: 10.1111/dom.14732.
    >> Share

  700. ZACCARDI F, Kloecker DE, Khunti K, Davies MJ, et al
    Noninferiority and clinical superiority of GLP-1 receptor agonists and SGLT2 inhibitors: systematic analysis of cardiorenal outcome trials in type 2 diabetes.
    Diabetes Obes Metab. 2022 May 1. doi: 10.1111/dom.14735.
    >> Share

  701. BAILEY TS, Gill J, Jones M, Shenoy L, et al
    Real-world outcomes of addition of insulin glargine 300 U/mL (Gla-300) to GLP-1 RA therapy in people with type 2 diabetes: The DELIVER-G study.
    Diabetes Obes Metab. 2022 May 1. doi: 10.1111/dom.14739.
    >> Share

  702. SPILIOTIS II, Chalk R, Gough S, Rorsman P, et al
    Reducing hyperglucagonemia in type 2 diabetes using low dose Glibenclamide: Results of the LEGEND-A pilot study.
    Diabetes Obes Metab. 2022 May 1. doi: 10.1111/dom.14740.
    >> Share

  703. STENSEN S, Krogh LL, Sparre-Ulrich AH, Dela F, et al
    Acute concomitant GIP receptor antagonism during GLP-1 receptor agonism does not affect appetite, resting energy expenditure or food intake in patients with type 2 diabetes and overweight/obesity.
    Diabetes Obes Metab. 2022 May 1. doi: 10.1111/dom.14736.
    >> Share

  704. DEO SV, Marsia S, McAllister DA, Elgudin Y, et al
    The Time-varying Cardiovascular benefits of Glucagon like peptide-1 receptor agonist therapy in patients with type 2 Diabetes Mellitus: Evidence from large multinational trials.
    Diabetes Obes Metab. 2022 May 1. doi: 10.1111/dom.14738.
    >> Share

    April 2022
  705. SEN T, Scholtes R, Greasley PJ, Cherney D, et al
    Effects of dapagliflozin on volume status and systemic hemodynamics in patients with CKD without diabetes: Results from DAPASALT and DIAMOND.
    Diabetes Obes Metab. 2022 Apr 28. doi: 10.1111/dom.14729.
    >> Share

  706. VENCIO S, Caiado-Vencio R, Caixeta LF, Masierek M, et al
    A randomized pharmacokinetic and pharmacodynamic trial of two regular human insulins demonstrates bioequivalence in type 1 diabetes and availability of biosimilar insulin may improve access to this medication.
    Diabetes Obes Metab. 2022 Apr 19. doi: 10.1111/dom.14724.
    >> Share

  707. ZIELINSKI M, Zalinska M, Iwaszkiewicz-Grzes D, Gliwinski M, et al
    Combined therapy with CD4 + CD25highCD127- T regulatory cells and anti-CD20 antibody in recent-onset type 1 diabetes is superior to monotherapy - randomized phase I/II trial.
    Diabetes Obes Metab. 2022 Apr 19. doi: 10.1111/dom.14723.
    >> Share

  708. SARGEANT JA, King JA, Yates T, Redman EL, et al
    The effects of empagliflozin, dietary energy restriction, or both on appetite-regulatory gut peptides in individuals with type 2 diabetes and overweight or obesity: the SEESAW randomised, double-blind, placebo-controlled trial.
    Diabetes Obes Metab. 2022 Apr 19. doi: 10.1111/dom.14721.
    >> Share

  709. YANG W, Dong X, Li Q, Cheng Z, et al
    Efficacy and safety benefits of iGlarLixi versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with suboptimally controlled type 2 diabetes on oral agents: The LixiLan-O-AP randomized controlled trial.
    Diabetes Obes Metab. 2022 Apr 19. doi: 10.1111/dom.14722.
    >> Share

  710. NOWAK C, Hannelius U, Ludvigsson J
    Association between treatment effect on C-peptide preservation and HbA1c in meta-analysis of GAD-alum immunotherapy in recent-onset Type 1 diabetes.
    Diabetes Obes Metab. 2022 Apr 17. doi: 10.1111/dom.14720.
    >> Share

  711. SEIDU S, Almaqhawi A, Abdool M, Kunutsor SK, et al
    Cardiovascular and renal outcomes of initial combination therapy with glucose-lowering agents versus stepwise approach in newly diagnosed or treatment naive type 2 diabetes: a systematic review and meta-analysis.
    Diabetes Obes Metab. 2022 Apr 17. doi: 10.1111/dom.14715.
    >> Share

  712. SIVALINGAM S, Zobel EH, Hansen CS, Ripa RS, et al
    The effect of liraglutide on cardiac autonomic function in type 2 diabetes: A prespecified secondary analysis from the LIRAFLAME randomized, double-blinded, placebo-controlled trial.
    Diabetes Obes Metab. 2022 Apr 12. doi: 10.1111/dom.14717.
    >> Share

  713. PARKER VER, Hoang T, Schlichthaar H, Gibb FW, et al
    Efficacy and safety of cotadutide, a dual GLP-1 and glucagon receptor agonist, in a randomized phase 2a study of patients with type 2 diabetes and chronic kidney disease.
    Diabetes Obes Metab. 2022 Apr 11. doi: 10.1111/dom.14712.
    >> Share

  714. DE BLOCK CEM, Van Cauwenberghe J, Bochanen N, Dirinck E, et al
    Rapid-Acting Insulin Analogues: Theory and Best Clinical Practice in Type 1 and Type 2 Diabetes.
    Diabetes Obes Metab. 2022 Apr 11. doi: 10.1111/dom.14713.
    >> Share

  715. EVANS M, Chandramouli AS, Faurby M, Matthiessen KS, et al
    Healthcare costs and hospitalizations in US patients with type 2 diabetes and cardiovascular disease: A retrospective database study (OFFSET).
    Diabetes Obes Metab. 2022 Apr 5. doi: 10.1111/dom.14703.
    >> Share

  716. PENG ZY, Yang CT, Ou HT, Kuo S, et al
    Cost-effectiveness of SGLT2is versus DPP4is among type 2 diabetes patients with and without established cardiovascular disease: A model-based simulation analysis using 10-year real-world data and targeted literature review.
    Diabetes Obes Metab. 2022 Apr 4. doi: 10.1111/dom.14708.
    >> Share

  717. BOONPOR J, Petermann-Rocha F, Parra-Soto S, Pell JP, et al
    Types of Diet, Obesity, and Incident Type 2 Diabetes: Findings from The UK Biobank Prospective Cohort Study.
    Diabetes Obes Metab. 2022 Apr 4. doi: 10.1111/dom.14711.
    >> Share

  718. WHYTE MB, Joy M, Hinton W, McGovern A, et al
    Early and ongoing stable glycaemic control is associated with a reduction in major adverse cardiovascular events (MACE) in people with type 2 diabetes: primary care cohort study.
    Diabetes Obes Metab. 2022 Apr 4. doi: 10.1111/dom.14705.
    >> Share

  719. LEITE AR, Angelico-Goncalves A, Vasques-Novoa F, Borges-Canha M, et al
    Effect of GLP-1 receptor agonists on cardiovascular events in overweight or obese adults without diabetes: a meta-analysis of placebo-controlled randomized trials.
    Diabetes Obes Metab. 2022 Apr 4. doi: 10.1111/dom.14707.
    >> Share

  720. GOMEZ-PERALTA F, Choudhary P, Cosson E, Irace C, et al
    Understanding the clinical implications of differences between glucose management indicator and glycated haemoglobin.
    Diabetes Obes Metab. 2022;24:599-608.
    >> Share

  721. HALL RM, Dyhrberg S, McTavish A, McTavish L, et al
    Where can you wear your Libre? Using the FreeStyle Libre continuous glucose monitor on alternative sites.
    Diabetes Obes Metab. 2022;24:675-683.
    >> Share

  722. CLEMENS KK, Ouedraogo AM, Lam M, Muanda FT, et al
    Trends in basal insulin prescribing in older adults with chronic kidney disease in Ontario, Canada: A population-based analysis from 2010 to 2020.
    Diabetes Obes Metab. 2022;24:641-651.
    >> Share

  723. HE K, Guo Q, Zhang H, Xi W, et al
    Once-weekly semaglutide for obesity or overweight: A systematic review and meta-analysis.
    Diabetes Obes Metab. 2022;24:722-726.
    >> Share

    March 2022
  724. VERMA S, Al-Omran M, Leiter LA, Mazer CD, et al
    Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease.
    Diabetes Obes Metab. 2022 Mar 24. doi: 10.1111/dom.14700.
    >> Share

  725. NORHAMMAR A, Bodegard J, Eriksson JW, Hermann H, et al
    Cost of healthcare utilization associated with incident cardiovascular and renal disease in individuals with type 2 diabetes: a multinational, observational study across 12 countries.
    Diabetes Obes Metab. 2022 Mar 23. doi: 10.1111/dom.14698.
    >> Share

  726. PIEBER TR, Aronson R, Christiansen MP, Bode B, et al
    Efficacy, safety, tolerability, and noninferiority phase 3 study of glucagon as a ready-to-use room temperature liquid stable formulation versus as a lyophilised formulation for the biochemical recovery and symptomatic relief of insulin-induced severe
    Diabetes Obes Metab. 2022 Mar 23. doi: 10.1111/dom.14699.
    >> Share

  727. DEFRONZO RA, Bakris GL
    Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes.
    Diabetes Obes Metab. 2022 Mar 18. doi: 10.1111/dom.14696.
    >> Share

  728. ENG PC, Distaso W, Durreshahwar H, Shaikhali Y, et al
    The benefit of dexamethasone in patients with COVID-19 infection is preserved in patients with diabetes.
    Diabetes Obes Metab. 2022 Mar 15. doi: 10.1111/dom.14692.
    >> Share

  729. SETTLES J, Kan H, Child CJ, Gorritz M, et al
    Previously unrecognised risk factors for severe hypoglycaemia requiring emergency medical care in insulin-treated type 2 diabetes: results from a real-world nested case-control study.
    Diabetes Obes Metab. 2022 Mar 9. doi: 10.1111/dom.14690.
    >> Share

  730. KASTNER JR, Venkatesh N, Brown K, Muchmore DB, et al
    Feasibility Study of a Prototype Extended-Wear Insulin Infusion Set in Adults with Type 1 Diabetes.
    Diabetes Obes Metab. 2022 Mar 8. doi: 10.1111/dom.14685.
    >> Share

  731. FERRANNINI E, Niemoeller E, Dex T, Servera S, et al
    Fixed-ratio combination of insulin glargine plus lixisenatide (iGlarLixi) improves ss-cell function in people with type 2 diabetes.
    Diabetes Obes Metab. 2022 Mar 7. doi: 10.1111/dom.14688.
    >> Share

  732. WILLIAMS BA, Brady JP, Voyce S, Kumar N, et al
    Changes Over Time in the Cardiovascular Risk Profile of Type 2 Diabetes from 2007-2020: A Community-Based Study.
    Diabetes Obes Metab. 2022 Mar 7. doi: 10.1111/dom.14686.
    >> Share

  733. BAE J, Liu D, Chinthammit C, Kadziola Z, et al
    Type 2 Diabetes Pharmacotherapy Trends in High-Risk Subgroups.
    Diabetes Obes Metab. 2022 Mar 3. doi: 10.1111/dom.14678.
    >> Share

  734. ANDERSEN A, Jorgensen PG, Bagger JI, Baldassarre MPA, et al
    Acute changes in plasma glucose increases left ventricular systolic function in insulin-treated patients with type 2 diabetes and controls.
    Diabetes Obes Metab. 2022 Mar 3. doi: 10.1111/dom.14682.
    >> Share

  735. WANG X, Chen C, Xie C, Huang W, et al
    Serum bile acid response to oral glucose is attenuated in patients with early type 2 diabetes and correlates with 2h plasma glucose in individuals without diabetes.
    Diabetes Obes Metab. 2022 Mar 3. doi: 10.1111/dom.14683.
    >> Share

  736. KHUNTIV K, Jabbour S, Cos X, Mudaliar S, et al
    Sodium-glucose cotransporter-2 (SGLT-2) inhibitors in patients with type 2 diabetes: Barriers and solutions for improving uptake in routine clinical practice.
    Diabetes Obes Metab. 2022 Mar 3. doi: 10.1111/dom.14684.
    >> Share

  737. SIMONSON DC, Hu B, Arterburn DE, Schauer PR, et al
    Alliance of Randomized Trials of Medicine vs. Metabolic Surgery in Type 2 Diabetes (ARMMS-T2D): Study Rationale, Design, and Methods.
    Diabetes Obes Metab. 2022 Mar 1. doi: 10.1111/dom.14680.
    >> Share

  738. LEE M, Lee WJ, Kim JH, Lee BW, et al
    Effectiveness and safety of teneligliptin added to patients with type 2 diabetes inadequately controlled by oral triple combination therapy: A multicentre, randomized, double-blind, and placebo-controlled study.
    Diabetes Obes Metab. 2022 Mar 1. doi: 10.1111/dom.14679.
    >> Share

  739. ABDELHALEEM IA, Abd-Elhamied MA, Morsi AE, Kenawy S, et al
    Efficacy and safety of efpeglenatide in adults with obesity and its associated metabolic disturbance: A systematic review and meta-analysis of randomized controlled trials.
    Diabetes Obes Metab. 2022;24:555-560.
    >> Share

  740. REGITTNIG W, Tschaikner M, Tuca AC, Simic A, et al
    Insulin induces a progressive increase in the resistance of subcutaneous tissue to fluid flow: Implications for insulin pump therapy.
    Diabetes Obes Metab. 2022;24:455-464.
    >> Share

  741. UEDA P, Wintzell V, Dahlqwist E, Eliasson B, et al
    The comparative cardiovascular and renal effectiveness of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: A Scandinavian cohort study.
    Diabetes Obes Metab. 2022;24:473-485.
    >> Share

  742. PATORNO E, Pawar A, Wexler DJ, Glynn RJ, et al
    Effectiveness and safety of empagliflozin in routine care patients: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study.
    Diabetes Obes Metab. 2022;24:442-454.
    >> Share

  743. LIN C, Cai X, Ji L
    Cardiovascular benefits beyond urinary glucose excretion: A hypothesis generated from two meta-analyses.
    Diabetes Obes Metab. 2022;24:550-554.
    >> Share

    February 2022
  744. SCHECHTER M, Fischer M, Mosenzon O
    Preventing all-cause hospitalizations in type-2 diabetes with SGLT2 inhibitors and GLP-1 receptor agonists - narrative review and clinical approach.
    Diabetes Obes Metab. 2022 Feb 25. doi: 10.1111/dom.14675.
    >> Share

  745. HETHERINGTON-RAUTH M, Magalhaes JP, Rosa GB, Correia IR, et al
    Morning vs. Afternoon Physical Activity and Health-Related Outcomes in Individuals with Type 2 Diabetes.
    Diabetes Obes Metab. 2022 Feb 24. doi: 10.1111/dom.14676.
    >> Share

  746. WANG W, Song X, Lou Y, Du L, et al
    Immunogenicity of LY2963016 insulin glargine and Lantus(R) insulin glargine in Chinese patients with type 1 or type 2 diabetes mellitus.
    Diabetes Obes Metab. 2022 Feb 20. doi: 10.1111/dom.14674.
    >> Share

  747. KOTSOPOULOS N, Connolly MP, Willis M, Nilsson A, et al
    The public economic burden of sub-optimal type-2 diabetes control on tax payors in Sweden: Looking beyond health costs.
    Diabetes Obes Metab. 2022 Feb 8. doi: 10.1111/dom.14667.
    >> Share

  748. RHEE JJ, Han J, Montez-Rath ME, Kim SH, et al
    Cardiovascular outcomes associated with prescription of SGLT-2 inhibitors versus DPP-4 inhibitors in patients with diabetes mellitus and chronic kidney disease.
    Diabetes Obes Metab. 2022 Feb 3. doi: 10.1111/dom.14657.
    >> Share

  749. BIRABAHARAN M, Kaelber DC, Pettus JH, Smith DM, et al
    Risk of New-Onset Type 2 Diabetes Mellitus in 600,055 Persons after COVID-19: a cohort study.
    Diabetes Obes Metab. 2022 Feb 3. doi: 10.1111/dom.14659.
    >> Share

  750. GAO B, Gao W, Wan H, Xu F, et al
    Efficacy and safety of alogliptin versus acarbose in Chinese type 2 diabetes patients with high cardiovascular risk or coronary heart disease treated with aspirin, and inadequately controlled with metformin monotherapy or drug naive: a multicenter, ra
    Diabetes Obes Metab. 2022 Feb 3. doi: 10.1111/dom.14661.
    >> Share

  751. NEWBY D, Garfield V
    Understanding the interrelationships of type-2 diabetes and hypertension with brain and cognitive health: a UK Biobank study.
    Diabetes Obes Metab. 2022 Feb 2. doi: 10.1111/dom.14658.
    >> Share

  752. FADINI GP, Del Prato S, Avogaro A, Solini A, et al
    Challenges and opportunities in real-world evidence on the renal effects of sodium-glucose cotransporter-2 inhibitors.
    Diabetes Obes Metab. 2022;24:177-186.
    >> Share

  753. CAI M, Shao X, Xing F, Zhang Y, et al
    Efficacy of canagliflozin versus metformin in women with polycystic ovary syndrome: A randomized, open-label, noninferiority trial.
    Diabetes Obes Metab. 2022;24:312-320.
    >> Share

  754. THAM LS, Pantalone KM, Dungan K, Munir K, et al
    A model-based simulation of glycaemic control and body weight when switching from semaglutide to 3.0- and 4.5-mg doses of once-weekly dulaglutide.
    Diabetes Obes Metab. 2022;24:302-311.
    >> Share

  755. COWART K, Gonzalez R, Carris NW
    Cardiovascular and microvascular outcomes with iGlarLixi versus iDegLira: A real-world, population-based cohort study.
    Diabetes Obes Metab. 2022;24:348-353.
    >> Share

  756. FINER N
    Weight loss interventions and nonalcoholic fatty liver disease: Optimizing liver outcomes.
    Diabetes Obes Metab. 2022;24 Suppl 2:44-54.
    >> Share

  757. HU X, Yang Y, Hu X, Jia X, et al
    Effects of sodium-glucose cotransporter 2 inhibitors on serum uric acid in patients with type 2 diabetes mellitus: A systematic review and network meta-analysis.
    Diabetes Obes Metab. 2022;24:228-238.
    >> Share

  758. BORODAVKIN P, Sheridan W, Coelho C, Ostarijas E, et al
    Effects of glucagon-like peptide-1 receptor agonists on histopathological and secondary biomarkers of non-alcoholic steatohepatitis: A systematic review and meta-analysis.
    Diabetes Obes Metab. 2022;24:337-342.
    >> Share

  759. BUZZETTI R, Bonadonna RC, Giaccari A, Perseghin G, et al
    Underestimation of hypoglycaemia using patients' diaries compared with downloaded glucometer data: an ITAS post hoc analysis.
    Diabetes Obes Metab. 2022;24:327-331.
    >> Share

    January 2022
  760. BENHAMOU PY, Lablanche S, Vambergue A, Pou S, et al
    Beneficial effects of closed-loop insulin delivery in highly unstable type 1 diabetes eligible for islet transplantation are maintained over 6 months. An extension study of DBLHU-WP10 trial.
    Diabetes Obes Metab. 2022 Jan 31. doi: 10.1111/dom.14654.
    >> Share

  761. GOEDECKE JH, Nguyen K, Kufe C, Masemola M, et al
    Waist circumference thresholds predicting incident dysglycaemia and type 2 diabetes in Black African men and women.
    Diabetes Obes Metab. 2022 Jan 27. doi: 10.1111/dom.14655.
    >> Share

  762. FARHAT R, Aiken J, D'Souza NC, Appadurai D, et al
    ZT-01 - A Novel Somatostatin Receptor Antagonist for Restoring the Glucagon Response to Hypoglycemia in Type 1 Diabetes.
    Diabetes Obes Metab. 2022 Jan 21. doi: 10.1111/dom.14652.
    >> Share

  763. CARIOU B
    The metabolic triad of NAFLD, visceral adiposity and type 2 diabetes: implications for treatment.
    Diabetes Obes Metab. 2022 Jan 11. doi: 10.1111/dom.14651.
    >> Share

  764. OJEDA-FERNANDEZ L, Foresta A, Macaluso G, Colacioppo P, et al
    Metformin use is associated with a decrease in risk of hospitalization and mortality in COVID-19 diabetic patients: a population-based study in Lombardy.
    Diabetes Obes Metab. 2022 Jan 10. doi: 10.1111/dom.14648.
    >> Share

  765. VAN DEN BOOM L, Kostev K
    Persistence of the insulin pump therapy in children and young adults with Type 1 diabetes (T1D) in Germany: an update.
    Diabetes Obes Metab. 2022 Jan 10. doi: 10.1111/dom.14647.
    >> Share

  766. LAVYNENKO O, Abdul-Ghani M, Alatrach M, Puckett C, et al
    Combination Therapy with Pioglitazone/Exenatide Metformin Reduces the Prevalence of Hepatic Fibrosis and Steatosis: The Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT) Trial.
    Diabetes Obes Metab. 2022 Jan 10. doi: 10.1111/dom.14650.
    >> Share

  767. KOBAYATI A, Haidar A, Tsoukas MA
    GLP-1 Receptor Agonists as Adjunctive Treatment for Type 1 Diabetes: Renewed Opportunities through Tailored Approaches?
    Diabetes Obes Metab. 2022 Jan 6. doi: 10.1111/dom.14637.
    >> Share

  768. ANTLANGER M, Domenig O, Kaltenecker CC, Kovarik JJ, et al
    Combined SGLT-2 and ACE inhibition upregulates the renin-angiotensin system in chronic kidney disease with type 2 diabetes: Results of a randomized, double-blind, placebo-controlled exploratory trial.
    Diabetes Obes Metab. 2022 Jan 4. doi: 10.1111/dom.14639.
    >> Share

  769. REILHAC C, Dubourg J, Thang C, Grouin JM, et al
    Efficacy and safety of imeglimin add-on to insulin monotherapy in Japanese patients with type 2 diabetes (TIMES 3): A randomized, double-blind, placebo-controlled phase 3 trial with a 36-week open-label extension period.
    Diabetes Obes Metab. 2022 Jan 4. doi: 10.1111/dom.14642.
    >> Share

  770. RAUBENHEIMER PJ, Cushman WC, Avezum A, Basile J, et al
    Dulaglutide and Incident Atrial Fibrillation or Flutter in patients with type 2 Diabetes; a post-hoc analysis from the REWIND Randomized Trial.
    Diabetes Obes Metab. 2022 Jan 4. doi: 10.1111/dom.14634.
    >> Share

  771. GRAM-KAMPMANN EM, Hansen CD, Hugger MB, Jensen JM, et al
    Effects of a six-month low-carbohydrate diet on glycemic control, body composition and cardiovascular risk factors in patients with type 2 diabetes: an open-label RCT.
    Diabetes Obes Metab. 2022 Jan 4. doi: 10.1111/dom.14633.
    >> Share

  772. SOURIJ C, Tripolt NJ, Aziz F, Aberer F, et al
    Humoral immune response to Covid-19 vaccination in diabetes: age-dependent but independent of type of diabetes and glycaemic control - the prospective COVAC-DM cohort study.
    Diabetes Obes Metab. 2022 Jan 4. doi: 10.1111/dom.14643.
    >> Share

  773. MEIER JJ, Quast DR, Nauck MA, Schenker N, et al
    Acute effects of linagliptin on intact and total GLP-1 and GIP levels in insulin-dependent type 2 diabetic patients with and without moderate renal impairment.
    Diabetes Obes Metab. 2022 Jan 4. doi: 10.1111/dom.14636.
    >> Share

  774. DE BLOCK CEM, Dirinck E, Verhaegen A, Van Gaal LF, et al
    Efficacy and safety of high-dose GLP-1, GLP-1/GIP and GLP-1/glucagon receptor agonists in type 2 diabetes.
    Diabetes Obes Metab. 2022 Jan 4. doi: 10.1111/dom.14640.
    >> Share

  775. RENARD E, Riveline JP, Hanaire H, Guerci B, et al
    Reduction of clinically important low glucose excursions with a long-term implantable continuous glucose monitoring (CGM) system in adults with type 1 diabetes prone to hypoglycemia. France Adoption randomized clinical trial.
    Diabetes Obes Metab. 2022 Jan 4. doi: 10.1111/dom.14644.
    >> Share

  776. LEITER LA, Banach M, Catapano AL, Duell PB, et al
    Bempedoic acid in patients with type 2 diabetes mellitus, prediabetes, and normoglycaemia: a post hoc analysis of efficacy and glycaemic control using pooled data from phase 3 clinical trials.
    Diabetes Obes Metab. 2022 Jan 3. doi: 10.1111/dom.14645.
    >> Share

  777. TURNER LV, Riddell MC
    Pushing the limits of insulin delivery 100 years later: A case study of a race across Canada.
    Diabetes Obes Metab. 2022;24 Suppl 1:58-62.
    >> Share

  778. OWENS DR, Monnier L, Ceriello A, Bolli GB, et al
    Insulin Centennial: Milestones influencing the development of insulin preparations since 1922.
    Diabetes Obes Metab. 2022;24 Suppl 1:27-42.
    >> Share

  779. BIESTER T, Tauschmann M, Chobot A, Kordonouri O, et al
    The automated pancreas: A review of technologies and clinical practice.
    Diabetes Obes Metab. 2022;24 Suppl 1:43-57.
    >> Share

  780. EKANAYAKE P, Mudaliar S
    A novel hypothesis linking low-grade ketonaemia to cardio-renal benefits with sodium-glucose cotransporter-2 inhibitors.
    Diabetes Obes Metab. 2022;24:3-11.
    >> Share

  781. RETNAKARAN R, Zinman B
    The ongoing evolution of basal insulin therapy over 100 years and its promise for the future.
    Diabetes Obes Metab. 2022;24 Suppl 1:17-26.
    >> Share

  782. WHARTON S, Calanna S, Davies M, Dicker D, et al
    Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss.
    Diabetes Obes Metab. 2022;24:94-105.
    >> Share

  783. TOKUTSU A, Okada Y, Mita T, Torimoto K, et al
    Relationship between blood glucose variability in ambulatory glucose profile and standardized continuous glucose monitoring metrics: Subanalysis of a prospective cohort study.
    Diabetes Obes Metab. 2022;24:82-93.
    >> Share

  784. TANG H, Kimmel SE, Hernandez I, Brooks MM, et al
    Are novel glucose-lowering agents' cardiorenal benefits generalizable to individuals of Black race? A meta-trial sequential analysis to address disparities in cardiovascular and renal outcome trials enrolment.
    Diabetes Obes Metab. 2022;24:154-159.
    >> Share

  785. WEIR MR, Gogate J, Damaraju CV, Correa-Rotter R, et al
    Effects of canagliflozin on major adverse cardiovascular events by baseline estimated glomerular filtration rate: Pooled Hispanic subgroup analyses from the CANVAS Program and CREDENCE trial.
    Diabetes Obes Metab. 2022;24:12-20.
    >> Share

  786. PAGET MB, Murray HE, Bailey CJ, Downing R, et al
    From insulin injections to islet transplantation: An overview of the journey.
    Diabetes Obes Metab. 2022;24 Suppl 1:5-16.
    >> Share

    December 2021
  787. MEIER JJ, Granhall C, Hoevelmann U, Navarria A, et al
    Effect of upper gastrointestinal disease on the pharmacokinetics of oral semaglutide in subjects with type 2 diabetes.
    Diabetes Obes Metab. 2021 Dec 26. doi: 10.1111/dom.14632.
    >> Share

  788. CZUPRYNIAK L, Danne T, Szymanska-Garbacz E, Zozulinska-Ziolkiewicz D, et al
    SGLT-2 inhibitor for type 1 diabetes - not any more?
    Diabetes Obes Metab. 2021 Dec 21. doi: 10.1111/dom.14631.
    >> Share

  789. HAN E, Huh JH, Lee EY, Bae JC, et al
    Efficacy and Safety of Evogliptin in Patients with Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease: A Multicenter, Double-blind, Randomized, Comparative trial.
    Diabetes Obes Metab. 2021 Dec 17. doi: 10.1111/dom.14623.
    >> Share

  790. REIFSNIDER OS, Pimple P, Brand S, Bergrath Washington E, et al
    Cost-Effectiveness of Second-Line Empagliflozin versus Liraglutide for Type 2 Diabetes in the United States.
    Diabetes Obes Metab. 2021 Dec 14. doi: 10.1111/dom.14625.
    >> Share

  791. KAKU K, Wanner C, Anker SD, Pocock S, et al
    The effect of empagliflozin on the total burden of cardiovascular and hospitalization events in the Asian and non-Asian populations of the EMPA-REG OUTCOME trial of patients with type 2 diabetes and cardiovascular disease.
    Diabetes Obes Metab. 2021 Dec 14. doi: 10.1111/dom.14626.
    >> Share

  792. LIM S, Sohn M, Shin Y, Ferrannini E, et al
    Initial combination of metformin, sitagliptin, and empagliflozin in drug-naive patients with type 2 diabetes: Safety and metabolic effects.
    Diabetes Obes Metab. 2021 Dec 14. doi: 10.1111/dom.14627.
    >> Share

  793. SEUFERT J, Lanzinger S, Danne T, Bramlage P, et al
    Real-world data of 12-month adjunct sodium-glucose co-transporter-2 inhibitor treatment in type 1 diabetes from the German/Austrian DPV registry: Improved HbA1c without diabetic ketoacidosis.
    Diabetes Obes Metab. 2021 Dec 12. doi: 10.1111/dom.14620.
    >> Share

  794. MEYHOFER S, Eckert AJ, Hummel M, Laimer M, et al
    Elevated liver enzymes and comorbidities in type 2 diabetes: Multicenter analysis of 51,645 patients of the DPV database.
    Diabetes Obes Metab. 2021 Dec 9. doi: 10.1111/dom.14616.
    >> Share

  795. PERLMAN JE, Gooley TA, Meyers J, Hirsch IB, et al
    The relationship between hypoglycaemia and glucose variability in type 1 diabetes.
    Diabetes Obes Metab. 2021 Dec 9. doi: 10.1111/dom.14617.
    >> Share

  796. MIDDLETON TL, Constantino MI, McGill M, D'Souza M, et al
    Improving beta-cell secretory function and glycemia in young-onset type 2 diabetes: A pilot, 12-month, randomized trial of a novel, CGM-guided, rapid treatment intensification strategy incorporating empagliflozin and liraglutide.
    Diabetes Obes Metab. 2021 Dec 9. doi: 10.1111/dom.14621.
    >> Share

  797. XUE P, Tang X, Tan X, Benedict C, et al
    Self-reported regular daytime napping is associated with indicators of poor type 2 diabetes control: a cohort study.
    Diabetes Obes Metab. 2021 Dec 9. doi: 10.1111/dom.14619.
    >> Share

  798. KENG MJ, Leal J, Bowman L, Armitage J, et al
    Decrements in health-related quality of life associated with adverse events in people with diabetes.
    Diabetes Obes Metab. 2021 Dec 6. doi: 10.1111/dom.14610.
    >> Share

  799. DUBOURG J, Fouqueray P, Quinslot D, Grouin JM, et al
    Long-term safety and efficacy of imeglimin as monotherapy or in combination with existing antidiabetic agents in Japanese patients with type 2 diabetes (TIMES 2): a 52-week open-label, multicenter phase 3 trial.
    Diabetes Obes Metab. 2021 Dec 6. doi: 10.1111/dom.14613.
    >> Share

  800. ALAM NN, Wright AK, Rutter MK, Buchan I, et al
    Body mass index and cancer mortality in patients with incident type 2 diabetes: a population-based study of adults in England.
    Diabetes Obes Metab. 2021 Dec 6. doi: 10.1111/dom.14614.
    >> Share

  801. MOSER O, Sternad C, Eckstein ML, Szadkowska A, et al
    Performance of intermittently scanned continuous glucose monitoring (isCGM) systems in people with type 1 diabetes: a pooled analysis.
    Diabetes Obes Metab. 2021 Dec 6. doi: 10.1111/dom.14609.
    >> Share

  802. JODAR E, Romera I, Wang Q, Roche SL, et al
    Glycemic variability in patients with type 2 diabetes mellitus treated with dulaglutide, with and without concomitant insulin: Post hoc analyses of randomized, clinical trials.
    Diabetes Obes Metab. 2021 Dec 6. doi: 10.1111/dom.14615.
    >> Share

  803. IIZUKA K, Baxter M, Watanabe D, Yabe D, et al
    Benefit of insulin glargine/lixisenatide for reducing residual hyperglycaemia in Japan: Post hoc analysis of the LixiLan JP-O2 trial.
    Diabetes Obes Metab. 2021;23:2795-2803.
    >> Share

  804. MARIAM A, Miller-Atkins G, Pantalone KM, Iyer N, et al
    Associations of weight loss with obesity-related comorbidities in a large integrated health system.
    Diabetes Obes Metab. 2021;23:2804-2813.
    >> Share

  805. FRIAS JP, Bonora E, Cox DA, Bethel MA, et al
    Glycaemic efficacy of an expanded dose range of dulaglutide according to baseline glycated haemoglobin (HbA1c) subgroup: Post hoc analysis of AWARD-11.
    Diabetes Obes Metab. 2021;23:2819-2824.
    >> Share

  806. HOME PD, Mehta R, Hafidh KAS, Gurova OY, et al
    Efficacy and safety of iGlarLixi versus IDegAsp: Results of a systematic literature review and indirect treatment comparison.
    Diabetes Obes Metab. 2021;23:2660-2669.
    >> Share

  807. KALANTAR-ZADEH K, Beddhu S, Kovesdy CP, Kramer HJ, et al
    Biologically plausible trends suggesting that a low-protein diet may enhance the effect of flozination caused by the sodium-glucose cotransporter-2 inhibitor dapagliflozin on albuminuria.
    Diabetes Obes Metab. 2021;23:2825-2826.
    >> Share

  808. SUISSA K, Schneeweiss S, Lin KJ, Brill G, et al
    Validation of obesity-related diagnosis codes in claims data.
    Diabetes Obes Metab. 2021;23:2623-2631.
    >> Share

    November 2021
  809. DOVC K, Van Name M, Jenko Bizjan B, Rusak E, et al
    Continuous Glucose Monitoring Use and Glucose Variability in Very Young Children with Type 1 Diabetes (VibRate): A Multinational Prospective Observational Real-World Cohort Study.
    Diabetes Obes Metab. 2021 Nov 24. doi: 10.1111/dom.14607.
    >> Share

  810. RENARD E, Tubiana-Rufi N, Bonnemaison E, Coutant R, et al
    Outcomes of Hybrid Closed-Loop Insulin Delivery Activated 24/7 versus Evening and Night in Free-living Pre-pubertal Children with Type 1 Diabetes. A Multicenter Randomized Clinical Trial.
    Diabetes Obes Metab. 2021 Nov 23. doi: 10.1111/dom.14605.
    >> Share

  811. WEEDA ER, Burnette B, Rowe S, Haas S, et al
    Disparity of rural-urban distribution of clinical trial sites used in studies cited by diabetes treatment guidelines.
    Diabetes Obes Metab. 2021 Nov 23. doi: 10.1111/dom.14606.
    >> Share

  812. EVANS M, Engberg S, Faurby M, Fernandes JDDR, et al
    Adherence to and persistence with antidiabetic medications and associations with clinical and economic outcomes in people with type 2 diabetes mellitus: A systematic literature review.
    Diabetes Obes Metab. 2021 Nov 14. doi: 10.1111/dom.14603.
    >> Share

  813. HIROSE N, Tsujimoto N, Katayose T, Chin R, et al
    Utilization of glucagon-like peptide-1 receptor agonists and changes in clinical characteristics in type 2 diabetes mellitus patients by chronic kidney disease stage in Japan: A descriptive observational study using nationwide electronic medical recor
    Diabetes Obes Metab. 2021 Nov 14. doi: 10.1111/dom.14600.
    >> Share

  814. CHAUDHURI A, Ghanim H, Arora P
    Improving Residual Risk of Renal and Cardiovascular Outcomes in Diabetic Kidney Disease: Review of Pathophysiology, Mechanisms and Evidence from Recent Trials.
    Diabetes Obes Metab. 2021 Nov 14. doi: 10.1111/dom.14601.
    >> Share

  815. ALHAKAK A, Butt JH, Gerds TA Dr.rer.nat, Fosbol EL, et al
    Glycated haemoglobin (HbA1c) levels among 3,295 hospitalised COVID-19 patients with and without diabetes and risk of severe infection, admission to an intensive care unit, and all-cause mortality.
    Diabetes Obes Metab. 2021 Nov 14. doi: 10.1111/dom.14604.
    >> Share

  816. MISTRY N, Shehata N, Carmona P, Bolliger D, et al
    Restrictive versus Liberal Transfusion in Patients with Diabetes Undergoing Cardiac Surgery: An Open-Label Randomized, Blinded Outcome Evaluation Trial.
    Diabetes Obes Metab. 2021 Nov 7. doi: 10.1111/dom.14591.
    >> Share

  817. PAAVILAINEN E, Tertti K, Nikkinen H, Veijola R, et al
    Metformin versus insulin therapy for gestational diabetes: Effects on offspring anthropometrics and metabolism at the age of 9 years-A follow-up study of two open-label, randomised, controlled trials.
    Diabetes Obes Metab. 2021 Nov 5. doi: 10.1111/dom.14589.
    >> Share

  818. QIU M, Zhou X, Zhang M
    Cardiorenal benefits of SGLT2i versus DPP4i in type 2 diabetes without cardiovascular and renal diseases.
    Diabetes Obes Metab. 2021 Nov 2. doi: 10.1111/dom.14588.
    >> Share

  819. MCDIARMID S, Harvie M, Johnson R, Vyas A, et al
    Manchester Intermittent versus Daily Diet App Study (MIDDAS): A pilot randomized controlled trial in patients with type 2 diabetes.
    Diabetes Obes Metab. 2021 Nov 2. doi: 10.1111/dom.14592.
    >> Share

  820. KLONOFF DC, Bassock S, Engels E, Frederiksen M, et al
    Semaglutide single-dose pen-injector: Post hoc analysis of summative usability testing for weight management.
    Diabetes Obes Metab. 2021;23:2590-2594.
    >> Share

  821. PRATLEY RE, Catarig AM, Lingvay I, Viljoen A, et al
    An indirect treatment comparison of the efficacy of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg.
    Diabetes Obes Metab. 2021;23:2513-2520.
    >> Share

  822. SUISSA K, Schneeweiss S, Douros A, Filion KB, et al
    The modifying effects of adiposity on the cardiovascular safety of sulphonylureas.
    Diabetes Obes Metab. 2021;23:2502-2512.
    >> Share

  823. MAI L, Wen W, Qiu M, Liu X, et al
    Association between prediabetes and adverse outcomes in heart failure.
    Diabetes Obes Metab. 2021;23:2476-2483.
    >> Share

    October 2021
  824. ROBERTSON CA, Earnest A, Chee M, Craig ME, et al
    Longitudinal audit of assessment and pharmaceutical intervention for cardiovascular risk in the Australasian Diabetes Data Network (ADDN).
    Diabetes Obes Metab. 2021 Oct 29. doi: 10.1111/dom.14584.
    >> Share

  825. ARSENYADIS F, Redman E, Coull N, Henson J, et al
    Energy intake and weight during the COVID-19 lockdown is not altered in a sample of older adults with Type 2 Diabetes in England.
    Diabetes Obes Metab. 2021 Oct 27. doi: 10.1111/dom.14585.
    >> Share

  826. ZOBEL EH, von Scholten BJ, Hansen TW, Persson F, et al
    The importance of addressing multiple risk markers in type 2 diabetes: results from the LEADER and SUSTAIN 6 trials.
    Diabetes Obes Metab. 2021 Oct 21. doi: 10.1111/dom.14578.
    >> Share

  827. VAN DEN BOOM L, Kostev K
    Patterns of insulin therapy and insulin daily doses in children and adolescents with type 1 diabetes in Germany.
    Diabetes Obes Metab. 2021 Oct 21. doi: 10.1111/dom.14581.
    >> Share

  828. WEBB J, Mount J, von Arx LB, Rachman J, et al
    Cardiovascular risk profiles: A cross-sectional study evaluating the generalisability of the glucagon-like peptide-1 receptor agonist cardiovascular outcome trials Rewind, Leader and Sustain-6 to the real-world type 2 diabetes population in the UK.
    Diabetes Obes Metab. 2021 Oct 20. doi: 10.1111/dom.14580.
    >> Share

  829. DIALLO A, Pichelin M, Wargny M, Gourdy P, et al
    Influenza vaccination and prognosis of COVID-19 in hospitalized patients with diabetes: Results from the CORONADO study.
    Diabetes Obes Metab. 2021 Oct 17. doi: 10.1111/dom.14577.
    >> Share

  830. FURIHATA K, Mimura H, Urva S, Oura T, et al
    A phase 1 multiple-ascending dose study of tirzepatide in Japanese participants with type 2 diabetes.
    Diabetes Obes Metab. 2021 Oct 13. doi: 10.1111/dom.14572.
    >> Share

  831. PEDERSEN-BJERGAARD U, Agesen RM, Brosen JMB, Alibegovic AC, et al
    Comparison of treatment with insulin degludec and glargine U100 in patients with type 1 diabetes prone to nocturnal severe hypoglycaemia: The HypoDeg randomised, controlled, open-label, cross-over trial.
    Diabetes Obes Metab. 2021 Oct 12. doi: 10.1111/dom.14574.
    >> Share

  832. UNGER J, Allison DC, Kaltoft M, Lakkole K, et al
    Maintenance of Glycemic Control with Liraglutide versus Oral Antidiabetic Drugs as Add-on Therapies in Patients with Type 2 Diabetes Uncontrolled with Metformin Alone: A Randomized Clinical Trial in Primary Care (LIRA-PRIME).
    Diabetes Obes Metab. 2021 Oct 7. doi: 10.1111/dom.14566.
    >> Share

  833. YAMADA Y, Yabe D, Hertz CL, Horio H, et al
    Efficacy and safety of oral semaglutide by baseline age in Japanese patients with type 2 diabetes: A subgroup analysis of the PIONEER 9 and 10 Japan trials.
    Diabetes Obes Metab. 2021 Oct 7. doi: 10.1111/dom.14571.
    >> Share

  834. DAVIES MJ, Rosenstock J, Ali A, Russell-Jones D, et al
    Efficacy of iGlarLixi in adults with type 2 diabetes inadequately controlled (glycated haemoglobin >/=8%, >/=64 mmol/mol) on two oral antidiabetes drugs: Post hoc analysis of the LixiLan-O randomized trial.
    Diabetes Obes Metab. 2021 Oct 6. doi: 10.1111/dom.14543.
    >> Share

  835. JOHANSEN NJ, Dejgaard TF, Lund A, Schluntz C, et al
    Effects of short-acting exenatide added three times daily to insulin therapy on bone metabolism in type 1 diabetes.
    Diabetes Obes Metab. 2021 Oct 6. doi: 10.1111/dom.14568.
    >> Share

  836. LEOHR J, Kazda C, Liu R, Reddy S, et al
    Ultra Rapid Lispro Shows Faster Pharmacokinetics and Reduces Postprandial Glucose Excursions vs. Humalog(R) in Patients with Type 2 Diabetes Mellitus in a Randomized, Controlled Cross-over Meal Test Early Phase Study.
    Diabetes Obes Metab. 2021 Oct 4. doi: 10.1111/dom.14561.
    >> Share

  837. PIEBER TR, Bajaj HS, Heller SR, Jia T, et al
    Impact of kidney function on the safety and efficacy of insulin degludec versus insulin glargine U300 in people with type 2 diabetes: A post hoc analysis of the CONCLUDE trial.
    Diabetes Obes Metab. 2021 Oct 4. doi: 10.1111/dom.14564.
    >> Share

  838. SAFFO S, Kaplan DE, Mahmud N, Serper M, et al
    Impact of SGLT2 inhibitors in comparison with DPP4 inhibitors on ascites and death in veterans with cirrhosis on metformin.
    Diabetes Obes Metab. 2021;23:2402-2408.
    >> Share

  839. BAILEY TS, Willard J, Klaff LJ, Yager Stone J, et al
    Dasiglucagon, a next-generation glucagon analogue, for treatment of severe hypoglycaemia via an autoinjector device: Results of a phase 3, randomized, double-blind trial.
    Diabetes Obes Metab. 2021;23:2329-2335.
    >> Share

  840. FRIAS JP, Bonora E, Nevarez Ruiz L, Hsia SH, et al
    Efficacy and safety of dulaglutide 3.0 and 4.5 mg in patients aged younger than 65 and 65 years or older: Post hoc analysis of the AWARD-11 trial.
    Diabetes Obes Metab. 2021;23:2279-2288.
    >> Share

  841. BLONDE L, Fainberg U, Kaltoft MS, Mosenzon O, et al
    Efficacy of liraglutide added to sodium-glucose cotransporter-2 inhibitors in type 2 diabetes, stratified by baseline characteristics: Post-hoc analysis of LIRA-ADD2SGLT2i.
    Diabetes Obes Metab. 2021;23:2234-2241.
    >> Share

  842. TAN X, Yang L, Khunti K, Zhang R, et al
    Factors associated with switching from sulphonylureas to dipeptidyl peptidase 4 inhibitors among patients with type 2 diabetes in the United States.
    Diabetes Obes Metab. 2021;23:2251-2260.
    >> Share

    September 2021
  843. SCHMIDT S, Frandsen CS, Dejgaard TF, Vistisen D, et al
    Liraglutide changes body composition and lowers added sugar intake in overweight persons with insulin pump-treated type 1 diabetes.
    Diabetes Obes Metab. 2021 Sep 30. doi: 10.1111/dom.14567.
    >> Share

  844. KAZDA C, Leohr J, Liu R, Reddy S, et al
    Ultra Rapid Lispro (URLi) Shows Accelerated Pharmacokinetics and Greater Reduction in Postprandial Glucose versus Humalog(R) in Patients with Type 1 Diabetes Mellitus in a Randomized, Double-blind Meal Test Early Phase Study.
    Diabetes Obes Metab. 2021 Sep 30. doi: 10.1111/dom.14563.
    >> Share

  845. ROSSING P, Agarwal R, Anker SD, Filippatos G, et al
    Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP-1RA treatment: A subgroup analysis from the FIDELIO-DKD trial.
    Diabetes Obes Metab. 2021 Sep 28. doi: 10.1111/dom.14558.
    >> Share

  846. MUSKIET MHA, Tonneijck L, Smits MM, Kramer MHH, et al
    Postprandial renal hemodynamic effects of DPP-4 inhibitor linagliptin versus sulfonylurea glimepiride in adults with type 2 diabetes (RENALIS): a pre-defined sub-study of a randomized, double-blind trial.
    Diabetes Obes Metab. 2021 Sep 28. doi: 10.1111/dom.14557.
    >> Share

  847. HUGHES MS, Bailey R, Calhoun P, Shah VN, et al
    Off-label use of sodium glucose co-transporter inhibitors among adults in type 1 diabetes exchange registry.
    Diabetes Obes Metab. 2021 Sep 21. doi: 10.1111/dom.14556.
    >> Share

  848. BAIN EK, Bain SC
    Recent developments in GLP-1RA therapy: A review of the latest evidence of efficacy and safety and differences within the class.
    Diabetes Obes Metab. 2021;23 Suppl 3:30-39.
    >> Share

  849. NAUCK MA, Quast DR, Wefers J, Pfeiffer AFH, et al
    The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update.
    Diabetes Obes Metab. 2021;23 Suppl 3:5-29.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016